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Abstract 
High dose rate (HDR) brachytherapy treatments are usually delivered in large dose 
fractions and have the clinical advantage of highly conformal dose distributions due to 
the steep dose gradient produced by the 192Ir source. The routine use of 3D imaging for 
treatment planning enables clinical teams to finely optimise the dose distribution 
around the defined target while limiting dose to the surrounding organs at risk. A 
significant challenge in brachytherapy is to ensure the dose is delivered to the patient as 
planned, which can be challenging due to factors that impact the accuracy of dose 
delivery. Due to the high degree of manual processes in brachytherapy, the relative risk 
of treatment delivery error is high when compared to other radiotherapy modalities. 
Additionally, interstitial and intracavitary brachytherapy suffer from anatomical motion 
and swelling due to catheter (or applicator) implant trauma.  
There are two fundamental ways to verify a HDR brachytherapy treatment delivery: (i) 
verify the source dwell positions and times are as per the treatment plan, or (ii) perform 
a measurement in vivo with a dosimeter. Although reported in many small patient 
studies, in vivo dosimetry (IVD) has many limitations (e.g. detector position 
uncertainty and limited sampling) making the interpretation of results for treatment 
verification difficult. These challenges may be the reason for the limited routine 
application of IVD as a treatment verification technique. Since the treatment plan is a 
planned set of dwell positions and times, the former approach has the potential to verify 
the dose over the entire treatment volume. 
This thesis addresses the need to improve the methodology for treatment verification in 
HDR brachytherapy. This work aims to establish a verification technique that can be 
used routinely in the clinical environment, not impact the patient and provide data that 
can be confidently interpreted to verify the entire treatment delivery. To achieve this, a 
novel approach to treatment verification was investigated, avoiding the challenges of 
directly measuring dose. Measurements of the source position, during the treatment 
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delivery (source tracking) were made, enabling direct comparison with the treatment 
plan for verification. Additionally, a method to establish a structured approach for 
performing this treatment verification process was accomplished, with the objective to 
enable routine use and widespread uptake of this process. The overall goal of this novel 
verification approach was to improve the quality of treatment delivery and patient 
safety in HDR brachytherapy. 
To investigate this new approach, a flat panel detector (FPD) was employed as the 
measurement device. The detector, originally designed for use as an electronic portal 
imaging device, was characterised for use with an 192Ir brachytherapy source. The FPD 
response and the image acquisition timing were investigated to demonstrate its 
capability for this work. The images of the response to the 192Ir source, acquired with 
the FPD, were interpreted by a range of algorithms, extracting metrics that could be 
correlated with the position of the source. A concept for integration into a clinical 
environment was developed, by placing the FPD in the treatment couch, immediately 
below the target volume. The potential for the brachytherapy implant to displace due to 
anatomical and other influences was addressed by performing pre-treatment image 
verification. An imaging geometry was established, allowing registration with the 
treatment plan, enabling identification and quantification of implant displacement (in 
the treatment bunker) immediately prior to treatment delivery. The relationship 
established between the measurement frame of reference and the treatment plan 
permitted direct comparison of the measured dwell positions with the planned dwell 
positions for verification of treatment delivery. Treatment delivery metrics were 
developed to detect the occurrence of a treatment error, and based on the unique 
signature of the error, identification of the error source was possible. This concept of 
treatment verification was transferred into the clinical environment and a patient 
measurement was performed to understand the challenges of clinical implementation. 
The FPD responded to the 192Ir source, for a range of clinically relevant distances (20 to 
200 mm) away from the FPD despite the low dose rates and the changing photon 
spectrum. The image acquisition time was one image capture every 1.8 seconds, and 
although not designed for this application, the FPD was adequate to perform this proof 
of principle work. Using a range of algorithms, the images acquired by the FPD were 
processed to determine the source position. It was determined that a centre of mass 
approach was the most accurate method (x and y s.d. 0.3 and 0.1 mm, up to 200 mm 
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from the FPD imaging plane) to determine source position in the 2D plane of the FPD. 
The influence of inhomogeneities and finite phantom geometry were quantified relative 
to their influence on the accuracy of determining the source position when applied in a 
clinical scenario. A structured approach to pre-treatment imaging was developed, with a 
robust method to perform a 3D reconstruction of the implant in the treatment bunker 
using a ‘shift image’ technique. A registration between the treatment planning system 
(TPS) and the measurement space (FPD) was established allowing quantitative 
evaluation of the implant changes since treatment planning imaging. Pre-treatment 
imaging was capable of identifying catheter displacements in the order of 2.0 mm with 
a confidence of 95%. Identification of a treatment delivery error was possible with the 
use of metrics that when combined define an error ‘signature’ that suggest the source of 
the error. The absolute relationship between the measurement space and the TPS allow 
error trapping to identify errors that would otherwise go undetected, for example an 
incorrect channel length definition error. This verification approach was applied 
successfully in a clinical setting. Pre-treatment imaging allowed confirmation that the 
implanted catheters had not significantly displaced prior to treatment and source 
tracking results confirmed the treatment was delivered as planned. The clinical 
implementation had minimal impact on the workflow, increasing the patient setup (and 
imaging) time by only 15 minutes while not adding any additional time to the radiation 
dose delivery portion of the treatment. 
This initial work using a FPD for treatment verification in HDR brachytherapy has 
highlighted the benefits of this approach. This novel approach provides multiple layers 
of verification, including pre-treatment imaging (in 2D and 3D) to identify potential 
sources of error prior to treatment delivery. Source tracking, in conjunction with pre-
treatment imaging, provides quantitative verification of the entire treatment delivery, 
currently not possible with other methods. This approach establishes a new standard of 
verification which has the potential to improve the quality of treatment delivery and 
improves patient safety in HDR brachytherapy. 
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Chapter 1 
Introduction 
 
1. Overview and Aim 
High dose rate (HDR) brachytherapy treatments are usually delivered in large dose 
fractions. Poor execution in the delivery of a planned treatment would have significant 
clinical impact, because high doses are delivered in seconds and mistakes in an 
individual fraction cannot be easily rectified. Two recent brachytherapy review articles 
[1, 2] highlight the need for an independent and comprehensive treatment verification 
system in HDR brachytherapy to ensure patient safety.  
In this thesis, a novel, non-invasive treatment verification system is described along 
with its initial clinical implementation. A treatment verification system based on a flat 
panel detector (FPD) is characterised, and used to perform pre-treatment image 
verification and HDR brachytherapy source tracking for direct comparison with the 
treatment planning system (TPS) to validate correct treatment delivery. The verification 
system described in this work is sensitive to most of the treatment delivery error types 
identified in Table I of the review article by Tanderup et al [1]. 
1.1 High Dose Rate Brachytherapy 
HDR brachytherapy is a radiation therapy modality used for treating cancer across 
almost all sites of the human body. HDR brachytherapy is practiced by placing a single 
radioactive source within or at short distances from the treatment (tumour) volume. 
Treatment can be achieved by delivering the radioactive source within body cavities 
(intracavitary), within the lumen of organs (intraluminal) or into soft tissue (interstitial). 
A common application of interstitial HDR brachytherapy is the treatment of prostate 
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cancer, where the source is delivered through the perineum, via a number of hollow 
catheters, into the prostate organ, and represents the clinical examples provided in this 
work. 
HDR brachytherapy offers highly conformal dose distributions, allowing large doses to 
be delivered to the treatment volume while sparing surrounding healthy tissue [3, 4]. It 
achieves excellent local control rates and relatively low side effects when compared to 
other treatment options [4, 5]. 
Treatment is performed by implanting the patient with applicators, designed to sit 
against or within the target volume. These implanted applicators define the path the 
radioactive source will travel and so correct placement relative to the patient’s anatomy 
is crucial. The position of these applicators can be accurately placed by the Surgeon or 
Radiation Oncologist without the risk of radiation exposure. The radioactive source is 
then later introduced into each applicator channel and the treatment delivered as 
programmed by a remote robotic afterloading machine and depicted in figure 1.1. 
 
Figure 1.1.  The microSelectron HDR brachytherapy robotic afterloader used in this work from 
Elekta ( Elekta, Stockholm, Sweden).  
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Understanding the process of treatment planning, patient preparation, and treatment 
delivery helps one understand the potential for mistakes to occur. Mistreatment could 
be due to software or hardware malfunctions, operator errors, or anatomical changes in 
the patient. The consequences could include under-dosing of the target (potentially 
failing to cure the patient) or over-dosing normal tissues with a corresponding increased 
risk of side effects or radiation injury. 
1.2 Treatment Planning 
HDR brachytherapy planning techniques typically involve three dimensional (3D) 
reconstruction or modelling of the implanted applicator(s) in a dedicated brachytherapy 
TPS. The TPS is a custom computer workstation which can provide the user with the 
functions and visualisations to create a radiation dose treatment plan for the patient. 
Images of the implanted applicator(s), commonly referred to as the ‘implant’, are 
captured using computed tomography (CT) imaging[6], ultrasound (US) imaging [7], or 
magnetic resonance imaging (MRI) if the implant materials are compatible [8, 9]. Clear 
and accurate imaging of the implant and surrounding anatomy is necessary as this 
forms the basis for treatment planning. 
The treatment planning procedure can be divided into three main steps, anatomical 
contouring, implant reconstruction and radiation dose planning, each of which have 
their own uncertainties [10-12] and risk of errors occurring. The contouring procedure 
involves a Radiation Oncologist defining in the TPS the anatomical planning target 
volume (PTV) and the surrounding organs at risk (OAR). The implant reconstruction 
process requires the brachytherapy source travel paths to be clearly defined, orientation 
of the applicator to be correctly identified and the channel numbering system to be clear 
to avoid possible confusion at treatment. An example of a reconstructed prostate 
implant is shown in figure 1.2. The contoured PTV is shown in red and the rectum 
OAR is shown in blue. The reconstructed applicator, in this case 18 prostate catheters, 
is shown as green paths passing through the PTV region.  
The aim of radiation dose planning is to achieve a dose distribution that covers the PTV 
with the prescription dose while minimising (below specified threshold values) the dose 
to surrounding tissues and OAR. A treatment plan is constructed from an array of 
brachytherapy source stop positions, known as ‘dwell positions’, defined along each 
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implant channel path. The planner creates active dwell positions by specifying where 
the source stops and how long the source dwells at each position (dwell time). Figure 
1.2(a) illustrates active dwell positions (red spheres) and inactive dwell positions (green 
spheres).The 3D array of active dwell positions create a cumulative dose ‘cloud’, 
shown as yellow in figure 1.2(b), as the source moves from one dwell position to the 
next. It is critically important, to achieve the treatment plan objectives, that the source 
is accurately delivered to each active dwell position relative to the surrounding 
anatomy. 
 
Figure 1.2.  (a) An example of a prostate HDR treatment plan, showing the implant catheter 
paths (green), the PTV (red), rectum OAR (blue) and active and inactive dwell positions in 
each catheter, red and green spheres respectively. (b) The cumulative dose ‘cloud’ shown in 
yellow covering the PTV with the prescription dose produced by all contributing active dwell 
positions. 
PTV 
Inactive Dwells 
Rectum (OAR) 
Active Dwells 
Dose ‘cloud’ 
(a) 
(b) 
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Activation of source dwell positions can be performed manually by the treatment 
planner but is not practical for complex brachytherapy implants consisting of many 
treatment channels or ‘catheters’ (e.g. prostate). These implants require advanced 
dosimetric optimisation algorithms that can auto-activate dwell positions and modulate 
the dwell time in order to achieve the prescribed PTV dose coverage while minimising 
the dose to OAR. A number of dosimetric optimisation algorithms exist and further 
details can be found in the following references [13, 14] . 
1.3 Treatment Delivery 
HDR brachytherapy treatment is administered using a robotic remote afterloading 
machine, as shown in figure 1.1. The implanted applicator channels are connected to 
the afterloader by transfer tubes, using a channel numbering system defined on the 
afterloader interface plate as shown in figure 1.3(a). The afterloader drives the 
radioactive source via each programmed channel, through the transfer tube and into the 
catheter in the patient, to deliver the programmed treatment. The distance the source 
travels into each channel, to reach the treatment volume (PTV), is specified at the time 
of treatment planning and is defined as the indexer length. The indexer length to be 
specified by the user depends on the lengths of the transfer tubes and catheters used. 
Treatment delivery occurs with the patient in a shielded bunker while the staff monitors 
the treatment progression from the safety of the control room. 
Isotopes used in HDR brachytherapy exhibit characteristics such as high specific 
activities enabling small sources to be produced with clinically adequate dose rates. 
One of the most commonly used isotopes is Iridium 192 (192Ir), which is exclusively 
used in Australia and is the subject of this work. Different manufacturers of HDR 
brachytherapy afterloaders produce sources that vary slightly in their geometry, but the 
general design consists of the isotope material confined within a titanium capsule which 
is then welded to a stainless steel cable. In this work, the source is contained in a 
titanium capsule 4.5 mm long, 0.9 mm in diameter, and is welded onto the end of a 
stainless steel cable as depicted in figure 1.3(b) and (c). The robotic remote afterloader 
machine drives the source to the specified active dwell position and dwells the source 
for the programmed length of time. The source is then stepped to the next active dwell 
position and again dwells for the programmed time. The process is repeated for all 
implanted catheters (applicator channels) until the entire treatment has been delivered.  
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Figure 1.3.  (a) A HDR brachytherapy remote afterloader interface plate showing the channel 
numbering system. (b) A photo of the 192Ir source used in this afterloader and (c) the details of 
the source geometry (from microSelectron V3 reference manual, Elekta Stockholm, Sweden). 
 
1.4 Treatment Verification 
Treating any patient with radiation carries the risk of misadministration. A treatment 
error may result in an under dose or over dose to the patient or even a complete 
geographical miss of the target volume. In many documented cases, the main 
contributor to radiation delivery treatment errors is human mistakes[15]. In order to 
reduce (and ideally eliminate) the frequency and severity of these errors, systematic 
processes are introduced into the treatment delivery process integrated with advanced 
technology to identify and trap errors before they impact the patient. Modern HDR 
brachytherapy afterloader systems contain a number of safety features to minimise the 
risk of error, but many opportunities for incorrect delivery of treatment remain. 
(a) 
(b) 
(c) 
 
Chapter 1: Introduction 
10 
There currently exists a disparity between external beam radiation therapy (EBRT) and 
HDR brachytherapy in validating correct treatment delivery. Treatment verification for 
EBRT includes various integrated systems to provide multiple levels of authentication. 
These include systems to ensure the correct patient treatment plan is loaded, pre-
treatment imaging (ionising and non-ionising) to ensure the patient’s treatment position 
is correct[16-19], position verification imaging during the radiation delivery[20, 21], 
patient dose measurement for the treatment field[22-24], and more recently dynamic 
verification allowing target tracking as the tumour moves during treatment delivery[25-
27]. Many of these systems are considered essential in EBRT to ensure patient safety 
and have enabled safe dose escalation improving tumour control and/or minimising 
harm to surrounding organs at risk[28-30]. 
1.5 Treatment Verification in HDR Brachytherapy 
HDR brachytherapy treatment quality assurance processes can be considered as two 
stages; (i) pre-treatment imaging to verify the implanted catheter (or applicator) is in 
the correct (as planned) position relative to the surrounding anatomy and (ii) 
verification of treatment delivery (monitored during or validated after treatment) to 
ensure the correct plan and dose is administered to the patient. The time pressure in the 
clinic and the lack of commercial verification tools available both influence the extent 
of routine verification that is performed in HDR brachytherapy. 
Deviation of treatment delivery from the plan can occur for two main reasons: (a) a 
treatment error due to human mistake[15] or system malfunction and (b) anatomical 
movement[31-34], where the implant moves inside the patient relative to the anatomy 
after treatment planning. Manual cross checking procedures, performed by many 
brachytherapy institutions, identify some treatment delivery errors, but their value is 
limited as they can be bypassed, forgotten, or incorrectly performed, and do not identify 
all possible errors. An independent system to verify treatment parameters, identify 
potential errors and ensure patient safety, both before and during treatment delivery, is 
sorely needed.  
1.5.1 Pre-treatment Verification Imaging 
Pre-treatment verification imaging is an important step but is often not performed 
routinely, possibly due to the lack of available treatment room imaging equipment and 
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software tools to swiftly perform verification. Changes to the brachytherapy implant 
geometry, between treatment planning and treatment delivery will potentially result in a 
geographical-miss delivery error.  
In HDR prostate brachytherapy, uncorrected catheter displacement can have a 
significant impact on dosimetry, with approximately every centimetre of catheter 
displacement resulting in the prostate V100 (prostate volume receiving 100% of the 
prescription dose) being decreased by 20% [35]. The catheter displacement is largely in 
the cranial-caudal direction with oedema, swelling and other external influences 
typically driving this catheter movement[31]. Identification of catheter displacement 
has been reported between treatment fractions [31, 32, 34, 36] and also between 
treatment planning and delivery, where the time frame is on the order of a few 
hours[33, 37]. External visual inspection of the catheters and template is important but 
does not truly capture the internal catheter to anatomy relationship. An imaging 
approach at the time of treatment, ideally with the patient in the treatment position, is 
necessary to correctly identify any catheter displacement relative to the target volume 
and ensure the accuracy of the dose delivered. 
An unidentified treatment misadministration (geographical miss) could potentially 
occur if pre-treatment imaging is not performed, although from the user/operator 
perspective, the treatment appears to be delivered correctly by the brachytherapy 
afterloader system.  
A systematic and reliable approach to capture the implant position relative to the 
surrounding anatomy, with software tools to compare against the expected (TPS) 
position is needed. A technique to express any observed deviations as a simple result is 
desirable, as informed clinical decisions need to be made promptly, at the treatment 
console.  
1.5.2 In vivo Dosimetry  
Treatment delivery verification in HDR brachytherapy has mainly employed in vivo 
dosimetry (IVD) as the detection mechanism [38-44]. At present IVD in HDR 
brachytherapy has failed to achieve widespread implementation as routine clinical 
practice and typically is applied in a research context. IVD is an attractive approach to 
verifying the treatment delivery as this provides a direct measurement of the patient 
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dose. IVD is well established in EBRT [22], but when applied to HDR brachytherapy 
additional challenges are introduced. Previous clinical studies of IVD have used point 
dose detectors, such as thermoluminescent dosimeters (TLDs) [45], metal oxide 
semiconductor field effect transistors (MOSFETs) [46] , diodes [39, 47, 48], and 
scintillation detectors [42, 49, 50].  
Treatment verification using IVD approaches provide valuable information, particularly 
in terms of individual organ protection. For example rectal wall dosimetry [38, 39, 48, 
51, 52] and urethral dosimetry [40, 45, 50, 53] can be used to confirm that the dose 
limit to an organ is not exceeded. Most of these approaches are inherently invasive, 
requiring the dosimeter or a probe containing it, to be inserted into the patient’s rectum 
or urethra or require the insertion of an additional interstitial catheter. However, point 
measurements such as these do not necessarily provide sufficient information to verify 
the correct delivery of a treatment plan. Some interstitial measurement approaches [54] 
using detectors inserted into adjacent treatment catheters for example, sample the dose 
(or dose rate) within or near the treatment volume.  
Challenges associated with the uncertainty of the detector position relative to the 
source, coupled with the presence of high dose gradients, make the interpretation of 
these measurements for the purpose of treatment delivery error detection extremely 
difficult[1]. Discrepancies of -31 % to +90 % between measured and expected doses 
have been reported [47] but not attributed to having detected a treatment delivery error. 
The discrepancies have been regarded as an inherent uncertainty of measuring dose in 
vivo due to source-to-detector distance uncertainties. Improving the confidence in 
identifying an error, if it is present, requires sophisticated analysis of measurements 
such as the statistical error detection algorithm implemented by Kertzscher et al [55]. 
This typically reflects the difficulty in knowing where the detector is relative to the 
source during treatment delivery [47, 51]. A notable improvement is the combination of 
a point dosimeter coupled to a position sensor as demonstrated by Reniers et al [56], 
although it has not been implemented clinically.  
IVD will continue to be a challenge to implement in the clinic due to the added 
workload, potential sterilization issues, interference in existing workflow practices and 
the invasive nature of the approach. Even if the detector position is well known, a 
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single (or a few) point measurements has limited power to verify the entire treatment 
delivery due to under-sampling. 
1.5.3 Source Position Verification 
An alternative approach for treatment verification is to determine the position of the 
source throughout the treatment delivery, identify where these source positions are 
relative to the implanted catheters/applicator, and where they occur in relation to the 
surrounding anatomy. From this positional information, combined with the time the 
source dwells at each position, it is possible to verify that the treatment was delivered 
as planned and reconstruct the dose that was delivered to the tumour and/or organs at 
risk. 
Some previous studies have investigated source position measurements aimed at system 
quality assurance [57, 58] and the potential for the source position approach to 
treatment verification [59-61], but none have progressed to clinical implementation as 
in vivo devices.  
1.6 An Ideal Verification System 
A comprehensive HDR brachytherapy treatment verification system should be able to 
provide the user with information about the implant prior to treatment as well as 
monitor the treatment as it is delivered. The following is a list of attributes that an ideal 
treatment verification system in HDR brachytherapy should exhibit: 
• Non-invasive to the patient (to minimise risk of harm e.g. via infection) and not 
create additional discomfort 
• Not significantly increase the treatment time 
• Be simple for the treating staff to operate, enabling routine use 
• Be sensitive to all potential treatment errors 
• Integrate seamlessly with the TPS and treatment console system 
• Be independent of the treatment console/delivery mechanism 
• Provide real-time feedback to the operator 
• Allow treatment interrupt when substantial deviations from planned treatment 
are observed 
• Document the delivered treatment as a dose logging mechanism 
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• Upload the delivered dose to the TPS for fraction summation and potential 
adaptive planning 
1.7 Thesis Aim 
The aim of this thesis was to develop a treatment verification system for HDR 
brachytherapy, that can be used to validate correct treatment, detect deviations and 
ultimately ensure patient safety. 
The approach taken in this thesis employs source tracking, whereby a FPD device is 
used to measure the source radiation exiting the patient surface during treatment 
delivery. The acquired radiation distribution at the FPD imaging plane is then processed 
to determine the position of the source inside the patient.  
By including an external x-ray unit, and using the same FPD as the image acquisition 
device, both 2D and 3D pre-treatment image verification can be performed. Combining 
the pre-treatment imaging with the source tracking, the aim is to perform absolute 
source position verification, relative to the implant and patient anatomy. Additionally, 
by processing the information provided by this system, and comparing against the 
treatment plan, error trapping could be performed as the treatment is delivered. 
The final objective is to integrate this concept into a clinical environment and perform 
pre-treatment and treatment delivery verification for HDR prostate brachytherapy. 
1.8 Measurement Device 
The detector device used in this work is an amorphous silicon electronic portal imaging 
device (EPID) (aS500, Varian Medical Systems, Palo Alto, CA, USA) removed from 
the linear accelerator and operated in a standalone mode. This FPD was not 
strategically selected for the purpose of HDR brachytherapy treatment verification, but 
rather was acquired by means of opportunity. The FPD was utilised to perform a proof-
of-principle concept for verification. 
1.9 Thesis Scope and Structure 
The primary aim of this work was to improve the quality of treatment delivery and 
patient safety in HDR brachytherapy. The goal is to establish a verification system that 
is robust, non–invasive and simple to use enabling routine use and widespread uptake 
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of such a process. The scope of this thesis covers the proof-of-principle measurements 
in treatment verification to establish a practical process that can potentially be used in a 
clinical environment. The thesis concludes with these concepts being applied in a true 
clinical environment. 
A review of the literature in the field of HDR brachytherapy with a focus on techniques 
to validate treatment delivery is provided in Chapter 2. The literature recently published 
on HDR brachytherapy verification highlights the need for a system that can provide 
independent verification of the delivered parameters. Many of the publications use IVD 
as the mechanism for treatment verification, while a few systems have applied source 
position measurement to perform quality assurance testing and not treatment 
verification. 
The FPD used in this work is optimised for megavoltage photon beams and so the 
response of the detector to a HDR brachytherapy source was characterised. In Chapter 
3, the experimental steps taken to characterise the FPD for use with the 192Ir source is 
described. This includes the response to photon energy, dose rate, depth dependent 
spectral change, response reproducibility and source-detector angular response. A 
method for calibrating the FPD to measure dose was established. A simple phantom 
case of measuring a dose plane and comparing to the TPS was also achieved. In later 
work, the detector was operated as a radiograph imaging receptor, and so the plane 
below the detector front surface where the image is formed was also determined.  
The images obtained by the FPD, when exposed to the brachytherapy source in a 
phantom, can be interpreted to obtain the position of the source. Chapter 4 contains a 
description of the algorithms used to determine the position of the source inside the 
phantom/patient. 
For the verification system to validate the measured source position against the 
patient’s anatomy, a method of localising the patient and FPD relative to each other was 
required. Chapter 5 describes the pre-treatment imaging approach used, how the 
radiograph data can be used to validate the geometry of the implant, and describes the 
methods applied to reduce position uncertainties. 
Identification of treatment errors and termination of the treatment before they have a 
significant impact on the patient is an ideal characteristic of a treatment verification 
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system. Chapter 6 describes the comparisons undertaken to determine if the treatment 
delivered is correct or represents a treatment error. Methods to identify the cause of the 
error are also investigated. 
Chapter 7 describes the initial clinical implementation of the FPD, methods to 
determine source position, and the pre-treatment imaging.  
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2 Overview 
Treatment delivery verification in HDR brachytherapy is warranted as potential 
treatment errors can occur without clinical staff noticing, primarily because of human 
mistakes and/or changes to the implant geometry post treatment planning imaging. 
Some of the potential error types that can occur are incorrect treatment plan selection, 
incorrect specification of the channel length for the selected applicator or catheter, the 
source step size incorrectly specified, and swapped channels connecting the afterloader 
to the patient. Implant geometry changes, due to swelling of the tissue, has the potential 
to displace the catheters relative to the surrounding anatomy and/or relative to each 
other. Therefore, a treatment verification system should be sensitive to these error types 
to ensure the patient receives a high quality of treatment. 
Approaches to treatment delivery verification in HDR brachytherapy have mainly 
employed IVD techniques. The dose measured by a dosimeter at one (or several) points 
within or near the treatment volume, is then compared with the expected planned dose 
at those points. IVD in HDR brachytherapy has been performed with a variety of 
detector types and used in various anatomical locations and these approaches to 
verification are reviewed in more detail below. 
One significant challenge with this approach is accurately knowing the relative 
positions of both the brachytherapy source and dosimeter at the time of treatment in 
order to confidently interpret the measurements for error detection. In clinical practice, 
an observed discrepancy of the measured dose from the expected dose may be due to 
the detector position changes and high dose gradients typical in HDR brachytherapy 
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and not necessarily a treatment delivery error. Furthermore, IVD only provides 
dosimetric information at the point(s) of measurement and therefore must make 
assumptions about what is occurring throughout the rest of the treatment volume in 
order to accomplish treatment verification.  
An alternative approach to achieve treatment delivery verification is to perform source 
tracking during the treatment. If the position of the (stepping) source is measured 
during the treatment and in combination with the time the source dwells at each 
position the overall treatment delivery can be verified. The concept of source tracking 
potentially avoids the uncertainties associated with IVD detector positioning and 
permits dose reconstruction throughout the entire treatment volume. Pre-treatment 
imaging performed immediately prior to source tracking, could be used to account for 
geometric changes in the brachytherapy implant, therefore producing a treatment 
verification process that can adapt to this new geometry. 
The recent vision 20/20 publication of Tanderup el al [1] promotes development and 
implementation of routine IVD for the purposes of treatment verification. Treatment 
verification in HDR brachytherapy is far from routine in most clinical brachytherapy 
practices with many challenges still to be overcome. This chapter reviews approaches 
to performing HDR brachytherapy treatment delivery verification in a clinical scenario 
and highlights the existing challenges that still need to be overcome.  
 
2.1 In vivo Dosimetry 
The approach to IVD performed in HDR brachytherapy has been established using the 
concepts of IVD developed for EBRT. In simple terms, a dosimeter is placed on or in a 
patient and the treatment delivery is confirmed by measuring a dose and comparing it 
against an expected value predicted by the TPS. In contrast to brachytherapy, the 
position of the radiation source in EBRT is fixed relative to the dosimeter and generally 
the position of the dosimeter is well known relative to the treatment field, via visual or 
by pre-treatment imaging techniques. Dosimeter placement in low dose gradient 
regions is also desirable to reduce position derived dose uncertainties. IVD in HDR 
brachytherapy is an extremely challenging arena to achieve treatment verification. The 
geometric relationship between the source and the dosimeter is changing throughout the 
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treatment, the dosimeter is often inserted inside the patient making localisation more 
difficult, detector temperature response effects need to be accounted for, infection 
control (sterilisation) needs to be considered and dosimeters are often positioned in 
high dose gradients. In spite of these potential problems with achieving treatment 
verification, IVD is the most commonly used approach and many authors have made 
significant contributions in order to overcome some these challenges. 
IVD techniques have changed considerably over the past 10 years, with previous 
approaches employing passive detectors that require post-processing of the dosimeter 
before a measurement can be determined. More recently the drive has been toward real 
time verification and so active detectors that can deliver measurement data in real-time 
have been the devices used in recent publications.  
In one of the largest patient studies using a passive IVD technique, Nose et al[62] used 
radiophotoluminescence glass dosimeters to evaluate dose to organs at risk in 66 
patients undergoing HDR brachytherapy for pelvic malignancies. Post treatment 
analysis revealed that discrepancies of over 20% were observed between measured and 
expected dose, with most discrepancies attributed to detector position uncertainty. 
Similar IVD studies involving TLDs have been also been performed. Toye et al [53] 
performed simultaneous measurements of dose profile along the urethra and rectum 
during HDR prostate brachytherapy using TLDs for comparison with the TPS and to 
evaluate apparent implant shifts. The peak differences between the measured and 
planned doses ranged from -34% to 66% for the urethra and -36% to 101% for the 
rectum. The accuracy of the rectal dosimetry measurements were hampered by the 
instability of the rectal catheter containing the TLDs. Anagnostopoulos et al [54] 
investigated the potential of TLD for IVD in transperineal prostate HDR brachytherapy. 
The study reported results for 18 treatment fractions (5 patients). For 2 of the 5 patients 
an additional catheter was implanted into the prostate to accommodate the train of 
TLDs. For the remaining 3 patients, the TLDs were inserted into treatment catheters. In 
this case, the treatment was delivered for all planned catheters, the TLDs were 
removed, and the remaining catheter was used. The agreement of measured values with 
the TPS values after correction of volume averaging effects and transit dose 
contributions showed a range from -2.7% to 8.6% over all measured fractions. No trend 
of increasing or decreasing deviations with fraction number was observed indicating 
that inter-fraction catheter displacement was not occurring. The study provided 
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relatively good agreement between measured and planned dose. However, the authors 
concluded that TLD IVD would be difficult to implement on a daily basis in clinical 
practice due to: (i) the invasive nature of TLD IVD, (ii) the subsequent time consuming 
reading and dose calculation procedure, (iii) the application of relevant correction 
factors and (iv) the fact that TLDs are not real time dosimeters not allowing monitoring 
of operational mistakes and enabling immediate correction. Brezovich et al [40] 
reported IVD measurements with TLDs along the urethra during HDR prostate 
brachytherapy. A linear array of 20 TLDs were loaded into a catheter. At treatment this 
catheter was inserted into the Foley urethral catheter and pushed up to the distal end. 
No imaging was performed at imaging to align the TLD array with the treatment 
region. For the 7 patient fractions reported the peak dose difference range was -11.7% 
to 8.0%. The uncertainty in the position of the TLDs along the urethra was identified as 
a weakness of the method. To address this limitation the authors suggested including 
radiopaque markers in the TLD array and perform imaging for localisation.  
These passive IVD approaches to treatment verification may be acceptable in 
EBRT[63], where dosimetric corrections can be made over many fractions, but this 
technique has limited value in modern HDR brachytherapy where large doses are 
generally delivered one or over only a few fractions.  
Recent dosimeter developments and clinical implementation have focused on active 
IVD techniques that can provide a dosimetric result during or immediately after 
treatment delivery. Waldhausl et al [47] used semiconductor diodes to verify the dose 
delivered to the rectum and bladder for 55 brachytherapy applications for cervix cancer 
patients. The measured doses were compared to the planned dose and for the rectum 36 
of 55 measurements differed by more than 10%, while 12 of 29 measurements of the 
bladder differed by more than 10%. The rectal dose differences showed large 
variations, ranging between -31% to 90% with most measurements reporting a lower 
dose than planned (44 of 55). The authors suggest the observed dose differences are due 
to detector movement (2.5 to 3.5 mm) causing dose differences of more than 10%. A 
geometrical shift of the probe after treatment planning imaging, movements of the 
patient, movement of the organs and applicator are all suggested as contributors to the 
discrepancies in measured dose.  
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Zaman et al [52] also used 5 semiconductor diodes to measure the rectal dose during 
HDR brachytherapy of 11 cervical cancer patients. The measurements differed from the 
predicted TPS values ranging from -8.5% to 41.2%. The authors acknowledged that the 
magnitude of the percentage differences were large and comparable with deviations 
reported by Waldhausl et al [47]. The authors suggest that two of the diodes were more 
prone to geometrical shift in between treatment planning and treatment delivery leading 
to the large observed dose differences. To address the observed dose differences due to 
geometrical displacement, the authors recommend the patient be imaged with a C-arm 
device to confirm the position of the diodes in the rectum just before treatment is 
delivered. 
Seymour et al [48] reported a study for rectal IVD using an array of 5 semiconductor 
diodes during intraoperative TRUS guided HDR prostate brachytherapy using the 
SWIFTTM TPS (SWIFT, Elekta, Stockholm, Sweden) In an attempt to address the 
previously reported IVD measurement uncertainties due to movement of the dosimeter 
in the rectum, the authors developed a device that would retain the position of the 
dosimeter between imaging and treatment delivery. A replica of the TRUS probe was 
constructed to host the diodes to perform the IVD. After the plan was completed the 
TRUS probe was replaced with the replica probe and aligned to fiducial markers using 
imaging. The coordinates for dose point comparisons was determined based on the 
updated positions of the diodes in the probe. The dose differences for the 28 patients 
included in this study ranged from -42% to 35% with 71% of the measurements 
experiencing a difference of less than 10%. The authors concluded that the performing 
dosimetry verification long term on a regular basis may not be economical due to the 
extra work involved.    
In another approach to address the detector position uncertainty issue, Carrara et al[64] 
have reported on the use of a novel prototype device integrating MOSkin 
dosimeters[65] with a trans-rectal ultrasound (TRUS) probe. The advantage of this 
approach is that imaging and the IVD dosimeter is in the same frame of reference, 
reducing the measurement uncertainty due to source to detector position uncertainty. 
Although the source to detector position uncertainty is reduced, the reported difference 
between measured and predicted values ranged from -18% to 19%. It was determined 
that this difference was due to changes in the prostate post imaging (for planning) due 
to swelling therefore introducing discrepancies. Re-imaging the prostate immediately 
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after treatment to re-calculate the source to detector distance (and hence an updated 
expected dose) reduced this measurement discrepancy range down to ~ +/-6%. In this 
case a reduction in dose difference was achieved but required post processing, similar 
to the passive IVD detectors, and therefore may limit the capacity to identify treatment 
delivery errors in real-time.  
In a recent study by Mason et al[46], a single MOSFET detector was used to perform 
IVD treatment verification of HDR prostate brachytherapy. The study reported the 
largest component contributing to the measurement uncertainty budget (from ~6 to 
55%) was the brachytherapy catheter position uncertainty (i.e. the source to detector 
relationship). In that study, a MOSFET was introduced into the mid region of a prostate 
using an additional catheter. Point dose comparisons were made once for each catheter 
and for the total treatment contribution at that point. The largest discrepancies occurred 
for measurements of catheters that were closest to the MOSFET, where the dose 
gradient is greatest, and therefore the positional uncertainties dominated. In a worst 
case example, the total predicted dose at the dosimeter position was due to a single 
catheter and therefore the total treatment uncertainty was large. These large associated 
measurement uncertainties and the use of using one detector (no spatial information), in 
this case limited IVD from achieving overall treatment verification with a high degree 
of confidence.  
The clinical use of a novel scintillation detector system for measuring urethral dose 
during HDR prostate brachytherapy was reported by Suchowerska et al [50]. The fibre 
optic dosimeter (FOD) was inserted into the urinary catheter, for 14 patients, before 
treatment and located with reference to the position of the catheter balloon in the 
bladder. To improve the detector localisation, the FOD was refined to include a radio-
opaque marker. A pre-treatment radiograph was used to adjust the dosimeter position 
prior to treatment delivery for a further 10 patients. For the initial 14 patients measured, 
the reported dose differences ranged from -67% to 9%, with the largest discrepancy 
being attributed to incorrect dosimeter placement. The improvement of detector 
localisation using imaging dramatically improved the agreement with the expected 
dose, with all 10 patients exhibiting a deviation of less than 10% from predicted. These 
reported deviations were suspected to arise from unaccounted for changes in patient 
anatomy.  
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Metal-oxide-semiconductor field-effect transistors (MOSFETs)[64], radioluminescence 
(RL) and plastic scintillation detectors (PSD)[66] all provide some level of real-time 
dose (or dose rate) readout to the operator during the treatment delivery. A summary of 
IVD detector characteristics can be found in Table III of Tanderup et al [1](2013), 
(reproduced in table 2.1) highlighting the strengths and weaknesses of each detector 
type that has been used clinically for IVD in brachytherapy. 
 
Table 2.1.  Characteristics of detectors and dosimetry systems of importance for precise routine 
IVD in brachytherapy. The items are rated according to: advantageous (++), good (+), and 
inconvenient (-). (reproduced from Table III of Tanderup et al [1](2013)) 
 TLD Diode MOSFET Alanine RL PSD 
Size + +/- +/++ - ++ ++ 
Sensitivity + ++ + - ++ +/++ 
Energy dependence + - - + - ++ 
Angular dependence ++ - + + ++ ++ 
Dynamic range ++ ++ + - ++ ++ 
Calibration 
procedures, QA, 
stability, robustness, 
size of system, ease 
of operation 
+ ++ ++ - -/+ +/++ 
Commercial 
availability 
++ ++ ++ ++ - + 
Online dosimetry - ++ + - ++ ++ 
Main advantages No cables, 
well 
studied 
system 
Commercial 
systems at 
reasonable 
price, well 
studied 
system 
Small size, 
commercial 
system at 
reasonable 
price 
Limited 
energy 
dependence, 
no cables 
Small size, 
high 
sensitivity 
Small size, 
no angular 
and energy 
dependence, 
sensitivity 
Main disadvantages Tedious 
procedures 
for 
calibration 
and 
readout, 
not online 
dosimetry 
Angular and 
dependence 
Limited life 
of detectors, 
energy 
dependence 
Not 
sensitive to 
low doses, 
tedious 
procedures 
for 
calibration 
and readout, 
not online 
dosimetry, 
expensive 
readout 
equipment 
not 
available in 
clinics 
Needs 
frequent 
recalibration, 
stem effect, 
not 
commercially 
available 
Stem effect 
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The capability of IVD approaches to identify treatment delivery errors is limited by the 
uncertainty budget associated with performing the measurement in vivo. Kertzscher et 
al [55] identified that many IVD approaches for identifying a treatment delivery error 
judge these treatments based on static reconstructions of the detector position. The large 
reported deviations between measured and planned doses from previous IVD studies 
suggest that only gross treatment errors could be confidently identified. In the reported 
study, the authors did not base the error detection algorithm on a priori dosimeter 
position but instead used a data driven approach. The study showed that IVD sensitivity 
to treatment errors could be improved by adopting this approach, but for a single 
dosimeter implementation, a swapped channel error was less likely to be identified.  
One common limiting theme for many reported IVD studies is the source to detector 
position uncertainties contributing to a large uncertainty in the ability to detect 
treatment errors. IVD approaches lack the spatial information required to identify 
certain error types. IVD can provide valuable information about the dose received by 
the organ containing the dosimeter. In this application, IVD can act as a monitoring 
system verifying the dose received by the organ does not exceed some specified 
threshold.  
2.2 Treatment Delivery Verification 
In principle, the HDR brachytherapy treatment can be verified without measuring dose, 
but by measuring the position of the source within the patient and the time the source 
dwells at each position. If these parameters are correct, and their absolute position 
relative to the patient anatomy is correct, then it can be concluded that the treatment 
was delivered as intended. This is only strictly true if the specified TPS air kerma rate 
(AKR) of the source matches the actual source in the afterloader. Unlike EBRT, where 
the beam output parameters may be incorrect, the HDR brachytherapy source AKR is a 
well defined function of the initial measured AKR and time. The source AKR is an 
afterloader machine parameter that should be correctly defined during the quality 
assurance program in conjunction with other afterloader functionality tests. The 
inclusion of a dose rate, or activity, sensitive detector measurement is a useful addition 
to source position and dwell time verification. 
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2.2.1 Source Tracking 
The notion of tracking the HDR brachytherapy source as it moves through the 
programmed treatment has been previously reported for the purposes of afterloader 
quality assurance. Evans et al [67] described the use of radiochromic film to perform 
source position verification. This approach provided an accurate method to verify 
programmed dwell positions against measured dwell positions, and is particularly 
useful during applicator commissioning. Rickey et al [68] designed a useful tool that 
also incorporated radiochromic film to validate programmed source dwell positions. 
The custom device was intended as a pre-treatment quality assurance tool to perform 
source position and dwell time checks. Nakano et al [69]reported on a feasibility study 
to determine the position of the source using three diamond detectors to perform a 
triangulation calculation based on the response from each detector. The authors 
reported challenges associated with detector correction factors and the uncertainties 
associated with source to detector distances. Duan et al [59] investigated the possibility 
of using a pinhole camera imaging system for real time monitoring of the source 
position. A commercial dual-pinhole collimator was used for measurements and was 
able to reconstruct the source positions in 3D. The approach was unable to resolve 
source step sizes of 2.5 mm and data was processed retrospectively. The use of an 
imaging detector to locate the brachytherapy source was reported by Song et al [70]. In 
this phantom based study, the detector was coupled to an array of ball bearings and the 
projected shadows were used to determine the source position. A sequence of 10 mm 
spaced dwell positions were measured and the system determined the distance between 
dwells to a mean difference of 0.7 mm. The authors noted the significantly larger 
uncertainty (approximately 10 times) in measured SDD compared with the position in 
the plane of the detector. Another challenge of this system was ensuring the projected 
ball bearing shadows remained on the sensitive region of the detector. The novel 
‘magic phantom’ device, consisting of a 2D (11 ×11) array of diodes, was reported by 
Espinoza et al [60, 71]. The magic phantom was used to verify synthetic patient plans 
delivered to the solid water phantom and identify errors that had been introduced to the 
plan. The authors reported the system can identify source position errors greater than 
1.3 mm and dwell time errors greater than 0.3 seconds. A plastic scintillator block and a 
charge-coupled device camera system was used by Kojima et al [72] to measure source 
position applying a method previously used for particle beam quantification. For the 
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purpose of quality assurance, the authors were able to measure a source step size of 5 
mm to a very high precision.  
The approaches described above all attempt to verify the position and movement of the 
source in a phantom geometry for system quality assurance or plan pre-treatment 
verification. As far as the author is aware, there has been no published data on 
quantitative approaches to source tracking in the clinical setting. This may represent the 
significant challenges that need to be overcome to achieve such a system. The use of 
continuous imaging during the patient’s treatment has been reported for treatment 
verification. A recent publication by Nose et al [73] used a modified C-arm 
fluoroscopic unit to perform real-time source tracking for the purposes of treatment 
verification. The approach uses continuous imaging to observe that the source is in the 
vicinity of the planned positions and correct relative to the patient’s anatomy. The 
system has the advantage of real-time monitoring enabling treatment interruption if 
required. Quantitative determination of source positions was not performed in that 
study, but rather the treatment staff observe the source travel during treatment and refer 
to a plan printout for verification. The approach is likely only to identify gross source 
position errors, and as reported by the authors, an error detection limit of 5 mm was 
possible but may be greater due to the subjective approach to compare the plan printout 
to the fluoroscope image in real time. 
2.3 Pre-Treatment Verification Imaging  
Pre-treatment verification of the catheter positions for HDR prostate brachytherapy has 
been reported by many authors. Early attempts to verify the catheter positions were 
performed using film. Damore et al [32] performed a retrospective study on 96 patients 
to determine if significant displacement of the catheters had occurred between 
treatment fractions. The first and second fraction AP radiograph films were analysed 
and the catheter displacements determined based on implanted fiducial markers. A 
mean displacement of 7.6 mm was reported and as a result the authors recommended 
large margins (up to 10 mm) to be added to the treatment volume to account for the 
shifts observed in this study. 
Martinez et al [74] also assessed inter-fraction catheter motion by performing 
fluoroscopic imaging on 10 patients between treatment fractions. The study compared 
catheter positions with bony anatomy, and reported a mean inferior displacement of 20 
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mm. Hoskin et al [31] used CT data to evaluate inter-fraction catheter displacement for 
20 patients. A CT scan was acquired on day 2 prior to treatment delivery to assess 
displacement relative to the prostate. The CT data sets were evaluated by comparing the 
position of catheter tips with bony landmarks and the prostate gland from day1 to day 2 
CT. A mean displacement of 11.5 mm relative to the prostate was reported. The authors 
acknowledged that catheter movement is an important issue and recommended that 
routine CT imaging be performed before each treatment fraction, and that flexibility is 
built into the implant to allow adjustments to be made. 
Many studies have followed evaluating catheter displacements, with the majority using 
CT as the preferred imaging modality and fiducial markers in the prostate as the 
reference element to assess displacement. A summary of these recent studies is shown 
in table 2.2  
Table 2.2. A summary of the studies performed to assess inter and intra-fraction catheter 
displacement in HDR prostate brachytherapy. P-F2 indicates the assessment was performed 
between the period of treatment planning imaging and second treatment fraction. P-F1 indicates 
the assessment was performed between treatment planning imaging and pre-treatment imaging. 
Study (Year) No.  
Patients 
Imaging 
modality 
Assessment Period Mean displ. 
(mm) 
Damore (2000) [32] 96 Film Fiducial markers P-F2 7.6 
Martinez (2001) [74] 10 Fluoroscopic Bony anatomy P-F2 20.0 
Hoskin (2003) [31] 20 CT Bone & Prostate 
anatomy 
P-F2 11.5 
Mullokandov (2004) [36] 50 CT Bony anatomy P-F2 2.0 
Kim (2007) [34] 10 CT Fiducial markers P-F2 5.5 
Simnor (2009) [75] 20 CT Prostate P-F2 7.9 
Tiong (2010) [76] 91 Radiograph Fiducial markers P-F2 5.4 
Yoshida (2010) [77] 64 CT Fiducial markers P-F2 7.0* 
Whitaker (2011) [33] 25 Radiograph Fiducial markers P-F1 7.5* 
Holly (2011) [35] 20 CBCT Fiducial markers P-F1 11.1 
Takenaka (2012) [78] 30 CT Fiducial markers P-F2 4.3 
Kovalchuk (2012) [79] 26 CT Fiducial markers P-F2 2.3+ 
Huang (2013) [80] 13 CT Fiducial markers P-F1 6.2 
Kawakami (2014) [37] 30  CT Fiducial markers P-F1 6.0 
Peddada (2015) [81] 33 CT Fiducial markers P-F2 1.0 
* Yoshida &Whitaker report the median displacement. 
+ Kovalchuk report mean displacement after readjustment. 
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Some of the studies in table 2.2 report measured catheter displacements calculated 
between the imaging data used for treatment planning (commonly CT) to imaging 
performed prior to treatment of fraction 2 (denoted as P-F2). Of these studies, 64% 
reported a mean catheter displacement of at least 5 mm and a maximum mean 
displacement of 20 mm. Often the period between treatment planning imaging and the 
delivery of the first fraction is on the order of many hours, and so some studies have 
evaluated the catheter displacement occurring during this period. Of these studies 
shown in table 2.2, all report a mean displacement of at least 6.0 mm. All of these 
authors recognised the potential impact this displacement could have on the patient’s 
dosimetry and suggested catheter position adjustment to correct the observed shifts. 
One notable outlier of these studies is the reported 1.0 mm mean displacement from 
Peddada et al [81]. The authors suggest the method for performing the procedure 
(preparation, implantation and postprocedural care) most likely account for the 
negligible catheter displacements observed. 
Many of the studies in table 2.2 use CT based treatment planning and so the patient is 
moved multiple times between the operating theatre (the implant procedure), imaging 
and treatment (bunker). An alternative approach is to perform all of these steps in the 
one setting. Known as ‘intra-operative’ or ‘real time’ HDR prostate brachytherapy[82], 
the approach is performed in a shielded operating theatre, with the patient anaesthetised 
in the lithotomy position. The Radiation Oncologist implants the prostate with TRUS 
guided imaging, which is also used to acquire the volumetric data of the prostate for 
treatment planning. The treatment plan is created and the treatment is delivered to the 
patient while still in the lithotomy position. The trade-off for this approach is a 
dedicated bunker (or operating theatre) is required, and additional specialised medical 
staff available. Typically, the time between implanting the catheters and the delivery of 
the first fraction on the order of a few hours, the influence of catheter displacement is 
reduced but not eliminated and still warrants confirmation. The study by Carrara et al 
[64] showed that re-imaging the prostate after treatment improved the IVD result. The 
study also noted that times greater than 1.5 hours between US image acquisition for 
planning and treatment delivery significantly increased the verification measurement 
uncertainty due to source to detector position changes resulting from intra-fraction 
changes of the prostate. Similar intra-fraction displacements have been identified by 
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Whitaker et al [33] showing up to 23.9 mm catheter displacement possible in the 
relatively short period between planning and treatment. 
The pre-treatment imaging studies have identified displacements, but in most cases 
these imaging assessments are not performed in the treatment bunker, and so patient 
transfer and setup for treatment may induce additional catheter displacements. The 
ideal approach would be to evaluate catheter displacements in the treatment bunker 
immediately prior to treatment delivery. 
Electromagnetic tracking (EMT) technology is an emerging development that has been 
applied to HDR prostate brachytherapy in preliminary proof of principle studies[83-85]. 
The system uses an electromagnetic field generator and a sensing unit to map the 
position of a sensor as it is passed through each brachytherapy catheter. to define the 
implanted catheter paths within the patient. The system reported by Beaulieu et al [86] 
can reconstruct a catheter path in the order of 10 seconds and define the catheter tip to 
better than 1mm accuracy. The system has the capability to define catheter paths for 
planning and repeat the process for verification as subsequent treatment fractions. 
2.4 Summary 
The efforts to perform treatment verification in HDR brachytherapy highlight three 
major shortcomings; (i) the source to detector uncertainty in IVD is a considerable 
challenge to overcome and has been acknowledged by many authors, (ii) the prohibitive 
nature of the additional work and time required to perform verification and (iii) the 
localisation of measured source dwell positions relative to the patient’s anatomy is a 
key element in order to validate treatment to the correct (spatial) target/anatomy. A true 
solution to treatment verification will overcome all of these limitations. 
To perform treatment verification effectively in the clinical setting, that is pre-treatment 
image verification and source tracking, a structured approach is required to achieve a 
reliable reference to compare against. Current methods to detect catheter displacements 
in prostate HDR brachytherapy use successive imaging and typically apply point based 
measurements (from the catheter tip) to evaluate any implant changes. The catheter tip 
is not (usually) the clinically relevant region of the implant, but the catheter positions 
need to be correct where the dose will be delivered. Therefore, verification should be 
performed against the treatment plan, assessing the path of the catheter, to provide a 
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detailed assessment of the implant geometry. In the clinical treatment verification 
scenario, there are 4 frames of reference that need to be combined in order to 
implement a quantitative verification approach. These are the patients’ anatomy, the 
brachytherapy implant (catheters/applicator), the source tracking/pre-treatment imaging 
device and the treatment plan. The current status of the field of HDR brachytherapy 
lacks any mechanism to combine these frames of reference to provide a reference set 
for verification. EBRT has been verifying treatment delivery against the treatment plan 
in a quantitative approach for some time, using the technologies of treatment room 
imaging[87, 88] and portal dosimetry[89, 90]. HDR brachytherapy needs to achieve the 
same standard of quality treatment delivery. 
The aim of this work was to develop a system to perform source tracking during 
treatment delivery. The proposed solution was to use a FPD for both source tracking 
and pre-treatment imaging. This would enable verification of the implanted catheters 
with the positions defined by the treatment plan, and allow verification of source dwell 
positions relative to the patient’s anatomy.  
This thesis aims to characterise the response of the FPD to the 192Ir source (spectrum), 
develop methods to determine the position of the source in 2D (detector plane) and 3D 
(inside the patient), establish methods to perform pre-treatment imaging (2D and 3D) in 
the treatment bunker, register the measurement space with the TPS and identify catheter 
possible displacements to a clinically relevant uncertainty. An additional aim is to 
integrate the approach into a clinical environment to better understand the practical 
needs of clinical staff. 
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3 Introduction 
The detector device used during this study was a FPD, which previously was used as an 
EPID on a Varian linear accelerator (LINAC) (2100C Clinac, Varian Medical Systems, 
Palo Alto, CA, USA). The FPD was physically removed from the LINAC during 
decommissioning and operated as a stand-alone detector.  
EPIDs were originally designed for geometric verification of the patient setup during 
EBRT, but have also been used to obtain dosimetric information – either pre-treatment 
verification or for in vivo dosimetry[91-94]. In principle, the dosimetric and geometric 
verification techniques developed in EBRT, can, with adaptation, be applied to HDR 
brachytherapy. Dose response characteristics of EPIDs have previously been 
determined for the megavoltage x-ray range[95, 96], but have not been demonstrated 
for an 192Ir HDR brachytherapy source. 
This chapter covers the measurements performed to characterise the response of this 
FPD for use with the 192Ir HDR brachytherapy source. Each characterisation 
experiment has its own section describing the method and results obtained, with the 
overall outcomes discussed at the end of the chapter. The content of this chapter is 
based on the publication Smith et al[97]. Part of that publication describes algorithms 
used to determine the brachytherapy source position, and that work is described in 
chapter 4. 
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3.1 Detector Characteristics 
The flat panel detector is an amorphous silicon (a-Si) electronic portal imaging device 
model aS-500. The device has a 400 × 300 mm2 detection area with a pixel pitch of 
0.784 mm (512 × 384 pixels), a 1 mm copper build-up layer, a scintillating screen of 
Gadolinium Oxide (Gd2O2S:Tb) and hydrogenated amorphous silicon (a-Si:H) 
photodiode array[98]. The flat panel detector is controlled using the image acquisition 
system (IAS2) hardware controller and operated using the ‘AM-Maintenance’ software 
version 7.1.2005.628 on a computer workstation, as shown in figure 3.1. 
 
Figure 3.1.  (a) The flat panel detector used in this work, model as-500 EPID from Varian 
Medical Systems. (b) The image acquisition system (IAS2) and the ‘AM-Maintenance’ 
software used to control the detector.  
 
The detector system is used to acquire images, where an image is defined as the 
average of all frames captured between start and stop signals and is corrected for dark 
current and response non-uniformity of the detector pixel array. A single frame is the 
read-out of the entire detector pixel array and an image is the average of frames 
acquired during the capture period. The FPD response (image or pixel array value) 
represents the average dose rate at the detection plane.  
(a) (b) 
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It should be noted that the term image when used in context for capturing the 2D 
distribution from the 192Ir source refers to an array of pixels, and does not contain a 
one-to-one correspondence of points in the image to points in the object, as in the 
‘optics’ sense. 
3.2 Initial Evaluation 
Exposures acquired from the brachytherapy source contain information that can be 
interpreted to potentially obtain source position and dosimetric data. Figure 3.2 
illustrates the change of FPD response as the source is moved away from the detection 
plane. The intensity of the response and shape of the profile clearly changes with source 
to detector distance (SDD), reflecting the change in dose rate. The distribution can also 
be used to localise the source position in the 2D plane of the detector and potentially 
the perpendicular distance from the detector plane. 
 
Figure 3.2.  Images acquired with the FPD system for the brachytherapy source at two different 
source to detector distances (SDD). (a) A SDD of 50mm and a line profile showing the 
intensity and shape of the detector response and (b) at a SDD of 100mm.  
 
Using the principles of EBRT verification, it is possible to interpret the FPD image as a 
transit (exit) dose distribution for a source within the patient. In order to initially 
evaluate this detector response, the acquired FPD image was compared to the dose 
exported from the TPS, for a source in a solid water phantom as shown in figure 3.3. 
50mm SDD 100mm SDD 
(a) (b) 
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Figure 3.3.  (a) The TPS sagittal view of the solid water phantom used for experimentation 
showing a single catheter path, a dwell position and the surrounding isodoses. (b) A 3D 
visualisation of the catheter path within the reconstructed phantom above the flat panel detector 
depicted in yellow. (c) The TPS coronal view of the source in the phantom showing the 
distance of the source to the flat panel detector. (d) A photo of the solid water phantom with a 
transfer tube attached, placed above the flat panel detector. 
 
We can compare the response with that generated by a TPS, which uses the TG-43 dose 
calculation formalism[99], in order to establish the raw agreement, normalised at the 
maximum response. It is observed in figure 3.4 that there are differences in the raw 
response, but also similarities that suggest the detector is a useful tool for treatment 
verification. 
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Figure 3.4.  The comparison of FPD response with the response predicted by the TPS using a 
TG-43 calculation algorithm. For comparison, the data is normalised at the maximum response 
and profiles aligned to this normalisation position. 
 
There are a number of factors expected to contribute to the observed discrepancy in 
detector response. These include the detector not being tissue equivalent, possible dose 
rate non-linearity, detector directional dependence, and finite phantom geometry size 
causing a reduced or asymmetric photon scatter field which may also influence the 
response. Energy dependent response of the FPD, as other authors have shown[95], 
may also impact the response, as a large fraction of photons reaching the detector at 
extended distances are lower energy scatter. The TG-43 dose calculation is also a poor 
estimate of dose at large distances from the source or when inhomogeneities are 
present. Therefore, we can expect large discrepancies between the predicted TPS curve 
and the raw (uncorrected) FPD measurement. 
 
The aim of this application is to use the FPD as a treatment verification device, it is not 
necessary for the FPD device to measure ‘true’ dose to water. The goal of treatment 
verification is to provide evidence the planned treatment is delivered without error, and 
so the response of the FPD should represent the expected result as predicted by the 
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TPS, and not deviate simply due to the limitations of the TG-43 algorithm. The 
evaluations made in the following sections reflect the comparisons of the FPD response 
with the TG-43 algorithm.  
The response of the FPD was characterised across a range of exposure conditions. The 
following sections detail the experimental method performed, the results observed, and 
factors contributing to observed deviations are assessed and methods for correction are 
established. 
3.3 Response to Photon Energy 
To determine the response of the FPD as a function of x-ray energy, for the same dose 
at the FPD surface, the FPD was exposed to a range of photon sources using facilities at 
the ionising radiation standards laboratory of the Australian Radiation Protection and 
Nuclear Safety Agency (ARPANSA). The ‘SIEFERT’ orthovoltage x-ray system 
(Isovolt 450/9, Rich. Seifert & Co) produces ISO 4037 standard ‘narrow-spectrum’ 
series x-ray beams[100] using a constant potential tungsten target x-ray tube and 
specified filtration. The FPD was set at 1 m from the x-ray source and exposed to seven 
ISO 4037 beams, with effective energies ranging from 48 to 251 keV. The effective 
energy of the x-ray beam is defined as the energy of a mono-energetic beam having the 
same half value layer (HVL) in Cu as the ISO narrow x-ray beam. 
To mimic the energy of the major peak in the 192Ir spectrum[101] at 317.5 keV, the ISO 
4037 formalism was extended to establish an additional higher energy x-ray beam on 
the ‘SIEFERT’ system. The x-ray tube potential (kVp) for this beam was 400 kV with a 
beam filtration of 6.6 mm Pb + 2 mm Sn + 4 mm Al, to produce an effective x-ray 
energy of 317.5 keV. The FPD was also exposed to 60Co (1.2 MeV), 137Cs (662 keV) 
and 192Ir isotope sources and a 6 MV Varian EX linear accelerator beam.  
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Figure 3.5.  The normalised flat panel detector response for a range of incident kilovoltage 
photon beams, isotopes and a 6MV linear accelerator (LINAC) beam. 
 
The FPD exhibits an over-response to incident photons at relatively low energies in the 
radiotherapy arena, with a peak response at approximately 100 keV, as seen in figure 
3.5. This has implications for use as a dosimetry validation tool for HDR brachytherapy 
and energy dependence must be incorporated into the dose calibration procedure. When 
exposed to an 192Ir source, at large distances, a substantial component of the dose to the 
FPD will consist of low energy scattered radiation[102] and this should be considered 
when applied in the clinical scenario where SDDs of 80 to 160 mm are expected. 
The hypersensitivity of the FPD to low energy photons, also reported by Kirkby[95] in 
the EBRT case, is an important characteristic to consider when planning to use such a 
device for dosimetry purposes. 
3.4 Response to Dose Rate 
A dose rate response measurement was performed at a fixed SDD geometry of 100 mm, 
over the clinical life of the source, in order to achieve a decline in dose rate without a 
change in the energy spectrum. A 300 x 300 mm solid water phantom containing a 
brachytherapy catheter was placed against the face of the FPD and the source driven to 
a central position. Exposures were acquired with the source at the central position and 
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the response was recorded for a 5x5 pixel region of interest (ROI) centered at the peak 
of the response. Over the period of approximately 3 months, the source decayed from 
3.866 to 1.680 cGy∙m2/h. The dose rate at the surface of the FPD for each measurement 
was calculated using the treatment planning system. 
 
Figure 3.6.  The dose rate response of the FPD measured in a solid water phantom, at a source 
to detector distance of 100 mm, over a period of approximately 3 months. 
 
While maintaining a constant energy spectrum reaching the FPD by using a fixed 
geometry, the FPD shows a highly linear (R2=0.9993) response to dose rate at 100 mm 
SDD (Figure 3.6). The SDD of 100 mm represents a typical patient source dwell 
position (mid-implant) to posterior treatment couch surface, as determined by 
evaluating approximately 50 patient CT scans. The error bars in figure 3.6 are 
approximately the size of the data point markers and represent one standard deviation 
of response of image pixels within the ROI (5x5 pixels) measured. These results show 
linearity over a clinical dose rate range at this SDD (approximately 0.05 to 0.12 cGy/s).  
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3.5 Response to Depth Dependent Spectral Change 
The response of the FPD was shown to vary non-linearly with photon energy and so 
was therefore expected to vary as a function of source to detector distance. This change 
in response to depth dependent spectral change was evaluated using a 300 x 300 mm 
solid water phantom containing a brachytherapy catheter, as previously depicted in 
figure 3.3. The source was driven to the central position of the phantom and images 
acquired for a range of SDDs (50, 80, 100, 120, 150, 180, 200 and 250 mm) for the 
same source activity.  
 
Figure 3.7.  The normalised FPD response measured in the solid water phantom of figure 3.3, 
at an SDD of 50, 80, 100, 120, 150, 180, 200 and 250 mm. The TPS TG-43 dose and the 
inverse square curve is also shown for comparative purposes. 
 
The over response of the FPD to scattered (low energy) radiation implies that the 
relationship between dose rate and FPD response output will change with SDD due to 
the changing primary to scatter ratio. Figure 3.7 compares the measured response fall-
off and an inverse square curve normalised to a SDD of 50 mm. The measured response 
lies above the inverse square curve, rather than below as would be expected considering 
photon attenuation (See TG-43 curve in figure 3.7). This highlights the influence of 
FPD over response to low energy scattered radiation at intermediate source to detector 
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distances. In section 3.10, we describe a solution to manage the spectral dependence, by 
employing a semi-emperical depth dependent calibration procedure. 
3.6 Response Reproducibility 
The response reproducibility of the FPD was investigated for a range of SDDs (50 to 
180 mm) using images acquired with 250, 100, 10 and 2 frames per image, to quantify 
the effect of image acquisition time. 
 
Figure 3.8.  The normalised detector response measured in the solid water phantom detailed in 
Figure 1, with an SDD of 100 mm.  (a) Measurements acquired with 2, 10, 100 and 250 frames. 
(b) Consecutive measurements acquired at 15 minute intervals with 250 frames. 
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To evaluate charge build-up effects (slight under response observed in short 
irradiations) as identified in EBRT studies[103], a series of consecutive acquisitions 
was made for each acquisition duration (2, 10, 100 and 250 frames; frame rate = 8.6 
frames/s).  
To further investigate the response reproducibility over time, the process was repeated 
at 15 minute intervals, acquiring six consecutive images each with 250 frames. 
The response of the FPD over successive images acquired with the source at a single 
dwell position shows an initial response lag over successive measurements until a 
stable value is achieved. This lag effect has also been reported by other 
investigators[103-105]. Decreasing the number of frames per image increases the 
number of measurements required, but decreases the irradiation time, before stability is 
reached (Figure 3.8(a)). Repeated measurements confirm that this behaviour is highly 
reproducible (see Figure 3.8(b)).  
The response of the FPD over a series of images at 15 minute intervals shows that the 
lag effect is the same over a 90 minute time period (Figure 3.8(b)). All data sets fall 
within a range of 0.3 % of the first (0 minute) data set. All data points were normalised 
to the average response value of the last 5 data points of the first acquisition set 
collected at time of 0 minutes. Since the lag effect is so reproducible, we can be 
confident the implementation of an empirical correction factor can be applied to 
measurements taken within the first 3 image acquisitions of a sequence. 
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Figure 3.9.  The FPD response uncertainty as a function of dose rate at the FPD for image 
acquisitions with 250, 100, 10 and 2 frames. 
 
The uncertainty of the FPD response was determined by calculating one standard 
deviation of the pixel range in the 5x5 ROI used for calculation of the response. The 
standard deviation was assessed as a function of the number of frames used in the 
image acquisition. Figure 3.9 shows the increasing uncertainty of response as the 
number of frames are reduced. Typically measurements at larger SDDs will result in 
lower dose rates and an increased uncertainty. 
3.7 Off Axis Response  
Prompted by discrepancies in the SDD dependent response measurements the incident 
angle dependence was investigated. The under response of the FPD at off axis positions 
relative to points aligned with the HDR brachytherapy source central axis at an equal 
SDD (Figure 3.10) were plotted against incident angle, θ, at the FPD surface. This was 
used to derive a fitted angular correction factor. 
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Figure 3.10.  The linear distance d from the source at position A to the detector ROI is the 
same as the distance d’ from the source at position B to the detector ROI with an incident angle 
of theta. The ratio of response between the two ROI for the same linear distance defines the 
incident angle response of the FPD. 
 
The measured off axis response of the FPD was shown to under respond relative to the 
central axis case, where the linear distance from the source to the FPD surface was the 
same. This means that the calibration factor at the perpendicular position does not apply 
at the equivalent distance off axis from the source position (i.e. for a smaller SDD). The 
relative response as a function of incident angle between the FPD plane and the ray line 
from the source to the measurement point/pixel can be used as an empirical correction 
function to the dose rate calibration (Figure 3.11). 
θ 
Solid Water 
d 
Flat Panel Detector 
Response ROI 
d' 
A 
B 
 
 Chapter 3: Flat Panel Detector Characterisation for 192Ir Measurement 
49 
 
Figure 3.11.  Incident angle correction factor for each pixel in the FPD image accounting for 
the observed off-axis response change. Note the truncated vertical axis. 
 
Figure 3.11 represents the under-response of the FPD for pixels that are off axis relative 
to the central axis case, where the linear distance from the source to the FPD surface is 
the same. The response correction factor can be fitted with a polynomial given by 
equation 3.1. 
𝑅𝑒𝑠𝑝𝑜𝑛𝑐𝑒 𝐶𝑜𝑟𝑟. = −6 × 10−5𝜃2 + 0.0098𝜃 + 0.5815 Eqn. (3.1) 
The reason for this under response at decreasing incident angles is not clear, but it is 
likely that the process of interaction of the photons with the scintillation layer at a 
narrow angle is different when compared to the perpendicular case. The deposition of 
charge to the photo diodes is less efficient or spatially less well defined for the narrow 
angle case. Additional reasons for under-response may be due to the greater effective 
thickness of the copper plate at narrow incident angles, especially for low energy 
photons, as well as the reduction of scatter off axis due to the finite size of the solid 
water phantom. 
The observed behaviour of the response suggested as incident angle response, but 
further analysis indicated that it was a combination of incident response and scatter 
conditions. Isolation experiments were performed to establish the contribution from 
each component. These are described in the next 2 sections. 
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3.8 Response to Source Orientation 
The orientation of the source relative to the plane of the FPD may influence the 
response observed. All previous investigations in this chapter have been performed 
with the long axis of the source parallel to the plane of the detector. In order to evaluate 
the influence of source orientation on detector response, a solid water slab was 
customised by cutting grooves to hold the plastic brachytherapy catheter at different 
angles relative to the FPD plane. The central piece was designed to rotate to allow each 
catheter to deliver the source to a rotational centre. 
 
Figure 3.12.  The solid water slab used to evaluate the influence of source orientation on the 
FPD imaging plane. The internal circular phantom can rotate to accommodate a brachytherapy 
catheter at each angular position θ. 
 
The custom solid water slab depicted in figure 3.12 was set up in a solid water phantom 
(300300300 mm) with the slabs of the phantom oriented vertically to accommodate 
the custom rotational slab.  
The brachytherapy catheter was initially setup parallel to the plane of the FPD (θ = 0°) 
and the source was driven to the central position of the phantom at the point of rotation 
and an image acquired. The catheter was then repositioned at each rotational position 
and images acquired at each increment.  
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Figure 3.13.  The experimental setup of the phantom to capture exposures with the 
brachytherapy source. The rotation of the source in the plane perpendicular to the FPD surface 
(out of the page). Profiles in the x and y axis were acquired as the source was rotated to each 
position. The orientation of the solid water phantom slabs are shown by the dashed lines. 
 
To evaluate the response change as a function of source rotation, profiles were 
extracted from the acquired images in the x and y planes as illustrated by figure 3.13.  
The acquired profiles were normalised to the central axis position of the FPD for the 
θ=0° acquisition, directly below the source. The results are shown in figure 3.14(a) for 
the x axis profiles and 3.14(b) for the y axis profiles. 
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Figure 3.14.  (a) The x axis profiles and (b) the y axis profiles of the acquired exposures of the 
source as the source is rotated from 0° to 90° relative to the imaging plane of the FPD. 
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The profiles acquired along the x axis show small discontinuities in the response near 
the profile peak. This arises from the vertical orientation of the solid water slabs, 
possibly due to a small gap, allowing transmission to occur between the slabs.  
The observed decrease in response of the FPD as the source is rotated is illustrated in 
figure 3.15 and is primarily due to the self-attenuation of the source. The source cable 
does not contribute to attenuation as it is not between the source and FPD. 
 
Figure 3.15.  The central axis response of the FPD for a 5 x 5 pixel ROI as the source is 
rotated. Note the y axis scale. 
 
As expected the shape of the profiles in the x axis do not change as the source is 
rotated. An asymmetry of the profiles in the y axis is observed as the source is rotated 
in this plane.  
The potential application of this verification system will initially focus on prostate 
brachytherapy, where catheters are likely to be parallel or at an angle of up to 30 
degrees to the FPD. The extension to gynaecological brachytherapy applications will 
potentially include brachytherapy applicators that will orientate the source at large 
angles relative to the FPD. 
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3.9 Finite Phantom Geometry 
Finite phantom geometries are expected to be a contributing factor to discrepancies 
observed between the measured response of the FPD and what is predicted by the TPS, 
if the closest air boundary is near enough the measurement point. The TG-43 formalism 
assumes an infinite uniform phantom surrounding the source, but a finite phantom 
geometry will create photon scatter disequilibrium, and considering the observed over 
response of the detector to low photon energies, the measured FPD response is 
expected to be affected.  
To investigate this influence of finite phantom geometry, a solid water phantom was 
created so slabs adjacent to the source could be removed, as illustrated in figure 3.16, to 
produce an asymmetric scattering geometry around the source position.  
 
Figure 3.16.  The experimental setup for investigating the influence of surrounding phantom 
geometry on FPD response. Slabs of solid water phantom are removed at each measurement 
increment to produce an asymmetric phantom geometry around the source position. 
 
The phantom consisted of 300 × 300 mm solid water slabs, with an additional 4×50 mm 
slabs of solid water to create a symmetric phantom around the source dwell position. To 
mimic the geometry of a source inside a patient, a SDD of 80 mm was used with an 
additional 60 mm of solid water was placed above the source. The position of the 
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phantom and source was aligned to be at the centre of the FPD in order to evaluate the 
expected asymmetric response. 
The source was driven to the dwell position and a FPD image was acquired. Solid water 
slabs of 50 mm thick increments (A, B, C and D) were removed and images acquired at 
each increment. 
 
Figure 3.17.  The FPD image for the asymmetric phantom geometry, with 50 mm of solid 
water adjacent to the source position. Image response profiles were extracted across the FPD 
from a to b, as illustrated.  
 
The mean FPD response for a 5×5 pixel region of interest (ROI) located at the centre of 
the FPD was calculated for each image and normalised to the response for the 
symmetric phantom case. FPD response profiles were also extracted from the images, 
as shown in figure 3.17, at each phantom geometry.  
The resulting FPD response as a function of adjacent phantom size is shown in figure 
3.18. It can be seen that a minimum of 150 mm of surrounding phantom material is 
required to maintain equilibrium in the photon scatter field and not impact the detector 
response. With less than 150 mm of phantom material, the response of the detector at 
the ROI reduces, emphasizing that photons scattered from slab ‘C’ (figure 3.17) 
influence the response of the ROI below the source position. 
a b 
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Figure 3.18.  The FPD response at the ROI position depicted in figure 3.17 as a function of 
adjacent phantom size. Note the truncated vertical axis. 
 
The influence of scattered photons on the response of the detector can also be evaluated 
by extracting response profiles (figure 3.19). It is clear for a full symmetric phantom 
geometry (250 mm of phantom material surrounding the source), the response profile is 
symmetric and the peak position appears at the source dwell position, centered on the 
FPD (at 150 mm). As the slabs are removed the profiles remain consistent for 200 and 
150 mm, but exhibits a deviation for 100 mm of scatter material. The effect is then 
emphasized when only 50 mm of scattering material is present, causing the peak of the 
profile to shift slightly away from the edge of the phantom (see 50 mm Scatter profile 
in figure 3.19), and so not coinciding above the actual physical source position. A 
change in the tailing of the 50 mm Scatter profile can be seen at a position of 
approximately 80 mm, due to part of the FPD being uncovered (phantom material 
removed), and the attenuation path from the source being radiologically shorter.  
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Figure 3.19.  The FPD response profiles for changes in the adjacent phantom size for the 
source position as illustrated in figure 3.16. 
 
The decrease of response in figure 3.18 indicates that a minimum of 150 mm adjacent 
scatter material is required to maintain an unchanging photon phantom scatter field, and 
not cause an asymmetric response of the FPD. This result is also supported by the 
earlier profile of figure 3.4 where the source was at the centre of a 300  300 mm 
phantom, producing a symmetric FPD response. 
The influence of finite phantom geometry is an important characteristic when 
considering the use of this device in the patient case. Treatment sites close to the skin 
(e.g. Interstitial Breast) or for prostate, where the perineum space is less than 150 mm 
from the prostate, a reduced detector response is likely and will need to be considered.  
3.10 Dose Rate Calibration 
The potential use of the FPD as a dosimetric verification device required calibration of 
the detector response with dose. When performing a verification dose measurement, the 
purpose of this system will be to validate delivery of the planned treatment, therefore 
the system is calibrated against the TPS (TG-43). The FPD response to dose rate is 
photon energy spectrum dependent and therefore depth dependent, as well as incident 
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angle dependent. A semi-empirical calibration procedure was developed to include 
these dependencies. 
A relationship between TPS derived dose rate and FPD response for a 5×5 pixel ROI 
was measured over a range of SDDs (50, 80, 100, 120, 150, 180 and 200 mm) and is 
shown in figure 3.20. A depth dependent calibration function was determined by fitting 
a curve to the dose rate response calibration points and is given by equation 3.2. 
𝑇𝑃𝑆𝑑𝑜𝑠𝑒 𝑟𝑎𝑡𝑒
𝐹𝑃𝐷 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒
= −7 × 10−6(𝑆𝐷𝐷)2 − 0.0017(𝑆𝐷𝐷) + 0.7729 Eqn. (3.2) 
The distance (and therefore spectral) dependent dose rate calibration function is shown 
in Figure 3.20. 
Across the set of all measurements, pixels with identical SDDs but different angles of 
incidence from the source were identified and used to derive an angular correction 
function, as shown previously in figure 3.11. The conversion of image pixel value to 
dose rate is achieved by combining the calibration function of figure 3.20 with the 
response lag correction of figure 3.8 and an angular correction factor from figure 3.11. 
 
Figure 3.20.  The TPS dose rate per FPD response as function of source to detector distance. 
The ratio of dose rate to FPD response decreases as the distance is increased due to the increase 
in scatter to primary photon ratio reaching the FPD . 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0 50 100 150 200 250
D
o
se
 R
a
te
 / 
R
e
sp
o
n
se
   
 (
 c
G
y
/h
 /
 5
x
5
R
O
I 
p
ix
e
l 
v
a
lu
e
)
Source to Detector Distance (mm)
 
 Chapter 3: Flat Panel Detector Characterisation for 192Ir Measurement 
59 
3.11 Image Plane Determination 
The FPD forms an image in the semi-conductor layer of the detector at a distance below 
the surface of the detector imaging face. In order to compare measured dose with the 
TPS or to determine the divergence correction factor that will be applied to a 
radiograph image, the imaging plane depth, where the image is formed, needs to be 
determined.  
The imaging plane depth within the FPD was determined using an ‘edge projection 
shift’ technique. The FPD was aligned with its surface at the isocentre of a treatment 
simulator (AcuityTM, Varian Medical Systems, Palo Alto, CA, U.S.A.). A thin copper 
sheet was placed flat against the FPD surface with an edge aligned at the isocentre. An 
image of the copper sheet was acquired with normal incidence (Gantry = 90 degrees), 
figure 3.21(a), and again with the gantry rotated to 45 degrees as shown in figure 
3.21(b). Images were also acquired for a range of gantry angles (Gantry = 30, 45, 60, 
70, 80 degrees), and the imaging plane depth was calculated using the geometric 
relationship depicted in figure 3.22. 
 
Figure 3.21.  (a) The image of the copper sheet edge with the simulator gantry at 90 degrees, 
and at 45 degrees (b). The shift of the copper sheet edge was used to calculate the imaging 
plane depth below the FPD surface. 
 
All acquired images were analysed using the ImageJ software (ImageJ ver. 1.44, 
Wayne Rasband, NIH, USA). The vertical pixel location (at the central axis) of the 
edge of the copper sheet was determined for each image. The difference between the 
(a) (b) 
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normal incidence projection and each rotated gantry angle projection, labelled a, was 
calculated. 
 
Figure 3.22.  The geometric relationship between the two gantry positions, where a represents 
the observed shift of the copper sheet edge. This is then used to calculate the position of the 
measurement plane below the surface of the flat panel detector, d. 
 
The FPD imaging plane depth is calculated by: 
𝑑 =
𝑎
𝑡𝑎𝑛𝜃
 Eqn. (3.3) 
The measured data used to calculate the image depth is summarised in table 3.1.  
Table 3.1. The measured data used to determine the depth below the surface of the FPD where 
the image is formed. 
Gantry Position (deg.) θ (deg.) a (mm) d (mm) 
30 60 22.7 13.1 
45 45 13.3 13.3 
60 30 7.5 12.9 
70 20 4.7 12.9 
80 10 2.4 13.3 
    
Mean   13.1 
 
The mean calculated depth below the FPD surface, d, where the image is formed is 13.1 
mm (s.d. 0.2 mm). This imaging plane depth is included in the calculation of a 
a 
d 
θ 
Copper sheet 
FPD Surface 
Imaging Plane 
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magnification correction factor when imaging geometries are described for pre-
treatment imaging purposes as described later in chapter 5.  
 
3.12 2D Dosimetric Verification 
To illustrate the use of a FPD as a dosimetric verification device, two simple treatment 
plans were delivered to the phantom of figure 3.3. The dose calibration and correction 
factors were applied to the 2D FPD image response and the distribution was compared 
to that predicted by the TPS. 
A single dwell position plan was delivered and a FPD image of 250 frames was 
captured while the source was stationary. The source position was calculated using an 
asymmetric Lorentz fitted function (details of methods to calculate the source position 
appear in chapter 4), and the FPD response converted to dose rate (using equation 3.2) 
and multiplied by the dwell time to obtain measured dose for direct comparison with 
TPS. A profile of measured dose was compared to the corresponding TPS dose profile. 
The TPS isodose distribution was compared to the measured isodoses using the 
FilmQA analysis software (3cognition LLC, New York, USA) and a dose difference 
map was generated. 
A second plan was delivered containing two dwell positions. FPD measurements were 
acquired for each dwell position, delivered at a separation of 80 mm. Individual and 
combined dose profiles and isodoses were calculated to demonstrate the convolution of 
individual dwell contributions to the net dose distribution. The resulting profiles, 
isodose maps and difference images for the two delivered plans are shown in figure 
3.23. 
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Figure 3.23:  (a) A profile through the centre of the distribution showing the FPD response, 
dose uncorrected for angular response and corrected measured dose compared with the TPS 
predicted dose. (b) A comparison of isodoses measured (fine line) and TPS (heavy line) at 100 
mm SDD. (c) The two dimensional dose difference, where the distribution is TPS minus 
measured dose, at 100 mm SDD. (d) A profile through the centre of a two dwell distribution 
showing the contribution each dwell to the total measured dose compared with the TPS. (e) A 
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comparison of isodoses measured (fineline) and TPS (heavy line) at 100 mm SDD. (f) The two 
dimensional dose difference, the distribution is TPS minus measured dose, at 100 mm SDD. 
 
3.13 FPD image frame rate  
The FPD can be operated in ‘continuous acquisition’ mode, allowing a sequence of 
images to be captured. The measurement of the position of the source, as it moves 
through a treatment catheter in time, can be performed by continually acquiring images 
with this mode. The frame rate of the image acquisition will define the minimum dwell 
time that can be captured. 
To determine the frame rate, the source was driven to a single dwell position and 
programmed to dwell for 30, 60, 90 and 120 seconds. The capture of images with the 
FPD was started before the source reached the dwell position and was stopped after it 
returned to the afterloader. The image sequence was analysed and the image time stamp 
for the first and last image containing a static source distribution (not a source in 
transit) was used to calculate the imaging period. The continuous acquisition mode 
image frame rate was then calculated for each dwell time data set, by dividing the 
number of static source images by the imaging period. A summary of these results are 
shown below in table 3.1. 
 
Table 3.1.  The calculated FPD image frame rate when operating in continuous acquisition 
mode. The Image Time (s) represents the time for the system to acquire one image.  
Dwell Time (s) Imaging Period (s) No. Images Frame Rate 
(Images/s) 
Image Time (s) 
30 30 17 0.57 1.8 
60 59 34 0.58 1.7 
90 93 53 0.57 1.8 
120 122 70 0.57 1.7 
Mean    1.8 
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3.14 Discussion 
The FPD can capture exposures with the brachytherapy source at clinically relevant 
distances for treatment verification. The distribution observed on the acquired 
exposures of the source contain relevant information that can be interpreted as dose or 
used to determine the location of the source in space. The uncertainty of this 
determined position may increase with increasing source to detector distance, 
asymmetric or finite phantom geometry and inhomogeneties within the phantom. 
Approaches to determine the source position from the measured exposures and the 
geometric influences of the phantom geometry are described in chapter 4.  
The detector response is x-ray energy dependent due to the composition of relatively 
high atomic number materials used in the construction, and so any dosimetric 
interpretation would have to include a correction, as described in section 3.10. Absolute 
dosimetry with non-water equivalent detectors is a very challenging field, but can be 
approximated using an empirical calibration function. And, as the objective in this work 
is treatment plan delivery verification, this is the preferred approach (calibrate to TG-
43) given that it is known that TG-43 is inaccurate this far from the source, and we do 
not want error triggers just because the plan dose calculation differs from the true 
measured dose at exit surface. 
For treatment verification with pelvic anatomical sites a logical approach would be to 
include the FPD in the treatment couch in such a way to minimise the distance between 
the detector and the source dwells within the patient. Such a design would enable in-
vivo source position verification, termed ‘source tracking’. This proposed source 
tracking approach for treatment verification has some advantages over IVD. Source 
tracking is non-invasive, enables the possibility of pre-treatment imaging in the 
treatment bunker and measures the entire treatment volume during treatment delivery. 
3.15 Chapter Conclusion 
The aS-500 FPD has been characterised for its use as a verification tool in HDR 
brachytherapy. The large detection area, pixel dimension and timing resolution make it 
acceptable to acquire exposures with the brachytherapy source. 
This chapter briefly explored the possibility of measuring dose for the purposes of 
treatment verification. The rest of this work will now focus on the determination of 
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source position in order to achieve treatment verification. Measured source positions 
can be compared to the treatment plan for verification. With the inclusion of pre-
treatment imaging, absolute source position verification relative to the anatomy can be 
achieved. Furthermore, with knowledge of source position and dwell time, the 
dosimetric distribution can also be reconstructed for comparison if desired. 
With the determined characterisation of the FPD with the brachytherapy source, the 
following chapters will cover methods for source position determination, 2D and 3D 
pre-treatment implant verification and methods to perform in-vivo error trapping during 
treatment delivery. 
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Chapter 4 
Source Tracking 
 
4 Introduction 
The previous chapter described the use of the FPD to capture exposures of the 
brachytherapy source distribution. These exposures acquired by the FPD contain 
information which can be processed to derive the position of the brachytherapy source 
relative to the FPD. This chapter describes the image analysis performed to extract 
parameters that can be used to determine the position of the source in 3 dimensions. 
These derived source positions are compared with the known (reference) position of the 
source determined using an independent method, to evaluate their accuracy and 
reproducibility.  
The term ‘image’ in the context of source tracking refers to the exposure image 
acquired by the FPD of the 192Ir source and not an x-ray projection image as used in 
chapter 5 (Pre-Treatment Verification Imaging). 
The aim of this chapter is to investigate different image processing approaches that can 
be used to determine the 2D coordinate of the source from the acquired FPD image. A 
dual exposure approach, using an additional x-ray source, is initially performed to 
determine the true source position in the phantom. This result is used as a reference to 
benchmark several possible analysis techniques explored to derive the source 
coordinates from the FPD image alone, as would be done in the patient case. Additional 
parameters that correlate with SDD are also extracted from the images, potentially 
enabling the position of the source to be determined in 3D (inside the patient). The 
robustness of these source position approaches were evaluated for detector edge effects. 
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4.1 Source Tracking 
The approach described by this proposed verification system is to verify measured 
dwell positions against the dwell positions specified by the treatment plan. This 
approach, termed ‘source tracking’, requires the FPD to capture images continuously 
during the treatment delivery. The captured image sequence is then processed to 
calculate the source dwell position over time, for verification with the treatment plan.  
Potentially a single dwell position may appear across multiple captured images, and so 
a process to determine the measured dwell position from a sequence of image captures 
must be developed.  
To avoid confusion the following terms are defined: 
‘measured source coordinate’ is the calculated position of the source from a single 
image. 
‘measured dwell position’ is the calculated position of the source determined from a 
collection of measured source coordinates. 
A proposed process to determine a measured dwell position from the sequence of 
acquired images occurs in two steps:  
(i) Image processing is performed on each image in the sequence and a 
measured source coordinate is calculated. 
(ii) The array of measured source coordinates are processed to extract the 
measured source dwell position for verification against the plan. 
This proposed process is described later in section 4.5.2. 
4.2 Source Coordinate in 2D 
The following sections describe approaches to determine the source coordinate in the 
plane of the FPD, (i.e. in 2D). These algorithms use a single image as the basis for 
processing, and calculate the source coordinate relative to the FPD image frame of 
reference.  
The FPD coordinate system is defined as follows: the top left pixel in the image 
represents the origin and is assigned the pixel coordinate (0, 0), and the detector 
orientation relative to patient coordinates is illustrated in figure 4.1.  
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Figure 4.1.  An acquired image for a source to detector distance (SDD) of 100 mm, illustrating 
the pixel coordinate system and the detector orientation relative to a patient coordinate system, 
viewed from above. I = inferior, S = superior, R = right, L = left. 
 
4.2.1 Source Position in 2D Methods 
To evaluate different approaches of determining the source position in 2D (position in 
the plane of the FPD), images of the source were acquired for a range of source to FPD 
distances. The parameter is known as the SDD and is the perpendicular distance from 
the FPD imaging plane to the brachytherapy source above.  
 
Figure 4.2.  The geometric arrangement for acquiring images of the source distribution for 
different source to detector distances (SDD). The solid water phantom is placed on the couch 
and contains a plastic brachytherapy catheter.  
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The geometry used to acquire the images is shown in figure 4.2, where the detector 
imaging plane is 13.1 mm below the surface of the FPD, as determined in section 3.11 
of chapter 3. In this application, the FPD is mounted below a carbon fibre couch, where 
the top of the couch is 40 mm above the detector imaging plane. (The distance from the 
surface of the FPD to the surface of the carbon fibre couch is 27 mm, resulting in couch 
top at a nominal distance of 40 mm above the imaging plane.) Mounting the FPD in the 
treatment couch is done to pre-empt its use with patients, and is described later in 
chapter 7. A 300300200 mm phantom of solid water slabs, containing a single plastic 
brachytherapy catheter, is placed on the couch top and centered over the FPD.  
The phantom was positioned on the couch as shown in figures 4.1 and 4.2 with various 
SDDs of 60, 70, 80, 90, 100, 110, 120, 130, 140, 160, 180 and 200 mm. The source was 
driven to a single dwell position at the centre of the phantom, and for each SDD, an 
image was captured with the FPD. This set of images were then used to evaluate the 
different approaches for determining the source position in the 2D plane of the detector.  
The next section describes the approach used to independently determine the reference 
source position, used to compare all other approaches. The following sections describe 
the different approaches used to determine the source position from the images 
obtained at different SDDs. 
4.2.1.1 Reference Coordinate Technique: Dual Exposure Approach 
An independent measure of the source position was performed, by using a dual 
exposure approach. This was achieved by capturing an image at the source dwell 
position, as shown in figure 4.3(a). During the source dwell, a ‘dual exposure’ image 
was captured containing a pulse from the x-ray tube positioned above the phantom and 
the 192Ir source exposure (figure 4.3(b)).  
The subtraction of the source dwell image from the dual exposure image then showed 
the position of the physical source capsule (figure 4.3(c)), which was used as the 
independent reference measure of the source coordinate. The dual exposure method 
was repeated at each SDD (60, 70, 80, 90, 100, 110, 120, 130, 140, 160, 180 and 200 
mm) to determine the reference position for each case. 
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Figure 4.3.  An example of the dual exposure approach. (a) The captured exposure of the 192Ir 
source using the FPD. (b) The simultaneous FPD exposure of the 192Ir source and the projection 
image of the phantom. (c) The result of subtraction of (a) from (b), showing a magnified view 
to illustrate the physical source capsule used as the reference source position. The source cable, 
carbon fibre couch structure and voids from the other unused empty catheter paths are visible.  
 
The dual exposure approach described here is strictly used as an independent method to 
provide a reference measured source coordinate, and is not proposed for clinical 
implementation. 
Several possible ways of deriving the measured source coordinate from the FPD image 
were explored, and these approaches are described in the following sections. 
4.2.1.2 Technique 1: Near-Maximum Pixel Intensity 
The pixel intensity distribution was used to determine the source coordinate based on 
the assumption that the highest intensity pixels in the image will represent the most 
likely position of the source. A histogram of the image pixel intensities was generated 
and the position of the maximum pixel value was determined. To filter possible pixel 
noise from the result, any potential maximum pixel value occurring only once in the 
histogram was excluded as illustrated in figure 4.4, where in this case, pixel values 546 
and 547 are excluded. The source coordinate was determined by calculating the mean 
of the pixel coordinates with the determined near-maximum pixel intensity. The source 
coordinate using the near-maximum pixel intensity approach was calculated for all 
images acquired at different SDDs and compared to the reference source coordinates. 
(a) (b) (c) 
Source Cable and Capsule 
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Figure 4.4.  A histogram of a source dwell image showing the distribution of pixel intensity. 
The near-maximum pixel intensity selected is the greatest pixel value that has a minimum 
histogram bin count of at least 2 pixels. In this example, the maximum pixel intensity result is 
545.  
 
4.2.1.3 Technique 2: Centre of Mass 
The near-maximum pixel method is a simple approach based on pixel intensity, and due 
to the small number of pixels contributing to the determined source coordinate, the 
method will likely be sensitive to different measurement situations. A potentially more 
robust approach is the centre of mass (COM) method, that use a larger number of pixels 
in the defined region to determine the source coordinate. The COM is defined as the 
mean pixel coordinate, for all pixels contributing to the defined region, where the 
region is defined by a pixel threshold range. The calculated COM pixel coordinate  
(xc, yc) is used as the source coordinate and the calculation can be expressed 
mathematically as: 
𝑥𝑐 =
1
𝑁
∑𝑥𝑖
𝑁
𝑖=1
 Eqn. (4.1) 
and 
𝑦𝑐 =
1
𝑁
∑𝑦𝑖
𝑁
𝑖=1
 Eqn. (4.2) 
 
where xi and yi are coordinates of each pixel in the defined object region and N is the 
total number of pixels in the object region. An object region was extracted from the 
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image, by thresholding (including) pixels that have an intensity value that falls within a 
specified range. Threshold ranges of 60% to 70%, 70% to 80% and 80% to 90% of the 
maximum pixel intensity in the image, were considered.  
The COM process is illustrated in figure 4.5 where figure 4.5(a) shows an image 
acquired at a SDD of 100 mm, threshold ranges of 80 to 90%, 70% to 80% and 60% to 
70% are shown in figure 4.5(b), (c) and (d) respectively. The annulus object defined (in 
red) is then used to calculate the COM source coordinate. The COM was calculated for 
each region across all images acquired at different SDDs and compared to the reference 
source coordinate. 
 
Figure 4.5.  (a) An image acquired at a SDD of 100 mm. The centre of mass approach is 
illustrated by applying a threshold value of 80 to 90 (b), 70 to 80 (c) and 60 to 70 (d) percent of 
the maximum pixel intensity. The pixels included in the threshold range are shown in red. 
 
4.2.1.4 Technique 3: Single Profile 
The shape of a profile acquired through the distribution on the FPD image possibly 
provides metrics that can be correlated with the source coordinate. To evaluate this 
SDD = 100 mm COM = 80 – 90% 
COM = 70 – 80% COM = 60 – 70% 
(a) (b) 
(c) (d) 
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method, single orthogonal profiles were considered as a method to calculate the source 
coordinate. A single profile along the x and y axes were extracted from the image and 
processed to determine the source coordinate. A starting point in the image was defined 
as the position of the maximum pixel intensity, and the orthogonal profiles were then 
extracted from this position. The single profile approach is illustrated in figure 4.6(a) 
showing the starting point and figure 4.6(b) showing location of the orthogonal single 
profiles in each axis. 
 
Figure 4.6.  An example of an image acquired at 100 mm SDD showing (a) the position of the 
maximum pixel intensity used as the starting point and (b) the orthogonal profiles extracted 
from the image to determine the source coordinate. 
 
The extracted x and y profiles were processed, and the mid-point of the line segment at 
80% of the maximum profile intensity was calculated, as shown in figure 4.7. This 
position was determined for the x and y profile separately and was used as the 
calculated source coordinate. The process was repeated for all SDDs and the calculated 
vales were compared with the reference source coordinate.  
SDD = 100 mm 
Max. Pixel  
COM = 60 – 70% 
x axis profile 
y axis profile 
(a) (b) 
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Figure 4.7.  The extracted orthogonal profile processed to determine the source coordinate. The 
mid-point at the 80% of the maximum profile intensity is used as the source coordinate. 
 
4.2.1.5 Technique 4: Multiple Profile 
The single profile approach was modified to include multiple orthogonal profiles. The 
purpose was to improve the reliability of the approach by attempting to reduce the 
influence of image noise from a single profile. Figure 4.8(a) shows that the same 
starting point used for the single profile was used (the position of the maximum pixel 
intensity) and (figure 4.8(b)) a set of 21 orthogonal profiles at 1 pixel intervals were 
extracted.  
 
Figure 4.8.  An example of an image acquired at 100 mm SDD showing (a) the profile position 
starting point and (b) an illustration of the 21 orthogonal profiles extracted in the image x and y 
axis. 10 profiles are extracted either side of the initial profile through the image start point. 
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The 21 extracted profiles in the x axis and the 21 profiles in the y axis were processed 
to calculate the mid-point of the segment at the 80% of the maximum profile intensity, 
as shown in figure 4.7. The source coordinate was determined by calculating the mean 
value for all profiles, and the calculated coordinates were compared to the reference 
source coordinate. 
4.2.1.6 Technique 5: Symmetric Lorentz Single Profile 
To improve on the Single Profile approach and to better represent the distribution of the 
acquired profile, a function was fitted to the data. The source coordinate was 
determined by fitting a symmetric Lorentz function to a profile extracted from the 
image. A single profile was extracted from the image using the process described in 
section 4.2.1.4. A symmetric Lorentz function in the form of equation 4.3 was then 
used to fit the extracted profiles in the x and y axis. 
𝑦 = 𝑎 +
𝑏
[1 + (
𝑥 − 𝑐
𝑑 )
2
]
 
Eqn. (4.3) 
The coefficients are the fit parameters where a is the baseline, b is the peak amplitude, 
c is the peak centre and d is the full width at half maximum, as illustrated in figure 4.9. 
The centre position of the fitted peak is used as the source coordinate value. 
 
Figure 4.9.  The symmetric Lorentz fit of the extracted profile, showing the coefficients a = 
baseline, b = peak amplitude, c = peak centre and d = full width at half maximum. The 
coefficient c is used as the source coordinate. 
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4.2.1.7 Technique 6: Asymmetric Lorentz Single Profile 
To accommodate the likely possibility of an asymmetric distribution, and to better fit 
the profile data, the fitting function was modified to include an asymmetric weighting 
component. The Lorentz function was modified to the asymmetric Lorentz function in 
the form of equation 4.4 was then used to fit the profiles in the x and y axes. 
𝑦 = 𝑎 +
𝑏
[1 + (
𝑥 − 𝑐
𝑑 )
2
]
+ 𝑒(𝑥 − 𝑐) 
Eqn. (4.4) 
 
The coefficients are the fit parameters where a is the baseline, b is the peak amplitude, 
c is the peak centre and d is the full width at half maximum, e is the asymmetry 
weighting component, as illustrated in figure 4.10. The centre position of the fitted peak 
is used as the source coordinate value. 
 
Figure 4.10.  The asymmetric Lorentz fit of the extracted profile, showing the coefficients a = 
baseline, b = peak amplitude, c = peak centre, d = full width at half maximum and e the 
asymmetry weighting component driving the asymmetry of the fit. The coefficient c is used as 
the source coordinate. 
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4.2.2 Results: Source Coordinate in 2D  
 
4.2.2.1 Reference Coordinate Technique: Dual Exposure Approach  
The reference source position coordinate, determined using this subtraction method, is 
the centre pixel of the projected source capsule (captured with the x-ray pulse), with 
which all other approaches are compared. The projection of the source capsule is 
corrected for x-ray beam divergence, to determine the corrected source reference 
position (xref, yref). Further details of the divergence correction applied are provided 
later in chapter 5. 
4.2.2.2 Technique 1: Near-Maximum Pixel Intensity 
The difference of the measured source coordinate from the reference coordinate in the x 
and y FPD axis is shown in figure 4.11 for each SDD. The near-maximum pixel 
intensity approach demonstrated 92% of calculated source positions were within ±2 
mm of the reference source position for SDDs ranging from 60 to 200 mm.  
 
Figure 4.11.  The determined source coordinate difference in the FPD x and y axes, using the 
near-maximum pixel intensity approach, as a function of the SDD. 
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4.2.2.3 Technique 2: Centre of Mass 
The threshold ranges of 60% to 70% and 70% to 80% produce regions as illustrated in 
figure 4.5(c) and (d). The relatively large diameter of the defined region used for COM 
calculation, especially in the 60 to 70% example, has a diameter that is approximately 
150 mm, making this threshold range impractical for source coordinate determination. 
A source that appears towards the edge of the detector, would not have the entire 
distribution of the annular region captured by the FPD and so report an incorrect COM 
source coordinate.  
This effect is considerably worse for sources at larger SDDs, as illustrated in figure 
4.12, In this example a source at 200 mm SDD, analysed for a threshold range of 80 to 
90%(figure 4.12(a)) and 60 to 70%(figure 4.12(b)) produce annular diameters of 150 
and 230 mm respectively. The large threshold region diameters are impractical for 
source coordinate determination due to compromised calculation of COM.  
 
Figure 4.12.  An illustration of the COM threshold applied to an image of the source at 200 
mm SDD. The 80 to 90% range has a diameter of approximately 150 mm(a), while 60 to 70% 
range has a diameter of approximately 230 mm (b), which is impractical for source position 
localisation. 
 
The source coordinates were calculated using the COM approach, only for a threshold 
range of 80% to 90. Source coordinates for all images acquired at different SDDs were 
calculated and compared to the reference source coordinates and the differences are 
shown in figure 4.13. 
SDD = 200 mm 
COM = 80 – 90% COM = 60 – 70% 
SDD = 200 mm 
(a) (b) 
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Figure 4.13.  The determined source position difference in the FPD x and y axes, using the 
COM threshold range 80-90%, as a function of source to detector distance (SDD). 
 
The COM approach for a threshold range of 80% to 90% produced a mean difference 
of 0.0 and 0.0 mm in the x and y directions respectively. All the calculated source 
coordinates were within ±1 mm of the expected positions, for both the x and y axes. 
 
4.2.2.4 Technique 3: Single Profile 
The single profile approach produced mean differences of -0.4 and 0.1 mm in the x and 
y directions respectively. Source coordinates for all images acquired at different SDDs 
were calculated and compared to the reference source coordinates and the differences 
are shown in figure 4.14. 
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Figure 4.14.  The determined source position difference, using the Single Profile approach, in 
the FPD x and y axis, as a function of source to detector distance (SDD). 
 
The single profile approach produced an agreement with the reference source 
coordinate in the x and y directions to within 1 mm for SDD up to 180 mm. This simple 
method appears to provide a robust approach to determine the source coordinate. 
4.2.2.5 Technique 4: Multiple Profile 
The multiple profile approach improved the agreement with the reference source 
coordinate producing a mean difference of -0.1 and -0.1 mm in the x and y directions 
respectively. The difference determined at each SDD is shown in figure 4.15. 
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Figure 4.15.  The determined source position difference, using the Multiple Profile approach, 
in the FPD x and y axis, as a function of source to detector distance (SDD). 
 
The multiple profile approach appears to improve on the single profile approach by 
determining the source coordinate in the x and y directions to be within 1 mm of the 
reference coordinate for SDDs of up to 200 mm.  
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4.2.2.6 Technique 5: Symmetric Lorentz Single Profile 
The difference for each SDD using the symmetric Lorentz fit is shown in figure 4.16. 
 
Figure 4.16.  The determined source position difference, using the Symmetric Lorentz Single 
Profile approach, in the FPD x and y axis, as a function of source to detector distance (SDD). 
 
The symmetric Lorentz data fit shows a systematic drift in the measured source 
coordinate for the x axis. The same is not observed in the y axis. 
 
4.2.2.7 Technique 6: Asymmetric Lorentz Single Profile  
The difference for each SDD using the asymmetric Lorentz fit is shown in figure 4.17. 
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Figure 4.17. The determined source position difference, using the Asymmetric Lorentz Single 
Profile approach, in the FPD x and y axis, as a function of source to detector distance (SDD). 
 
The asymmetric approach has improved the agreement with the reference coordinate 
position in the x axis, but shows slightly worse agreement at large SDDs in the y axis. 
 
 
4.2.3 Discussion: Source Coordinate in 2D  
 
4.2.3.1 Summary of 2D Source Position Determination 
The six methods investigated to determine the source coordinate for a range of SDDs 
were compared using the mean difference and maximum difference compared to the 
reference source coordinate. Table 4.1 is a summary of the results for comparison. 
Columns 2 and 3 show the mean differences where the numbers in the brackets 
represent one standard deviation. Columns 4 and 5 show the maximum difference from 
the reference source and the brackets illustrate the SDD that this maximum difference 
occurred at.  
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Table 4.1. The mean difference and standard deviation between the reference source position 
and the measured position calculated by each algorithm for source to detector distances (SDD) 
of 60 to 200 mm. The maximum difference (for x and y) occurred at the SDD shown in 
brackets. 
Method x Mean diff. 
mm 
y Mean diff. 
mm 
x Max. diff. 
mm 
y Max. diff. 
mm 
Near-Max. Intensity 0.7 (0.5) 0.5 (1.2) 2.0 (110) 2.3 (140) 
Centre of Mass 0.0 (0.5) 0.0 (0.3) 0.9 (180) -0.4 (200) 
Single Profile -0.4 (0.1) 0.1 (0.5) -1.9 (200) -1.4 (200) 
Multiple Profile -0.1 (0.4) -0.1 (0.4) -0.8 (90) -1.0 (200) 
Symmetric Lorentz 0.8 (0.7) -0.2 (0.4) 2.1 (200) -1.1 (200) 
Asymmetric Lorentz -0.5 (0.3) 0.7 (0.5) -1.0 (160) 1.6 (180) 
 
The near-maximum pixel intensity approach is the most basic attempt at interpreting 
the image information. The wide distribution of differences in the y direction (figure 
4.11) suggest that pixel noise in the image, even though an attempt to reduce this was 
performed, still influences the calculated source coordinate. The algorithm exhibits 
large individual deviations suggesting it is not robust to image noise variations. 
The COM approach has limited value in this application when the defined pixel region 
for calculation has a large diameter. The source will not necessarily appear in the centre 
of the FPD and so 60% to 70% and 70% to 80% regions are impractical. The 80% to 
90% produces a region diameter that is practical for SDD up to 200 mm. The advantage 
of this approach is that it appears robust to image noise and is not sensitive to local 
variations of pixel intensities. The process may be refined by evaluating different 
percentage ranges. The COM 80-90% approach produced maximum deviations of less 
than 1 mm at large SDDs. 
The single profile approach also produced large maximum differences as seen in figure 
4.14, but again at large SDDs which are less likely to be used clinically. The single 
profile approach is subject to the local deviation in pixel value. The inclusion of more 
profiles for calculating the source coordinate improved the agreement with the 
reference source coordinate. 
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The fitted symmetric Lorentz approach produced a systematic deviation in the x axis as 
the SDD increased, as depicted in figure 4.16. The reason for this deviation is unclear, 
and possible causes such as the source cable are not in this axis. This method is not 
likely to be used clinically as the non uniformity of the patients’ density will likely 
produce an asymmetric distribution on the FPD. 
The asymmetric fitted Lorentz approach improved on the previous approach by 
eliminating the systematic drift that was observed. The method produced a mean 
difference of less than 1 mm for both the x and y axes, making it a potential option for 
clinical use. 
The techniques evaluated for determining the source coordinate all performed well 
considering the large SDDs used during this evaluation. For a potential clinical 
application, it is not expected that the SDD will be greater than 150 mm, based on 
inspection on assessment of a large number of patient CT images. Almost all 
techniques (except the near-maximum pixel intensity technique) calculated the source 
to within 2 mm of the reference coordinate for SDDs up to 160 mm. The COM 
technique is simple to implement, and therefore possible to automate in a real-time 
application, it is efficient and exhibits excellent agreement with the reference source 
coordinate. Considering these characteristics, the COM technique was applied during 
the source tracking processes described throughout this work.  
The following section investigates characteristics of the FPD response that can be used 
to correlate with the source distance in the z axis, i.e. perpendicular from the FPD 
imaging plane.  
4.3 Source Coordinate in 3D 
The following sections describe approaches to determine the SDD using metrics 
extracted from the acquired FPD images. The distance to the source from the FPD is 
termed the z axis and is the perpendicular distance from the FPD imaging plane.  
The SDDs used to acquire the FPD images are defined as the reference z source 
coordinate and are used for comparison of each technique defined in the following 
sections. 
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4.3.1 Source Coordinate in 3D Methods 
The set of measurements acquired using the phantom setup and geometry defined in 
figure 4.2 is used to evaluate techniques to determine the source position in the z axis. 
The source was positioned at SDDs of 60, 70, 80, 90, 100, 110, 120, 130, 140, 160, 180 
and 200 mm for each FPD image capture.  
Profiles were acquired at each SDD through the known source (x, y) reference position 
and normalised to the profile maximum. The x axis profiles are shown in figure 4.18 
and illustrate the broadening of the distribution and the noise in the profile as the SDD 
increases.  
 
Figure 4.18.  The x axis profiles, acquired through the known source position, normalised to 
the maximum value, for the range of SDDs of 60 to 200 mm.  
 
4.3.1.1 Technique 1: Profile Width: 
The width of the profiles depicted in figure 4.18 increase as the SDD is increased. This 
parameter may provide a reliable metric to measure the z source coordinate. The width 
of the profile is determined for the x and y profile, and the mean width is calculated, 
and this is performed at 50% and 80% of the profile maximum value. The full profile 
width metric at 50% and 80% (FW 80% Max, FW 50% Max) was plotted as a function 
of SDD and function fitted to the data for evaluation. 
 
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.1
0 50 100 150 200 250 300 350 400
N
o
rm
a
li
se
d
 P
ix
el
 r
es
p
o
n
se
Profile position (mm)
60 mm SDD
80 mm SDD
100 mm SDD
120 mm SDD
140 mm SDD
160 mm SDD
180 mm SDD
200 mm SDD
 
Chapter 4: Source Tracking 
87 
4.3.1.2 Technique 2: Threshold Pixel Count: 
The COM approach, described in section 4.2.1.3, implements a method to threshold the 
image across a pixel range of 80% to 90% of the image maximum pixel value. The 
number of pixels within this threshold range, potentially increases with SDD, as 
illustrated in figure 4.19, and so was evaluated as a possible z coordinate metric. The 
number of pixels determined by the threshold range were plotted as a function of SDD. 
 
Figure 4.19.  An example of the 80% to 90% threshold pixel range for 60, 100, 140 and 200 
mm SDD. The pixel count in this threshold range is used as a measure of source distance in the 
z axis. 
 
4.3.2 Results: Source Coordinate in 3D  
4.3.2.1 Technique 1: Profile Width 
The calculated mean width for the profiles is shown in figure 4.20 as a function of 
SDD. The data for the FW 50% max was fitted with an exponential function and shows 
good agreement up to 160 mm SDD, which is likely to be the typical clinical range for 
a prostate case.  
SDD = 60 mm SDD = 100 mm 
SDD = 140 mm SDD = 200 mm 
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Due to the shallower gradient of the SDD-profile width relationship, the FW 50% max 
approach provides a more sensitive measure of source coordinate distance than the FW 
80% max approach.  
 
Figure 4.20.  The relationship between profile width and SDD for the width at 50% of the 
maximum (FW 50% max) and width at 80% of the maximum (FW 80% Max).  
4.3.2.2 Technique 2: Pixel Threshold Count 
The number of pixels determined within the 80% to 90% threshold range is illustrated 
in figure 4.21. The COM 80%-90% pixel threshold number exhibits a linear 
relationship between SDD with gradient of approximately 88 pixels per mm.  
 
Figure 4.21.  The relationship between threshold pixel count for the COM 80%-90% approach 
and the SDD. A linear fit to the data has been applied to establish a function to determine the z 
source coordinate for each source image. 
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4.3.3 Discussion: Source Coordinate in 3D  
4.3.3.1 Summary of 3D Source Coordinate Determination 
The proposed methods described to determine the z source coordinate provide a metric 
that can be used as a surrogate for SDD. The COM approach reports a linear correlation 
with z coordinate distance and therefore provides a constant sensitivity to SDD over the 
measured range (60 to 200 mm). The FW 80% Max approach represents a less sensitive 
measure of SDD compared to the FW 50% Max approach, as the width of the profile 
does not change as rapidly over the measured range. The FW 50% Max profile may 
suffer from the finite detector size and as illustrated in figure 4.5(d), the large physical 
dimension of this profile width may not be recorded on the FPD. The COM provides a 
reliable measure of z coordinate distance and for most cases where the source is not in 
proximity of the detector edge (see next section), the metric is sensitive to the SDD. 
4.4 Discussion 
There are a few considerations that add to the complexity of source tracking. In the 
following sections three key items are discussed; (i) the influence of detector edge, (ii) 
the influence of phantom size and (iii) extraction of source dwell positions from image 
sequences. 
4.4.1 Influence of Detector Edge on Source Coordinate 
Some algorithms used to determine the source coordinate in the plane of the FPD use 
the captured distribution across the entire image. The bounds of the sensitive region of 
the FPD may influence the calculated source coordinate result. This may be applicable 
in a clinical situation when the treatment region of the patient is not centered over the 
FPD and detector edge effects become relevant. 
The solid water phantom was placed on the couch centered above the FPD, 200 mm 
from the detector edge, as illustrated in figure 4.22(a). The source was driven into the 
phantom for SDDs of 60, 80, 100, 120, 140 and 160 mm and an image was acquired. 
The dual exposure method described in section 4.2.1.1 was used to determine the 
source reference position. The phantom was moved and the image capture process was 
repeated for the source at 125 mm from the detector edge (figure 4.22(b)) and for the 
source at 50 mm from the detector edge (figure 4.22(c)). 
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Figure 4.22.  The investigation of detector edge effects on the FPD response for the (a) source 
centered on the panel, (b) the source 125 mm from the edge and (c) the source 50 mm from the 
detector edge. The blue line in each image represents the position of the response profile shown 
in figure 4.23. 
 
The acquired images were processed using the COM approach (described in section 
4.2.1.3) and the calculated source coordinates were compared to the reference source 
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position. Profiles were also extracted across the images at 100 mm SDD as illustrated in 
figure 4.23.  
The differences between the reference source position and the calculated position using 
the COM algorithm is shown in figure 4.24. The agreement for the centered, 125 mm 
and 50 mm positions are within 2 mm of the reference position for up to 160 mm from 
the detector. At 180 mm SDD, the 50 mm and 125 mm detector edge datasets deviate 
from the reference source position by more than 2 mm. This deviation is due to the 
interaction of the detector edge, distorting the COM 80%-90% calculation as shown in 
figure 4.25 (d) and (e).  
The profiles in figure 4.23 show the detector edge produces an over response. This is 
probably due to the additional scatter reaching the edge of the detector from the 
aluminium frame and protection layer around the sensitive region of the detector. 
The detector edge effect combined with the missing data points in the threshold annular 
region degrades the accuracy of the COM method. Up to 50 mm from the detector edge 
the source coordinate error is up to 2 mm for SDDs up to 160 mm. The proximity of the 
detector edge skews the measured coordinate away from the detector boundary. The 
effect appears to be negligible when the distance to the detector edge is greater than the 
SDD.  
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Figure 4.23. The profiles across the images for a SDD 100 mm, showing the distribution 
acquired by the FPD at each source position and the three profiles overlayed showing the 
increased response of the detector at the boundaries of the sensitive imaging region. 
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Figure 4.24. The determined source position difference in the FPD x and y axes, using the 
COM 80%-90% approach, as a function of SDD, to evaluate the influence of detector edge. 
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Figure 4.25.  The 80-90% COM approach for determining the source coordinate in x,y and z. 
The red region represents the pixels in the threshold range (80% to 90% of image maximum) 
that are used as metric for the source coordinate. (a) is the source centered on the FPD at 
100mm SDD, (b) is also centered at 180mm SDD, (c) and (d) is the source 125 mm from the 
edge of the FPD , and (e) and (f) is the source 50 mm from the edge of the FPD. 
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4.4.2 Influence of Phantom Size on Source Coordinate 
The reduced phantom material surrounding the source position was shown to influence 
the response of the FPD. As described in chapter 3 and shown in figure 3.19, the 
change in response resulting from this phantom geometry change will potentially 
influence source coordinate determination. To evaluate this influence, the experimental 
setup shown in figure 4.26 was used. Phantom slabs were added and images were 
captured at each increment and the COM algorithm was used to determine the source 
coordinate. The measured source coordinate was compared to the reference source 
coordinate determined using the subtraction method previously described. 
 
Figure 4.26. The phantom setup for investigating the influence of asymmetric scatter 
conditions when determining the source coordinate. Slabs of phantom material were added in 
50 mm increments.  
 
The orientation of missing phantom material relative to the FPD is shown in figure 
4.27. The COM annular region is shown for the ‘full’ material scenario 4.27(a) and the 
‘limited’ material scenario 4.27(b). The lack of lateral scattering material adjacent to 
the source position results in an asymmetric 80-90% COM annular region. 
The difference between the calculated source coordinates and the reference source 
coordinates for the FPD y axis is shown in figure 4.28.  
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Figure 4.27.  The acquired FPD images showing the 80-90% COM approach for determining 
the source coordinate. (a) The image showing the orientation of the surrounding phantom 
material and (b) the image showing an asymmetry of the 80-90% annular region and the 
orientation of the missing phantom material. 
 
 
Figure 4.28. The determined source position difference using the COM approach, in the FPD y 
axis, as a function adjacent phantom material size. 
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The nearby boundary of the phantom influences the source coordinate determination 
and should be considered in some clinical situations. As determined in section 3.9, 
approximately 150 mm of surrounding phantom material is required to determined the 
source coordinate correctly. In some treatment sites, this requirement of surrounding 
tissue may not be achievable, for example, at the nearby perineum for prostate 
treatments. One approach to overcome this influence might be to fill the missing tissue 
region with bolus material to maintain a uniform scatter field. Other approaches may 
include modelling the geometry and adjusting the COM algorithm to account for the 
lack of surrounding tissue and therefore reduced scatter contribution. 
4.4.3 Source Dwell Position from Image Sequences 
The aim of this section is to characterise the capability of the FPD to determine 
measured dwell positions from a sequence of images as the time at each dwell position 
is reduced. 
4.4.3.1 Method 
A treatment plan was created for a single catheter containing 7 dwell positions at 10 
mm steps in a catheter 100 mm from the detector (SDD) as illustrated in figure 4.29 All 
dwell positions were initially programmed with 20 second dwell times. The FPD 
acquired images in continuous acquisition mode and captured images of the source 
during the entire treatment sequence. The process was repeated and an image sequence 
was acquired with dwells 6 to 2 reduced to 15, 10, 5, 4, 3.6, 3, 2, 1 and 0.5 seconds.  
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Figure 4.29.  The setup of the phantom on the FPD showing a single catheter and the series of 
7 dwell positions spaced 10 mm apart. 
The COM source approach described in section 4.2.1.3 was used to calculate the source 
coordinate for each image of the acquired image sequences. 
4.4.3.2 Results 
The measured source coordinates for each timing sequence are shown in figure 4.30, 
where the planned dwell locations are shown at 10 mm intervals. The measured source 
coordinate calculated from each image is represented by a single point. Most of these 
measured source coordinate points overlap, as the calculated coordinates are almost 
identical when the source is stationary at a dwell position. However, it can be seen that 
some image captures occur during source transit between dwell positions (and/or on 
catheter arrival/departure). The processing of all images in the captured sequence 
results in apparent measured dwells that do not in fact represent dwell stops of the 
source. It is also seen that some very short dwells are not captured in any image due to 
the sampling frequency. Strategies for dealing with these cases are proposed below.  
 
Figure 4.30. The calculated source coordinates along the long axis of the catheter for the series 
of planned dwells with reducing dwell times. The source progresses through the dwell positions 
as depicted by the arrow. Data points between the planned dwell positions (D1 to D7) represent 
measured source coordinate positions while the source was in transit. 
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The frequency of measured source coordinates at each planned dwell position is shown 
in figure 4.31 for 20, 5, 3.6 and 1 second timing sequences. At least one measured 
source coordinate is recorded at dwell positions where the dwell time is greater than or 
equal to 3.6 seconds. 
 
Figure 4.31. The frequency of measured source coordinates corresponding to the planned dwell 
positions for the 20, 5 3.6 and 1 second sequences. Below the Nyquist sampling time (3.6s) 
there is no guarantee a source coordinate will be recorded that does not contain motion artifact. 
 
4.4.3.3 Discussion 
Two particular challenges are evident in the measurement of the source dwell position: 
(i) extra recorded dwell positions due to captures occurring during a source transit, and 
(ii) missing dwell positions due to limited image capture rate.:  
As alluded to in the introduction, the acquired sequence of image captures needs to be 
processed to ‘filter out’ these additional dwell positions. A possible approach is to  
filter out the measured coordinates based on the frequency yielding a subset of 
measured dwell positions that can be evaluated with a higher degree of confidence. 
This is a function of the time the source dwells at each position, the longer the dwell 
time the more images acquired at that position, increasing the confidence that this data 
represents a dwell. In contrast, a recorded single source coordinate may be either a 
short dwell or a capture of the source in transit. This may be resolved by performing 
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shape analysis on these captured images and extracting a metric that shows that the 
source is in transit. 
As shown in figure 4.31, reducing the dwell times for dwells 2 to 6 decreased the 
number of measured source coordinates captured at each planned dwell position. At 
twice the sampling frequency (Nyquist criteria) of 3.6 seconds, at least one image is 
acquired at the planned dwell position that does exhibit artefact due to source motion. 
Below this dwell time (3.6 s) to a dwell time of 1.8 seconds, a measured source 
coordinate calculated at a planned dwell position is possible but not guaranteed.  
Converting measured source coordinates into measured dwell positions requires 
processing of the data to exclude measured source coordinates that (i) represent the 
source in transit (between dwell positions, or between the afterloader and the 
programmed dwell positions), and (ii) coordinates that contain multiple dwell positions 
with short dwell times exhibiting motion artefact.  
4.5 Conclusion 
The evaluation of source tracking needed to know the true reference position of the 
brachytherapy source. This led to the development of the subtraction imaging technique 
allowing direct imaging of the source capsule. This is in itself novel and is likely to 
prove useful for a range of quality assurance measurements including applicator 
commissioning and afterloader quality assurance tests. 
After exploring a variety of techniques for extracting the source coordinate a COM 
approach was adopted. This enabled extracting the source coordinate, from the phantom 
geometry, in the x and y directions to within 0.5 and 0.3 mm respectively, over the 
likely clinical range. The COM approach also offers a strategy for deriving the SDD, 
although to a lesser resolution on the order of 5 mm. 
Three complications have been identified that are likely to be important considerations 
for the clinical implementation. In the next chapter, a pre-treatment imaging component 
of treatment verification is introduced. It achieves three primary objectives; (i) enables 
the registration of the source tracking with the anatomy and treatment plan, (ii) assesses 
the implant geometry immediately prior to treatment geometry delivery and (iii) 
enables any source tracking differences to be identified as treatment delivery errors or 
accountable due to catheter displacements. 
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5 Verification Imaging 
In the previous chapter we have described the process of locating the position of the 
HDR brachytherapy source during treatment delivery. In this chapter we focus on the 
important task of localising the implanted catheters in the patient. The imaging data 
used for treatment planning of HDR brachytherapy (e.g. CT, MR or US) represents a 
‘snap shot’ in time of the implant geometry, but changes do occur over the time taken 
from planning to treatment delivery. Swelling and other influences impact the position 
of the interstitial catheters (or applicator) relative to the surrounding anatomy, and so 
pre-treatment implant verification using imaging is recommended. Any changes 
detected in catheter positions relative to the treatment plan influence the interpretation 
of source tracking results and will represent an upper limit on the agreement that can be 
expected in the absence of any delivery error. 
This chapter describes pre-treatment verification imaging for HDR prostate 
brachytherapy performed with a flat panel detector and x-ray imaging equipment. The 
first part of this chapter covers 2D verification techniques, which can be performed 
with any typical mobile x-ray system. The verification approach is then extended to 
include a 3D catheter reconstruction method that allows (direct 3D) comparison with 
the treatment plan derived from the 3D imaging. The 3D approach uses a ceiling-
suspended x-ray system, which provides reproducible movements and facilitates 
oblique shift imaging. Corrections for image divergence are described, a 3D 
reconstruction approach is given, and a method to register the TPS space with the 
measurement space enabling direct comparison is provided. A solid water phantom, 
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described in section 5.1, containing prostate brachytherapy catheters was constructed 
and is used for both 2D and 3D pre-treatment verification imaging investigations. 
5.1 Phantom Construction 
A rectangular phantom was constructed from 10 solid water slabs each of 
300×300×10mm, containing a simulated brachytherapy implant of 18 plastic catheters 
(6F Proguide, Elekta, Stockholm, Sweden) spaced at 10 mm intervals, in a grid-like 
design as depicted in figure 5.1(a). Also embedded in the phantom were three fiducial 
markers representing prostate anatomical fiducial markers which are typically used for 
patient positioning in the external beam component of prostate radiotherapy treatment. 
 
Figure 5.1.  (a) The rectangular solid water phantom containing 18 plastic catheters and 3 
fiducial markers positioned on the CT couch ready for the planning scan. (b) A sample of the 
radio-opaque dwell position markers with 10 mm spaced lead markers used during x-ray 
imaging.  
 
5.2 Treatment Planning Imaging 
Radio-opaque CT markers were inserted into each catheter and a CT scan (representing 
the treatment planning scan) of the phantom was acquired using The Alfred Hospital 
standard clinical HDR prostate brachytherapy protocol (2.5 mm spaced, 2.5 mm thick 
slices). The CT images were transferred to the treatment planning system (TPS) 
(Oncentra v4.3, Elekta, Stockholm, Sweden) and the ‘implanted’ catheters 
reconstructed. TPS patient points were assigned to the centre of each of the three 
fiducial markers identified in the CT data.  
(a) (b) 
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A plane representing the position of the imaging plane of the flat panel detector (FPD) 
was created in the TPS. All reconstructed catheter paths and fiducial marker points 
were projected on to this plane for direct comparison with the 2D measured treatment 
data acquired in section 5.3. 
The 3D coordinates of the reconstructed catheter paths and the identified fiducial 
marker points were exported for later comparison with the 3D measured treatment data 
acquired in section 5.4. 
5.3 2D Pre-Treatment Imaging 
Pre-treatment image verification can be performed with the patient in the treatment 
position, in the brachytherapy bunker, with a single planar anterior-posterior (A-P) 
image. Catheter comparison with the treatment plan, performed in the 2D plane of the 
detector, allows a measure of implant integrity, immediately prior to treatment. 
Catheters can move independently of each other, with most significant displacements 
reported in the literature are predominately in the superior-inferior (S-I) direction[31, 
33, 37, 75]. In HDR prostate brachytherapy, if the anatomy (prostate) has fiducial 
markers implanted (as a surrogate for prostate position, often used for EBRT image 
guided radiotherapy), then the catheter positions relative to the surrounding anatomy 
can be determined and verified against the treatment plan. 
In this work, pre-treatment imaging is performed using an external x-ray source and the 
FPD as the image receptor. The imaging geometry is illustrated in figure 5.2, with the 
solid water phantom (as described in section 5.1) depicted on the couch top and a ball 
bearing (BB) array is positioned in the field for x-ray source and detector localisation. 
The distance from the x-ray source to imaging plane is defined as the focus to imager 
distance, FID, the distance from the source to the top of BB array is defined as A, and 
the distance from the BB array to the imaging plane is defined as B.   
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Figure 5.2.  An illustration of the geometric arrangement for performing 2D pre-treatment 
image verification. The solid water phantom containing brachytherapy catheters and dwell 
position markers, on the treatment couch, with the x-ray source at a distance defined by the 
focus to imager distance (FID).  
 
The phantom was transferred to the HDR brachytherapy treatment bunker and setup on 
the couch above the sensitive region of the FPD. Catheter markers (radio-opaque x-ray 
dwell position markers), different from those used at CT (figure 5.1(b)), were inserted 
into the 7 selected catheters (catheters 1, 3, 5, 6, 11, 13 and 18) used for this pre-
treatment image verification demonstration. The distance from the FPD imaging plane 
to the catheter (dwell position) marker is defined as the height of the marker, hm. The hm 
for catheters 1, 3, 5 was 80 mm, catheter 6 was 90 mm, catheter 11 and 13 was 100 mm 
and catheter 18 was 110 mm. The ceiling suspended x-ray system (QRad OTS x-ray 
suspension system, Carestream Health, Rochester, NY, USA) was positioned above the 
phantom with a FID of 1000 mm. A single A-P image was acquired with the FPD and 
is shown in figure 5.3. A BB array attached to the x-ray source was used in the 
radiation field during the image acquisition.  
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Figure 5.3.  The AP x-ray image of the solid water phantom, containing 18 plastic catheters 
and 3 fiducial markers. The catheter markers inserted into catheters 1, 3, 5, 6, 11, 13 and 18 are 
also visible. The three fiducial markers are highlighted by the black arrows. 
 
In order to compare the acquired A-P image directly with the TPS data (exported as a 
2D plane described in section 5.2), and verify the implanted catheters are correct 
relative to the surrounding anatomy, the following steps must occur: 
• Correction of the image divergence in the acquired A-P image. 
• Perform a 2D registration between the TPS and the measurement space. 
• Compare the planned catheter paths with the measured catheter paths. 
The following sections describe in detail how these steps are accomplished to complete 
2D pre-treatment verification.  
The treatment room coordinate system is defined to enable registration of the treatment 
plan (TPS space) to the measured (FPD space) positions. The orientation of the room 
coordinate system is shown in figure 5.4. 
5 1 6 11 18 3 13 
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Figure 5.4.  The room coordinate system with the origin placed at the top left of the imaging 
device. The plane of the detector is in the x-y plane and the patient and points above the 
detector is in the positive z direction.  
 
5.3.1 Image Divergence Correction 
The AP x-ray images acquired using the geometry described in figure 5.2 contain 
geometric distortion resulting from the divergence of the x-ray beam. Features in the 
AP x-ray image, such as catheter paths and fiducial markers and the distances between 
them are magnified and corrections need to be applied in order to compare with the 
TPS data. The x-ray beam central axis position on the A-P image needs to be 
determined to correct the divergence of each projected feature, transforming the 
projection to a parallel geometry. The magnification is illustrated in figure 5.5(a), 
where a catheter marker or a fiducial marker (object) in the patient/phantom is 
projected on to a plane representing the FPD imaging plane. For a marker at a distance 
a away from the central axis of the x-ray beam, a divergence correction of d is applied 
to produce the orthogonal (parallel) projection for this marker, as illustrated in figure 
5.5(b).  
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Figure 5.5.  (a) The magnification correction for a fiducial marker feature in the patient a 
height hm above the imaging plane, for an x-ray source focus to imager distance FID and (b) the 
divergence correction for a fiducial marker in the patient which is height hm above the imaging 
plane and a distance a away from the central axis of the x-ray beam. A divergence correction of 
d is applied to produce the orthogonal projection for this marker (shown as a dashed line). 
 
A BB array is included in the x-ray field, just below the x-ray collimator, and the 
design of the BB array used in this work is illustrated in figure 5.6. The BB array 
provides a mechanism to localise the position of the x-ray source relative to the 
imaging plane by determining the x-ray central axis position. 
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Figure 5.6.  The foam block holding the 3mm diameter steel ball bearings (BBs) in a 90 mm 
square design with each BB plane spaced 75 mm apart. The projected BBs in the AP image are 
used to localise the FPD with the x-ray imaging focal spot position. 
 
The x-ray central axis position on the AP image was determined by projecting a line 
through each pair of BBs visible on the image as shown in figure 5.7(a). The 
intersection point of these projected lines is the x-ray central axis position and 
represents the perpendicular intersection of the central axis ray from the x-ray source to 
the imaging plane of the detector. Uncertainties associated with identifying the centre 
of the projected BB marker on the image can lead to directional discrepancies of the BB 
projected lines, and so may produce an x-ray central axis region (area) of intersection 
rather than a point. To account for this measurement variation, the x-ray central axis 
position is determined by calculating the centre of mass (COM) of all BB line 
intersection points (4 BB pairs produce 6 possible intersection points). 
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Figure 5.7.  (a) The x-ray central axis position determined from the intersection of lines 
projected between the pairs of BBs. (b) The four sets of BB markers and the projected line 
spread for a BB marker uncertainty of ±1 pixel. The orange area represents the region where 
outlier intersection points may occur. The most likely central axis position is shown by the 
black cross at the centre of the FPD image. 
 
The uncertainty in calculating the x-ray central axis position was determined by 
performing a simulation to determine the possible region of intersection for all 
projected lines, based on an individual BB marker point identification uncertainty of ±1 
pixel (±0.784 mm). Figure 5.7(b) shows the four sets of projected BB pairs and the 
range the projected lines can take. The region defined by the central diamond, of size 
±16.6 mm, is the region where perpendicular pairs of BB projected lines can possibly 
intersect, while the long ‘wedge shaped’ regions, shown as the orange hatched region in 
figure 5.7(b), represent the area that opposing BB projected lines can possibly intersect. 
The intersecting lines of opposed BB sets can therefore contribute the greatest 
uncertainty when determining the x-ray central axis position. Intersection points 
occurring in this region are outliers, and will skew the centre of mass calculation, 
influencing the divergence correction applied to the A-P image. 
If we ignore outlier intersection points region, determined by the BB opposed 
projections, the x-ray central axis position divergence correction uncertainty, ΔDivCorr, 
can be determined for a measured x-ray central axis within the ±16.6 mm diamond. For 
a FID of 1000 mm, and a marker point (in the object) of 50, 100, 150 and 200 mm 
above the FPD imager plane (hm), the divergence correction applied, d, to the projected 
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point from the central axis a distance a, (as in figure 5.5(b)) has an uncertainty as 
described in figure 5.8. A marker offset distance of 100 mm from the central axis and 
200 mm from the imaging plane, which would be an extreme in a clinical case, 
produces a divergence correction uncertainty of ±2.8 mm.  
 
Figure 5.8.  The divergence correction uncertainty, ΔDivCorr, for the correction applied to a 
marker point at distance a from the central axis and a height hm above the imaging plane using 
the square BB design. 
 
One approach to reduce the uncertainty produced by the BB line projection is to 
increase the distance between the two BB planes (figure 5.6), resulting in an increased 
separation between each projected BB pair on the A-P image, therefore reducing the 
range of the projected ‘wedge shaped’ region of projected BB intersection lines. The 
area of the central diamond will also be reduced, but the long ‘wedges’ due to opposing 
BB pairs will remain, although narrowed. To eliminate these ‘wedges’, a new BB array 
design is proposed, that does not have opposing sets of BB pairs and is described in the 
next section. 
5.3.2 Improving the Ball Bearing Array Design 
In order to reduce the event of intersection outlier positions a new BB array design was 
proposed, and the design is illustrated in figure 5.9(a). The new design distributes 5 
pairs of BBs around a 70 mm diameter circle in such a way to avoid opposing BB 
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projection sets. The BB array was constructed to attach to the accessory tray of the 
ceiling suspended x-ray system, below the x-ray collimator, as shown in figure 5.9(b), 
allowing practical use in the clinical environment. 
 
Figure 5.9.  (a) The foam block holding the 3 mm diameter steel BBs arranged in a custom 
design on a 70 mm diameter circle. The positions of the BBs projected on the A-P image are 
such that when each BB pair is projected they do not meet an opposing BB pair line projection. 
(b) The BB array attached to the x-ray system collimator accessory tray. 
 
The BB array design also considered the clinical application, in this case HDR prostate 
brachytherapy. As illustrated in figure 5.10, the projection of the BB pairs avoid the 
catheter dwell position markers and implant region containing prostate fiducial markers 
while still projecting on to the FPD imager. 
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Figure 5.10.  An example of the custom designed BB array in a clinical situation. The 
projected BB pairs are not opposing and they do not obscure the catheter dwell position 
markers inserted for pre-treatment imaging. 
 
The x-ray central axis position uncertainty was estimated by performing the same 
simulation described in section 5.3.1, where the possible region of intersection of all 
lines was determined, based on a BB marker point identification uncertainty of ±1 pixel 
(±0.8 mm). Figure 5.11 shows the five sets of projected BB pairs and the range the 
projected lines can take. The central region, where all pairs of BB projected lines can 
intersect, has a smaller size than the square BB design, with x = ±10 mm and y = ±6 
mm. The long ‘wedges’ observed in the square BB design are eliminated, with only two 
relatively short regions where intersection outliers can exist, shown as orange hatched 
regions in figure 5.11. 
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Figure 5.11.  The five sets of BB markers and the projected line spread  for a BB marker 
uncertainty of ±1 pixel. The orange area represents the region where outlier intersection points 
may occur. The ‘true’ central axis position is shown by the black cross at the centre of the FPD 
image. 
 
The divergence correction uncertainty, Δd, was evaluated for this circular BB design by 
considering a measured x-ray central axis within the ±10 mm central region. For a FID 
of 1000 mm, and a marker point (in the object) of 50, 100, 150 and 200 mm above the 
FPD imager plane (hm), the divergence correction applied, d, to the projected point 
from the central axis a distance a, (as in figure 5.5(b)) has an uncertainty as described 
in figure 5.12.  
The divergence correction uncertainty shown in figure 5.12 does not vary strongly with 
marker off axis distance a, at each marker height hm. Therefore not aligning the implant 
directly with x-ray central axis position on the FPD will have only a small (±0.2 mm) 
influence on total measurement uncertainty, and hence the sensitivity to detect catheter 
displacements. 
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Figure 5.12.  The divergence correction uncertainty, ΔDivCorr, for the correction applied to a 
marker point at distance a from the x-ray central axis and a height hm above the imaging plane 
using the circular BB design. 
 
To characterise the performance of the new BB array design, the x-ray central axis 
position was measured and compared against the performance of the square BB design. 
The next section describes the procedure to evaluate the two BB designs. 
5.3.3 X-ray Central Axis Position Measurement 
The uncertainty of x-ray central axis position was evaluated, for each BB design, by 
calculating one standard deviation of projected BB line intersection points. This was 
evaluated for a source to imager geometry as illustrated in figure 5.13(a), where the 
focus to imager distance (FID) was fixed at 1000 mm. The BB array was placed in the 
x-ray field with the light field cross hairs of the x-ray system set to the centre of the BB 
array. Each BB array was positioned at a distance from the x-ray source, A, of 650, 500 
and 350 mm and an image acquired at each position. Additionally, the circular BB 
array was placed in the x-ray system accessory tray where A = 250 mm. To evaluate 
reproducibility, the BB array was rotated by 90 degrees increments (positions of 0°, 
90°, 180°, 270°) for each height A, and images also acquired. All 28 central axis 
position measurements were made without altering the x-ray tube and FPD positions. 
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Figure 5.13.   (a) The arrangement of the x-ray source, BB array and imaging plane used to 
measure the x-ray central axis position on the imaging plane. (b) An image of the square BB 
array with BB pair number 1 marked and (c) an image using the custom BB array. A steel 
washer, visible in (b) and (c), was attached to the BB array to help define orientation. 
 
A steel washer was attached to the BB array to identify the orientation as it was rotated 
from 0° to 270°. An x-ray dwell position marker was placed on the surface of the FPD 
as a reference of patient inferior image orientation. An example of a square BB array 
image and the circular BB array image is shown in figure 5.13(b) and 5.13(c) 
respectively.  
Each image was processed using in house software shown in figure 5.14, allowing each 
pair of projected BBs to be identified using a pixel intensity centre of mass (COM) 
algorithm to determine the centre pixel of the BB marker. The line projection for each 
BB pair was determined and the intersection points for all lines calculated, as shown by 
cyan crosses in figure 5.14. The COM calculated centre position is shown by the red 
cross.  
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Figure 5.14.  The in house software used to process the image to determine the x-ray central 
axis position. The centre of the projected BBs were identified by using a pixel intensity based 
centre of mass algorithm, and results are shown as yellow crosses. The intersection point of the 
projected BB pair lines are shown as cyan crosses and the calculated x-ray central axis position 
is displayed as a red cross. 
 
The mean and standard deviation of these intersection points was calculated for the 
square BB and circular BB arrays at each rotated position and the comparison of 
standard deviation is shown in figure 5.15. It is clear the circular BB array produces 
less deviation from the calculated x-ray central axis mean position than the square BB 
array. This reinforces the design concept of eliminating the possibility of outlier 
intersection points due to BB marker point uncertainty, producing a more precise 
determination of the x-ray central axis position. 
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Figure 5.15.  The variation of x-ray central axis position for the square BB array and the 
circular BB array. Each bar represents one standard deviation of BB pair intersection lines, 
acquired for the three distances of A. 
 
The reproducibility results of determining the x-ray central axis is shown in table 5.1 
for the square BB array and in table 5.2 for the circular BB array. The mean x and y 
coordinates is the absolute mean position of the x-ray central axis position across the 
four orientations of the BB array. The standard deviation across all distances, A, for the 
circular BB design (column 4 and 5 of table 5.2) is less than the square BB design 
(column 4 and 5 of table 5.1).  
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Table 5.1.  The calculated x-ray central axis position for the square BB array at a distance A 
from the x-ray source. The x and y coordinate is the calculated mean position for the array in 
the four orientations (0°, 90°, 180° and 270°) with an uncertainty of 1 standard deviation.  
A (mm) Mean x (mm) Mean y (mm) S.D. x (mm) S.D. y (mm) 
350 195.1 165.5 12.7 8.7 
500 192.8 158.9 7.7 8.2 
650 189.1 154.3 4.9 8.7 
 
 
Table 5.2.  The calculated x-ray central axis position for the circular BB array at a distance A 
from the x-ray source. The x and y coordinate is the calculated mean position for the array in 
the four orientations (0°, 90°, 180° and 270°) with an uncertainty of 1 standard deviation.  
A (mm) Mean x (mm) Mean y (mm) S.D. x (mm) S.D. y (mm) 
350 189.0 160.7 3.1 1.9 
500 188.7 161.1 2.6 1.9 
650 185.1 161.4 2.5 1.2 
250 (In Tray) 185.4 158.2 0.4 0.1 
 
 
To further highlight the improved reproducibility of the circular BB design over the 
square BB, all measured intersection points are shown in figure 5.16, for all distances 
(A) and BB array orientations. The circular BB array design produces a more 
reproducible result then the square BB which has a greater spread of points and notable 
outliers. 
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Figure 5.16.  The spread of all intersection points used to determine the x-ray central axis 
position. The circular BB array design produces a more reproducible result then the square BB 
which has a greater spread of points and notable outliers. 
 
In conclusion, the circular BB array design results in a more reproducible determination 
of the x-ray central axis position compared with the square BB design. At a distance A 
of 350 mm, the circular BB shows a spread of (x) ±3.1 and (y) ±1.9 mm, while the 
square BB is approximately 4 times greater, (x) ±12.7 and (y) ±8.7 mm. An algorithm 
using a template based approach could be implemented to automatically segment and 
identify the BB array pairs in the A-P image.  
5.3.4 2D Registration of Planned (TPS) with Measured (FPD) Space 
Direct comparison of the treatment plan with the measured catheter positions, for pre-
treatment verification, required a relationship between the planned (TPS) space and the 
measured (FPD) space to be established. The positions of three fiducial markers 
embedded in the solid water phantom, shown in figure 5.3, were determined in the 
acquired A-P image. A divergence correction was applied to the measured fiducial 
marker positions using a correction factor determined by the BB array, as previously 
described. The measured fiducial marker positions were paired with the corresponding 
fiducial markers previously identified in the treatment plan. A non-iterative, least 
squares method of registration was performed [106] (in 2D) to determine the rigid 
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spatial transformation (rotation and translation) between the planned (TPS) and 
measured (FPD) spaces.  
The reported registration residual from this process, R, can be used as a measure of 
match between the datasets, and is the sum of the squared differences for each 
registered fiducial marker pair. The registration uncertainty, ΔReg.2D, is then defined as 
the mean difference between all fiducial marker pairs in the plane of the FPD, and can 
be derived from the registration residual by 
∆𝑅𝑒𝑔.2𝐷 = √ 
𝑅
𝑛
   Eqn. (5.1) 
 
where R is the registration residual and n is the number of fiducial marker pairs 
participating the in the registration. 
The registration process is illustrated in figure 5.17 showing the registration between 
the two corresponding sets of fiducial markers in the TPS and FPD space and the 
resulting transformation matrix, T, which establishes a link between the two frames of 
reference. The registration uncertainty can be used as a metric for the agreement 
between the planned and measured geometries and is normalised for the number of 
fiducial marker pairs used in the registration process. The registration uncertainty 
therefore represents the geometric uncertainty, in each coordinate, of any point that is 
transformed using the transformation matrix T. 
 
 
 
 Chapter 5: Pre-Treatment Verification Imaging 
121 
 
Figure 5.17.  An illustration showing the 2D registration process for corresponding fiducial 
marker points in the treatment plan and the measured image. The resulting transformation 
matrix, T, where θ represents the counter-clockwise rotation of the fiducial markers about the 
origin, and Tx and Ty represent a translation in the x and y directions respectively.   
 
Establishing a geometric transformation between the two frames of reference then 
allows information to be passed in either direction. In this application of pre-treatment 
verification, the brachytherapy staff require a comparison at the treatment console and 
so it is logical to map the planned data to the measurement frame of reference. 
To illustrate the reproducibility of the process, the phantom was repositioned on the 
treatment couch two additional times and the A-P image acquired. The sensitivity to 
catheter displacement from the planned positions was evaluated by shifting the inserted 
catheter markers out of the plastic catheters (inferiorly), to simulate catheter 
displacement in the S-I direction. All 7 catheters were displaced by 2, 3, 5 and 10 mm 
and an A-P image was acquired at each position.  
To evaluate the registration robustness under rotation, the solid water phantom was 
rotated 10.0° in the plane of the FPD (Yaw about the z-axis) to simulate patient setup 
differences from CT. The phantom was also rotated about the x-axis (tilt out of the 
plane of the FPD), to simulate patient pelvic tilt. The phantom was rotated by 1.9°, 3.8° 
and 5.7°, representing rotational deviations from the original planned position, and an 
A-P image was captured at each position. The fiducial markers were identified in all 
acquired A-P images and registration performed with the fiducial markers previously 
Transformation: T =  ൥
𝑐𝑜𝑠 𝜃 −𝑠𝑖𝑛 𝜃 𝑇𝑥
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identified in the TPS data. The registration uncertainty, ΔReg.2D, and the reported 
rotations for these datasets are shown in table 5.3 and 5.4. 
 
Table 5.3. The reported registration uncertainty, ΔReg.2D, and rotation, θ, after the 2D 
registration of the measured fiducial markers with the TPS fiducial markers.  
Dataset ΔReg.2D (mm)  Rotation θ  
Initial 0.3  -0.1  
Repeat 1 0.5  0.5  
Repeat 2 0.4  0.5  
2 mm Shift 0.4  -0.5  
3 mm Shift 0.3  -0.5  
5 mm Shift 0.3  -0.2  
10 mm Shift 0.3  -0.2  
     
Mean 0.4  -0.1  
 
The registration uncertainties, presented in table 5.3, for all datasets produce an average 
registration uncertainty of 0.4 ±0.1 mm, suggesting the registration procedure is highly 
reproducible.  
Simulated rotation of the phantom at treatment, to a position different from that at 
treatment planning imaging, produces fiducial markers projected on to a plane, that 
have a different marker position inter-spacing from that at planning. This deviation of 
projected marker pattern will limit the registration agreement possible, increasing the 
registration uncertainty indices, while also influencing the catheter agreement. 
The rotations applied to the phantom (Tilt about x-axis) caused only a minor increase of 
the registration uncertainty. The average registration uncertainty recorded for 7 datasets 
was 0.4 mm, and when a tilt of 5.7° is applied the registration uncertainty increases to 
1.0 mm (table 5.4). The rotation recorded in the third column of table 5.4 is the rotation 
result calculated from the registration process in the plane of the FPD (rotation about 
the z-axis).  
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Table 5.4. The reported registration uncertainty, ΔReg.2D, and calculated rotation, θ, for the 
datasets with applied phantom tilt to simulate patient pelvic tilt. 
Dataset ΔReg.2D (mm)  Rotation θ  
10.0° Yaw 0.7  10.5  
0.0° Tilt 0.6  0.4  
1.9° Tilt 0.3  0.3  
3.8° Tilt 0.8  -0.5  
5.7° Tilt 1.0  -0.8  
 
In a clinical scenario, when the patient is set up on the couch for treatment, any patient 
pelvic tilt present, different from the setup at treatment planning imaging, would 
increase the registration uncertainty. Catheter position comparisons would therefore 
have larger tolerances applied, as the overall measurement uncertainty is increased, and 
so would reduce the confidence in detecting small catheter displacements. To combat 
this, the introduction of a reproducible patient setup protocol to clinical practice would 
be beneficial. This approach could range from a simple set of lines drawn on the patient 
skin using the CT laser system as a reference to a more advanced pelvic support (vac-
bag) device. 
5.3.5 Catheter Path Comparison 
Any geometric changes that may have occurred between treatment planning and 
treatment delivery can be quantified by evaluating the position of the implanted 
catheters relative to the expected planned positions. Using the spatial transformation 
established in the previous section, the planned catheter paths can be mapped to the 
measurement (FPD) space and can be directly compared with the catheter paths 
identified in the acquired image, as illustrated in figure 5.18. 
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Figure 5.18.  The transformation of planned catheter paths into the measurement frame of 
reference for direct comparison with catheter paths immediately prior to treatment. 
 
The path of each catheter in the A-P image was identified manually by assigning the 
centres of the 10 mm spaced x-ray dwell position markers, using in-house software. 
The planned catheter paths, previously exported from the TPS (section 5.2), were 
transformed to the measurement (FPD) frame of reference, and overlayed on the 
acquired A-P image. This is illustrated in figure 5.19 for the 5 mm shift dataset, 
showing the identified catheter marker positions in red and the transformed planned 
catheter points overlayed on the A-P image in white.  
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Figure 5.19.  The measured (red crosses) and planned (white dots) catheter paths overlayed on 
the pre-treatment A-P image. A shift of 5mm was applied to the catheter dwell position markers 
to simulate catheter displacement. 
 
The agreement between planned and measured catheters positions was determined by 
evaluating the difference between each individual catheter marker point. The quantified 
differences observed are reported in several ways: 
• The mean x and y (vector) difference for all catheter marker points calculated in 
the image.  
• The mean absolute (scalar) difference for all catheter marker points calculated 
in the image.  
• The maximum mean absolute (scalar) catheter difference. This quantity is 
determined by calculating the mean absolute difference for each catheter. The 
maximum value across all calculated catheters is then reported. 
• A graphical representation of the absolute difference of catheter marker points 
per catheter 
The mean x and y differences report the directional implant changes that have occurred 
between the planning and treatment. The absolute differences reported represent the 
 
 Chapter 5: Pre-Treatment Verification Imaging 
126 
overall implant changes from the plan. The maximum absolute catheter difference 
reports the greatest absolute deviation by a single catheter in the implant. 
The reported catheter agreement quantities described are shown in table 5.5 for the 
measurements performed on the solid water phantom, including the shifted catheter sets 
and the phantom rotation. 
 
Table 5.5. The mean directional differences between all planned and measured catheter marker 
points (x and y), the mean absolute difference and the maximum mean catheter difference. The 
values in the brackets represent one standard deviation. 
Dataset x (σx)  
mm 
y (σy)  
mm 
Abs. (σabs) 
mm 
Max. Catheter 
mm 
Initial -0.5 (0.4) 0.2 (0.6) 0.9 (0.4) 1.3 
Repeat 1 0.0 (0.4) 0.2 (0.5) 0.6 (0.3) 0.9 
Repeat 2 0.0 (0.5) 0.4 (0.6) 0.8 (0.3) 1.1 
2 mm Shift -0.4 (0.5) 2.3 (0.5) 2.4 (0.5) 2.9 
3 mm Shift -0.2 (0.4) 3.2 (0.5) 3.3 (0.5) 3.8 
5 mm Shift 0.1 (0.4) 5.3 (0.6) 5.3 (0.6) 6.1 
10 mm Shift 0.2 (0.4) 9.8 (0.5) 9.9 (0.5) 10.6 
10.0° Yaw 0.0 (0.4) 0.2 (0.4) 0.5 (0.3) 1.1 
0.0° Tilt -0.1 (0.4) -0.1 (0.5) 0.6 (0.3) 0.9 
1.9° Tilt -0.3 (0.3) 0.3 (0.5) 0.6 (0.3) 1.1 
3.8° Tilt -0.1 (0.6) 0.5 (0.8) 1.0 (0.5) 1.5 
5.7° Tilt -0.7 (0.9) 0.8 (1.2) 1.6 (0.9) 2.5 
 
The datasets with simulated inferior catheter displacement were correctly identified to 
within ±0.5 mm in the S-I direction. The rotation datasets have larger reconstruction 
uncertainty and therefore show a greater average marker disagreement. 
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Figure 5.20.  The absolute catheter marker difference for the Yaw 10.0 dataset showing the 
difference at each 10 mm spaced catheter marker point from the catheter tip for all 6 catheters 
used. The arrow represents the orientation of the catheter tip to connector end.  
 
The absolute marker difference was calculated along each catheter and these are 
displayed from the catheter tip for each 10 mm spaced marker point, as shown in figure 
5.20. This measure can be used to identify individual catheter displacement or highlight 
differences along the length of the catheter. Note that when prostate catheters are 
inserted into the bladder, the agreement at the catheter tip may be poor, while still 
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potentially having acceptable agreement near the PTV. Thus it can be useful to have 
access to this analysis along the length of the catheters. 
5.3.6 Measurement Uncertainty 
The measurement uncertainties for performing 2D pre-treatment image verification are; 
the divergence correction uncertainty applied to correct the A-P image, the TPS and 
measurement space registration uncertainties, the uncertainty of identifying catheter 
marker points in the A-P image, and the uncertainty of identifying marker points in the 
TPS (CT) image data. 
The divergence correction uncertainty, ΔDivCorr, for the circular BB array, as described 
in section 5.3.2, demonstrates a small dependence with off axis marker distance, a. The 
divergence correction uncertainty does vary as a function of marker height above the 
FPD, hm, and this is illustrated in figure 5.12. 
The average registration uncertainty for the 7 datasets in table 5.3 is 0.4 mm, and 
represents the geometric uncertainty of a TPS catheter marker point transformed into 
the measurement space for comparison. Equation 5.1 indicates that the registration 
uncertainty, ΔReg.2D, can be reduced by increasing the number of fiducial markers 
participating in the registration process. 
The catheter marker point identification uncertainty, ΔAPMarker, when the catheter 
marker point is localised in the A-P image, is defined as ±1 pixel (±0.784 mm). 
The TPS imaging uncertainty, ΔTPS, in localising a marker point, in the S-I direction, is 
due to the finite CT slice thickness (2.5 mm), and can be expressed as a measurement 
uncertainty of ±1.25 mm to account for partial volume effects.  
The total 2D pre-treatment imaging measurement uncertainty presented in figure 5.21, 
is calculated by summing the above components in quadrature as shown by equation 
5.2. 
∆𝑇𝑜𝑡𝑎𝑙.2𝐷 = √∆𝐷𝑖𝑣𝐶𝑜𝑟𝑟
2 + ∆𝑅𝑒𝑔.2𝐷
2 + ∆𝐴𝑃𝑀𝑎𝑟𝑘𝑒𝑟
2
+ ∆𝑇𝑃𝑆
2
 Eqn. (5.2) 
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Figure 5.21.  The total measurement uncertainty as a function of marker height, hm, above the 
FPD, showing the TPS imaging uncertainty in localising a marker point, the divergence 
correction uncertainty (for a = 100 mm) and the registration uncertainty.  
 
The total measurement uncertainty for catheter path comparison defines the catheter 
displacement detection threshold, which is the capacity of the verification imaging 
system to detect a difference in measured catheter marker position from the planned 
position, and is described in the next section. 
 
5.3.7 Catheter Displacement Detection 
The sensitivity to catheter displacement in the S-I direction was determined for this 2D 
pre-treatment imaging approach. A catheter displacement detection threshold (Dt) was 
defined as the minimum magnitude a measured and planned catheter point (transformed 
into measurement space) are required to differ by, before it can be considered a ‘true’ 
displacement and not unlikely to be simply due to the measurement uncertainty. The 
measurement uncertainties described in section 5.3.6 are combined to calculate the Dt, 
as a function of marker height hm, for an imaging geometry with a FID of 1000 mm and 
using the circular BB array.  
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To illustrate the Dt dependence on the height of the marker hm, Dt is shown in figure 
5.22 as a function of registration uncertainty for marker heights of 50, 100, 150, 200 
and 250 mm. This figure combines the total measurement uncertainties present in the 
pre-treatment verification imaging process to determine a catheter displacement 
detection threshold for any given registration uncertainty reported. 
 
Figure 5.22.  The catheter displacement detection threshold, Dt, as a function of registration 
uncertainty, for a marker height, hm, above the FPD for 50, 100, 150, 200 and 250 mm, for a 
marker off axis distance, a, of 100 mm.  
 
When applied clinically, it is expected that the registration uncertainty, ΔReg.2D, will be 
greater than the value measured for these phantom studies, due to patient internal organ 
movements. The increased registration uncertainty only slightly increases the Dt. For 
example, a registration uncertainty of 0.4 mm will produce a Dt of 1.7 mm for a 
catheter marker height of 100 mm above the FPD. For a relatively poor registration, 
ΔReg.2D of 1.0 mm, the Dt is 2.0 mm, which is still clinically useful. 
 
5.3.8 2D Pre-Treatment Imaging Conclusion 
Pre-treatment image verification, using an A-P image acquired with the FPD, provides 
a method to verify the implant geometry relative to the anatomy. With knowledge of 
the imaging geometry, as defined by the BB array, the divergence present in the A-P 
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
0 0.5 1 1.5 2 2.5
D
is
p
la
ce
m
en
t 
D
et
ec
ti
o
n
 T
h
re
sh
o
ld
 D
t
(m
m
)
Registration Uncertainty, ΔReg (mm)
hm = 50 mm
hm = 100 mm
hm = 150 mm
hm = 200 mm
hm = 250 mma = 100 mm 
 
 Chapter 5: Pre-Treatment Verification Imaging 
131 
image can be corrected. Improving the BB array design for this application allowed the 
divergence correction uncertainty to be reduced from ±2.8 mm to ±1.7 mm for a marker 
point 200 mm from the FPD imaging plane and 50 mm off axis. The new circular BB 
design calculates a more reproducible x-ray central axis position when compared to the 
classic square BB array.  
The 2D registration between the TPS and the measurements space is reproducible, with 
an average registration uncertainty of 0.4 ±0.1 mm for 7 datasets. When rotation of the 
phantom is applied (simulating patient pelvic rotation), the 2D registration uncertainty 
increases for large rotations and the catheter agreement degrades.  
With this 2D pre-treatment verification approach, a registration uncertainty of 0.4 mm 
can identify a catheter displacement of 1.7 mm for a marker 100 mm above the FPD. 
This detection capability is sensitive enough to identify clinically relevant catheter 
displacements.  
The following section extends the pre-treatment imaging capability from 2D to 3D, 
using the same FPD, by applying a shift image approach to reconstruct the 
brachytherapy catheters in 3D. 
5.4 Extension to 3D Pre-Treatment Imaging 
A HDR brachytherapy implant has the potential for displacement in all three 
dimensions after treatment planning imaging. To completely evaluate possible changes 
of the catheter positions (relative to the surrounding anatomy) volumetric imaging is 
necessary, in the treatment bunker, immediately before treatment delivery. This section 
of chapter 5 presents a more comprehensive imaging technique that enables direct 
comparison of the pre-treatment implant geometry with the treatment plan in 3D.  
The 3D pre-treatment imaging approach presented follows the subsequent steps: 
• Capture two shift images of the implant using the FPD 
• Use a back projection approach to reconstruct the catheter paths 
• Perform 3D registration with the TPS 
• Compare the planned and measured catheter paths in 3D 
The following sections describe in detail each of these steps, including examples using 
the solid water phantom defined earlier in section 5.1. 
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5.4.1 Shift Imaging 
A shift imaging approach is performed to acquire two oblique x-ray images of the 
object, by moving an x-ray source above the object. The apparent shift of features 
between the two images, are used to reconstruct the object in 3D. The use of multiple 
image projections has previously been applied to the reconstruction of brachytherapy 
catheters, applicators[107-110] and implanted low dose rate seeds[111-114] for 
treatment planning purposes, but not for HDR brachytherapy pre-treatment verification, 
as performed in this work. In this section an approach using the flat panel detector 
(FPD) under the patient and an x-ray source moving laterally above the patient is 
described. The imaging geometry used to acquire the two shift images is illustrated in 
figure 5.23, showing the FPD under the brachytherapy treatment couch and the x-ray 
source on a ceiling-suspended rail.  
Two shift images are captured with the x-ray source at position P1, and position P3 as 
shown in figure 5.23. The implanted marker, Pm(xm, ym, zm), has an apparent ‘shift’ of 
position in the two corresponding images (P2P4), and with knowledge of the 
acquisition geometry, the 3D position of the marker can be reconstructed. The use of 
multiple image projections has been applied to the reconstruction of brachytherapy 
applicators, implanted catheters and implanted low dose rate seeds for treatment 
planning purposes, but not for HDR brachytherapy pre-treatment verification. This 
approach is novel for HDR brachytherapy, enabling reconstruction of the implant, in 
the treatment bunker, for comparison with the treatment plan immediately before 
treatment commences.  
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Figure 5.23.  The imaging geometry to acquire the two shift images for catheter position 
reconstruction. The x-ray source is shifted by a distance d, FID is the focus to imaging plane 
distance and hm represents the distance of a marker point above the FPD imaging plane.   
 
5.4.2 Shift Image Reconstruction 
The reconstruction of a brachytherapy catheter is achieved by identifying the path of 
the catheter in each of the acquired shift images. The 2D catheter path defined in each 
shift image is then back projected toward the position of the x-ray source, as shown in 
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figure 5.24, where the reconstructed 3D path of the catheter appears at the intersection 
of the back-projected catheter paths. 
 
Figure 5.24.  An illustration of the catheter reconstruction method showing the 2D catheter 
paths from each acquired image. The 2D catheter paths are back projected to the x-ray source 
positions, at 1000 mm above the imaging plane (FID) and shifted off-axis by a distance d. The 
path of the catheter in 3D, at a distance hm above the imaging plane, is determined by the 
intersection of these back projections. 
 
This process can be expressed mathematically by determining the point of intersection 
for the vectors 𝑉1⃗⃗  ⃗ and 𝑉2⃗⃗  ⃗ as illustrated in figure 5.25. This intersection point exists if the 
imaging geometry is ideal, but in reality the uncertainty associated with the localisation 
of the x-ray source and the position of the projected marker in the image may not 
guarantee that these two vectors will intersect. In 3D space it is expected the vectors 
hm 
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will pass close to each other, and so the mid-point of the shortest segment between 
them, Pm, as illustrated in figure 5.25, is used as the reconstructed position of the 
implanted marker. 
 
Figure 5.25.  The 3D vectors 𝑉1⃗⃗  ⃗ and 𝑉2⃗⃗  ⃗, connecting the x-ray source to the projected point on 
the imaging plane. If the vectors in 3D space do not intersect due to position uncertainty, the 
mid-point Pm of the shortest segment between the two vectors represents the intersection point 
and is used as the reconstructed position of the marker. 
 
The process to reconstruct the marker position requires knowledge of the x-ray focal 
spot positions, P1 and P3, and localising the projected marker positions in each image, 
P2 and P4. To determine the reconstructed marker position, Pm, the following process is 
followed: 
The two projection vectors are defined as the lines connecting P1 to P2 and P3 to P4: 
𝑉1⃗⃗  ⃗ = 𝑃12⃗⃗ ⃗⃗ ⃗⃗  ⃗ = (
𝑥2 − 𝑥1
𝑦2 − 𝑦1
𝑧2 − 𝑧1
) Eqn. (5.3) 
 
𝑉2⃗⃗  ⃗ = 𝑃34⃗⃗ ⃗⃗ ⃗⃗  ⃗ = (
𝑥4 − 𝑥3
𝑦4 − 𝑦3
𝑧4 − 𝑧3
) Eqn. (5.4) 
 
The points that exist on each line that represent the shortest distance between the two 
vectors are defined as P and Q, where these points are determined by:  
P3 P1 
P2 P4 
P 
Q 
Pm 
𝑉1⃗⃗  ⃗ 𝑉2
⃗⃗  ⃗ 
𝑃𝑄⃗⃗⃗⃗  ⃗ 
X-ray Source 
Imaging Plane 
 
 Chapter 5: Pre-Treatment Verification Imaging 
136 
𝑃𝑥 = 𝑥1 + (𝑥2 − 𝑥1)𝑡 
𝑃𝑦 = 𝑦1 + (𝑦2 − 𝑦1)𝑡 
𝑃𝑧 = 𝑧1 + (𝑧2 − 𝑧1)𝑡 
Eqn. (5.5) 
and 
𝑄𝑥 = 𝑥3 + (𝑥4 − 𝑥3)𝑠 
𝑄𝑦 = 𝑦3 + (𝑦4 − 𝑦3)𝑠 
𝑄𝑧 = 𝑧3 + (𝑧4 − 𝑧3)𝑠 
Eqn. (5.6) 
 
𝑃𝑥 = 𝑥1 + 𝑉1𝑥⃗⃗⃗⃗⃗⃗ 𝑡 
𝑃𝑦 = 𝑦1 + 𝑉1𝑦𝑡 
𝑃𝑧 = 𝑧1 + 𝑉1𝑧𝑡 
Eqn. (5.7) 
and 
𝑄𝑥 = 𝑥3 + 𝑉2𝑥⃗⃗⃗⃗⃗⃗ 𝑠 
𝑄𝑦 = 𝑦3 + 𝑉2𝑦𝑠 
𝑄𝑧 = 𝑧3 + 𝑉2𝑧𝑠 
Eqn. (5.8) 
 
where t and s are scalar coefficients. 
The vector 𝑃𝑄⃗⃗⃗⃗  ⃗ can then be defined as: 
𝑃𝑄⃗⃗⃗⃗  ⃗ = (
𝑄𝑥 − 𝑃𝑥
𝑄𝑦 − 𝑃𝑦
𝑄𝑧 − 𝑃𝑧
) Eqn. (5.9) 
 
The vector 𝑃𝑄⃗⃗⃗⃗  ⃗ represents the shortest distance between the vectors 𝑉1⃗⃗  ⃗ and 𝑉2⃗⃗  ⃗ if 𝑃𝑄⃗⃗⃗⃗  ⃗ is 
perpendicular to both. In the case where the vectors do intersect, the vector 𝑃𝑄⃗⃗⃗⃗  ⃗ will 
equal zero. To constrain  𝑃𝑄⃗⃗⃗⃗  ⃗ to be perpendicular to both, the scalar (dot) product should 
be zero as shown: 
𝑃𝑄⃗⃗⃗⃗  ⃗  ∙  𝑉1⃗⃗  ⃗ = 0 Eqn. (5.10) 
and 
𝑃𝑄⃗⃗⃗⃗  ⃗  ∙  𝑉2⃗⃗  ⃗ = 0 Eqn. (5.11) 
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expanding this gives: 
(
𝑄𝑥 − 𝑃𝑥
𝑄𝑦 − 𝑃𝑦
𝑄𝑧 − 𝑃𝑧
) ∙ (
𝑥2 − 𝑥1
𝑦2 − 𝑦1
𝑧2 − 𝑧1
) = 0 Eqn. (5.12) 
and 
(
𝑄𝑥 − 𝑃𝑥
𝑄𝑦 − 𝑃𝑦
𝑄𝑧 − 𝑃𝑧
) ∙  (
𝑥4 − 𝑥3
𝑦4 − 𝑦3
𝑧4 − 𝑧3
) = 0 Eqn. (5.13) 
 
(𝑄𝑥 − 𝑃𝑥)?⃗? 1𝑥 + (𝑄𝑦 − 𝑃𝑦)?⃗? 1𝑦 + (𝑄𝑧 − 𝑃𝑧)?⃗? 1𝑧 = 0 Eqn. (5.14) 
and 
(𝑄𝑥 − 𝑃𝑥)?⃗? 2𝑥 + (𝑄𝑦 − 𝑃𝑦)?⃗? 2𝑦 + (𝑄𝑧 − 𝑃𝑧)?⃗? 2𝑧 = 0 Eqn. (5.15) 
 
 
(?⃗? 1𝑥?⃗? 2𝑥 + ?⃗? 1𝑦?⃗? 2𝑦 + ?⃗? 1𝑧?⃗? 2𝑧)𝑠 − (?⃗? 1𝑥
2
+ ?⃗? 1𝑦
2
+ ?⃗? 1𝑧
2
) 𝑡 …
+ ?⃗? 1𝑥(𝑥3 − 𝑥1) + ?⃗? 1𝑦(𝑦3 − 𝑦1) + ?⃗? 1𝑧(𝑧3 − 𝑧1) = 0 
Eqn. (5.16) 
and 
(?⃗? 2𝑥
2
+ ?⃗? 2𝑦
2
+ ?⃗? 2𝑧
2
) 𝑠 − (?⃗? 1𝑥?⃗? 2𝑥 + ?⃗? 1𝑦?⃗? 2𝑦 + ?⃗? 1𝑧?⃗? 2𝑧)𝑡 …
+ ?⃗? 2𝑥(𝑥3 − 𝑥1) + ?⃗? 2𝑦(𝑦3 − 𝑦1) + ?⃗? 2𝑧(𝑧3 − 𝑧1) = 0 
Eqn. (5.17) 
 
Equations 5.16 and 5.17 are simultaneous equations and solving for the parameters s 
and t will allow the position of point P and Q to be determined. 
These simultaneous equations can be expressed in matrix notation as: 
[
𝑎 𝑏
𝑐 𝑑
] [
𝑠
𝑡
] = [
𝑒
𝑓] Eqn. (5.18) 
 
where from Eqn. 5.16 and Eqn. 5.17 
𝑎 = (?⃗? 1𝑥?⃗? 2𝑥 + ?⃗? 1𝑦?⃗? 2𝑦 + ?⃗? 1𝑧?⃗? 2𝑧) 
𝑏 = −(?⃗? 1𝑥
2
+ ?⃗? 1𝑦
2
+ ?⃗? 1𝑧
2
) 
𝑒 = −(?⃗? 1𝑥(𝑥3 − 𝑥1) + ?⃗? 1𝑦(𝑦3 − 𝑦1) + ?⃗? 1𝑧(𝑧3 − 𝑧1)) 
Eqn. (5.19) 
and 
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𝑐 = (?⃗? 2𝑥
2
+ ?⃗? 2𝑦
2
+ ?⃗? 2𝑧
2
) 
𝑑 = −(?⃗? 1𝑥?⃗? 2𝑥 + ?⃗? 1𝑦?⃗? 2𝑦 + ?⃗? 1𝑧?⃗? 2𝑧) 
𝑓 = −(?⃗? 2𝑥(𝑥3 − 𝑥1) + ?⃗? 2𝑦(𝑦3 − 𝑦1) + ?⃗? 2𝑧(𝑧3 − 𝑧1)) 
Eqn. (5.20) 
 
Solving for s and t using an inverse matrix approach is: 
𝐴𝑋 =  𝐵 Eqn. (5.21) 
 
𝑋 =  𝐴−1𝐵 Eqn. (5.22) 
 
[
𝑠
𝑡
] =  
1
𝑘
[
𝑑. 𝑒 − (𝑏. 𝑓)
−(𝑐. 𝑒) + (𝑎. 𝑓)
] 
Eqn. (5.23) 
where  
𝑘 =  [
1
𝑎𝑑 − 𝑏𝑐
] 
Eqn. (5.24) 
 
and so the parameters s and t are: 
𝑠 =  
1
𝑘
[𝑑. 𝑒 − (𝑏. 𝑓)] 
Eqn. (5.25) 
and  
𝑡 =  
1
𝑘
[−(𝑐. 𝑒) + (𝑎. 𝑓)] 
Eqn. (5.26) 
 
inserting s and t into Eqn. 5.7 and Eqn. 5.8 gives the coordinate of points P and Q. The 
position of the reconstructed marker, Pm, is the mid-point between points P and Q 
which is determined by: 
𝑃𝑚𝑥 =
(𝑃𝑥 + 𝑄𝑥)
2
 
𝑃𝑚𝑦 =
(𝑃𝑦 + 𝑄𝑦)
2
 
𝑃𝑚𝑧 =
(𝑃𝑧 + 𝑄𝑧)
2
 
Eqn. (5.27) 
 
The reconstruction procedure described is applied practically by using in-house 
software that allows corresponding catheter marker points in each image to be assigned, 
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an example of this is shown in figure 5.26. The back projection reconstruction is then 
performed for each pair of marker points and the 3D position of the reconstructed 
marker Pm is determined. 
 
Figure 5.26.  An example of assigning corresponding catheter marker points to define the 
catheter path in each shift image. The apparent shift of each catheter can be seen relative to the 
central axis reference, shown as the red dashed line. 
 
To demonstrate the shift image reconstruction process, images were acquired of the 
solid water phantom (described in section 5.1), with catheter markers inserted into 
catheters 1, 3, 5, 6, 11, 13 and 18. The images were acquired using the imaging 
geometry defined in figure 5.23, with a FID = 1000 mm and a d = 400 mm and an 
example of the acquired shift images is shown in figure 5.27. To illustrate the 
reproducibility of the reconstruction process, the phantom was placed on the treatment 
couch two more times and shift images acquired at each instance. 
Source at P3 (Patient Left) Source at P1 (Patient Right) 
1 1 2 2 3 3 
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Figure 5.27.  The two shift images acquired with the x-ray source shifted to the patient left (a) 
and then shifted to the patient right (b).  The x-ray central axis is shown as the red dashed line. 
The corresponding fiducial markers in the phantom are highlighted by the black arrows. The 
dwell position markers for each catheter are identified in each shift image to define the 2D path 
of the catheter. The catheter numbers (labelled) are identified by the coded sequence of dots 
and dashes. 
 
For the three acquisitions, the catheter paths were reconstructed in 3D using the back 
projection method described. To verify the geometric quality of the reconstruction 
result (not introducing systematic distortions), the agreement between reconstructed 
and known (model) catheter marker positions was determined for all catheter marker 
points in the implant. To determine the reproducibility of the shift image reconstruction 
method, the solid water phantom was re-positioned on the treatment couch 2 additional 
times, and the 3D reconstruction was repeated.  
The differences for the initial and repeat datasets are shown in table 5.6, where the 
mean absolute error of 0.8 mm (s.d. 0.4 mm), and featured a 3D root mean square error 
(RMSE3D) of 0.9 mm. This is the radius of the sphere centred at the true position, 
containing the reconstructed point with a probability of 68%. This was calculated using 
13 catheter marker positions, in each of 7 catheters and 3 repetitions (n=273 marker 
points). This is a measure of the implant reconstruction integrity achievable in the 
control case where there are no changes to the implant geometry i.e. the relative 
positions of all markers and catheters.  
1 1 3 3 5 5 6 6 11 11 13 13 18 18 
(a) (b) 
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Table 5.6. The reported absolute and RMSE difference between the reconstructed and known 
catheter marker positions to verify the geometric integrity of the reconstruction process. The 
bracket values represent 1 standard deviation. 
Dataset Absolute Error (mm) RMSE3D (mm) 
Initial (n= 91) 0.9 (0.4) 0.9 
Repeat 1 (n=91) 0.8 (0.3) 0.9 
Repeat 2 (n= 91) 0.8 (0.4) 0.9 
   
Mean 0.8 0.9 
 
5.4.3 Shift Image Reconstruction Field of View 
The application of shift imaging for reconstruction requires that the brachytherapy 
implant be captured in both images. Corresponding features are then identified in each 
image and reconstructed as described in the previous section. The size of the implant 
that can be reconstructed depends on the imaging geometry and detector size used. This 
section characterises the size of a brachytherapy implant that can be reconstructed using 
this shift image method, for FPD widths, Dw, and for a range of x-ray shift distances, d. 
To quantify the size of a brachytherapy implant that can be captured, an imaging field 
of view width parameter, FOVw, was defined, and is illustrated in figure 5.28. The 
FOVw, is defined as the imaging field width at a height of 150 mm above the FPD 
imaging plane for an x-ray shift distance, d, and a detector width, Dw. The parameter is 
defined at a height of 150 mm which represents an approximate distance from the FPD 
imaging plane to a distal source dwell position in a typical prostate implant. 
 
 Chapter 5: Pre-Treatment Verification Imaging 
142 
 
Figure 5.28.  An illustration showing the shift image area (orange region) achieved with an x-
ray source shift distance d, focus imager distance FID =1000 mm and with a detector width, 
Dw. The imaging field of view parameter, FOVw, is defined as the imaging field width at a 
height of 150 mm above the FPD imaging plane. 
 
The FOVw was evaluated over a range of x-ray source shift distances, d, for a detector 
width, Dw, of 400, 300 and 200 mm. It can be seen in figure 5.29 the FOVw increases as 
the x-ray shift distance d decreases, for all detector widths. A smaller x-ray shift, d, 
X-ray Source Rail 
FPD Imaging Plane 
P1 (x1, y1, z1) 
View from foot couch 
Dw 
x 
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z 
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3
) 
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may provide a greater imaging FOVw, but the trade-off is an increased reconstruction 
uncertainty in the x axis (patient L-R direction), as described later in section 5.3.4.  
 
Figure 5.29.  Imaging field of view width w at 150mm above the treatment couch as the x-ray 
source shift is increased. The height of 150mm above the couch is typical of catheter positions 
implanted in a patient and the width w represents an available view to include the entire 
template. Smaller shifts d produce greater field of view but as seen later increase the 
reconstruction uncertainty.  
 
The FOVw is expressed as a function of Dw, d, hm and FID in equation 5.26. 
𝐹𝑂𝑉𝑤 = 𝐷𝑤 −
ℎ𝑚𝐷𝑤
𝐹𝐼𝐷
−
2ℎ𝑚𝑑
𝐹𝐼𝐷
 Eqn. (5.26) 
 
The expression can be used to define the applied imaging geometry based on the 
available FPD width. 
5.4.4 3D Registration with TPS 
The measurement (FPD) space and the planning (TPS) space have distinct frames of 
reference. A registration between the two is required to compare the planned catheter 
paths with the measured catheter paths immediately prior to treatment. The registration 
applied in this work is a rigid registration using corresponding landmark points that can 
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be identified in each space. In this application fiducial markers implanted into the 
prostate, visible in both imaging sets, are used as the registration landmark points. The 
fiducial markers are routinely implanted into the prostate for EBRT treatment position 
verification and were not specifically included for this exercise. 
The registration algorithm used in this work follows the method described by Arun et 
al[106], and performs a non-iterative least squares based rigid registration between 
corresponding pairs of landmark points, producing a geometric transformation between 
the two frames of reference.  
The goal of pre-treatment verification imaging is to evaluate possible displacement of 
the implant from the intended (planned) position, relative to the surrounding anatomy, 
immediately prior to treatment. It is therefore practical to visualise the planned catheter 
positions in the measurement (FPD) frame of reference, as the patient is in treatment 
delivery position awaiting confirmation.  
In terms of the registration algorithm, the reference geometry (static) will be the FPD 
space and the registration process will transform the TPS geometry to the FPD frame of 
reference. This transformation is given by 
𝑃𝐹𝑃𝐷𝑖 = 𝑅. 𝑃𝑇𝑃𝑆𝑖 + 𝑇 Eqn. (5.27) 
 
where 𝑃𝐹𝑃𝐷𝑖 and 𝑃𝑇𝑃𝑆𝑖 are 3x1 column matrices representing the (x,y,z) coordinates of 
each corresponding pairs of fiducial points i, R is the 3x3 rotation matrix and T is the 
3x1 translation matrix. 
A non-iterative least squares fitting method of the two data sets is performed, based on 
a singular value decomposition of a 3x3 matrix, which aims to find R and T to minimise 
the difference between the data sets as described by 
𝐸2 = ∑‖𝑃𝐹𝑃𝐷𝑖 − (𝑃𝑇𝑃𝑆𝑖 + 𝑇)‖
2
𝑛
𝑖=1
 Eqn. (5.28) 
 
where E can be used as measure of the match between the data sets. 
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The resulting rotation matrix is a 3x3 matrix in the form: 
𝑅 = ൥
𝑟11 𝑟12 𝑟13
𝑟21 𝑟22 𝑟23
𝑟31 𝑟32 𝑟33
൩ Eqn. (5.29) 
 
Decomposing the rotation matrix into the three components gives: 
𝑅 = 𝑍𝑌𝑋 Eqn. (5.30) 
where 
𝑋 = ൥
1 0 0
0 cos(𝜃𝑥) − sin(𝜃𝑥)
0 sin(𝜃𝑥) cos(𝜃𝑥)
൩ Eqn. (5.31) 
and 
𝑌 = [
cos(𝜃𝑦) 0 sin(𝜃𝑦)
0 1 0
−sin(𝜃𝑦) 0 cos(𝜃𝑦)
] Eqn. (5.32) 
and 
𝑍 = ൥
cos(𝜃𝑧) − sin(𝜃𝑧) 0
sin(𝜃𝑧) cos(𝜃𝑧) 0
0 0 1
൩ Eqn. (5.33) 
 
The three Euler rotations can then be calculated by 
𝜃𝑥 = tan
−1(𝑟32. 𝑟33) Eqn. (5.34) 
 
𝜃𝑦 = tan
−1 (−𝑟31. √𝑟32
2 × 𝑟33
2 ) Eqn. (5.35) 
 
𝜃𝑧 = tan
−1(𝑟21. 𝑟11) Eqn. (5.36) 
These Euler rotations can be used to describe the movements applied between treatment 
imaging and treatment delivery. This result may be useful for reporting possible 
internal rotation of the implant that may be clinically relevant. The orientation of the 
reported rotations is depicted in figure 5.30.  
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Figure 5.30.  An illustration defining the orientation and direction of the reported rotations (tilt, 
roll, yaw) from the registration process.  
 
The registration process reports a registration residual value, E, defined by equation 
5.27. The residual value reports a measure of the registration quality, for all 
corresponding fiducial marker pairs participating in the registration. This is a poor 
metric for comparing registration quality across data sets as the value increases with the 
number of fiducials used in the process.  
The registration uncertainty (Reg.3D) represents the uncertainty of the geometric 
transformation between the two spaces (TPS and measurement), and is derived from the 
reported registration residual as shown in equation 5.37: 
∆𝑅𝑒𝑔.3𝐷= √ 
𝐸
𝑛
  Eqn (5.37) 
 
where n is the number of fiducial marker pairs participating in the registration. Reg.3D 
may be interpreted as the square-weighted average residual error per marker, and is an 
indicator of the consequential error likely to be observed in other points under the same 
transformation. The registration uncertainty contributes to the total measurement 
uncertainty and is therefore later included in the evaluation of catheter displacement 
detection.  
The three sets of shift image reconstructions performed on the phantom in section 5.4.2 
was registered with the TPS data using the three sets of corresponding fiducial markers. 
Tilt about x-axis Roll about y-axis Yaw about z-axis 
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The reported residual, registration uncertainty and the reported rotations for the three 
datasets are shown in table 5.7. 
 
Table 5.7.  The reported residual, registration uncertainty and the reported rotation after 
registration between the TPS data and reconstructed fiducial markers for the three datasets. 
Dataset Residual 
(mm) 
ΔReg.3D 
(mm) 
Tilt 
x-axis (ᵒ) 
Roll 
y-axis (ᵒ) 
Yaw 
z-axis (ᵒ) 
Initial 0.9 0.6 0.6 -0.5 -0.1 
Repeat 1 0.6 0.5 -0.6 -0.9 0.1 
Repeat 2 1.1 0.6 0.6 -0.6 0.3 
 
 
5.4.5 Reconstruction and Registration Robustness 
To evaluate the robustness of the 3D reconstruction and registration process, in the 
presence of possible patient setup variations, a pelvic rotation of the patient was 
simulated by elevating the inferior edge of the solid water phantom. Clinically this 
would represent the difference in pelvic tilt at CT (legs down), compared with legs 
elevated (lithotomy position) at treatment. The inferior edge of the phantom was 
elevated by 10, 20 and 30 mm producing phantom tilt (about x-axis) of 1.9°, 3.8° and 
5.7° respectively. Images were captured at each rotational tilt position using the shift 
image acquisition method described, reconstruction was performed, and registration 
with the TPS was achieved.  
The agreement between reconstructed and known (model) catheter marker positions 
was determined for all catheter marker points in the implant, to verify the geometric 
quality of the reconstruction result, and the results for the three rotation datasets are 
shown in table 5.8. 
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Table 5.8.  The reported difference (and S.D.) between the reconstructed and known catheter 
marker positions for the 3 rotation datasets to verify the geometric integrity of the 
reconstruction process. 
Dataset Absolute Error (mm)  RMSE3D (mm)  
1.9° rotation 0.7 (0.3)  0.7  
3.8° rotation 0.6 (0.3)  0.7  
5.7° rotation 0.6 (0.2)  0.7  
 
The residual, registration uncertainty and reported rotations is shown in table 5.9 for the 
three rotation datasets. The derived transformation matrix provided a measure of 
rotations which was then compared to the known applied rotations. The rotations 
reported by the registration algorithm were 1.0°, 3.9° and 5.5° for the 1.9°, 3.8° and 
5.7° applied rotations respectively. 
 
Table 5.9.  The measured residual, registration uncertainty and the reported rotation after 
registration between the TPS data and reconstructed fiducial markers for three datasets. 
Dataset Residual 
(mm) 
ΔReg 
(mm) 
Tilt 
x-axis (ᵒ) 
Roll 
y-axis (ᵒ) 
Yaw 
z-axis (ᵒ) 
1.9° rotation 0.3 0.3 1.0 -0.3 0.2 
3.8° rotation 0.9 0.5 3.9 0.6 0.7 
5.7° rotation 0.3 0.3 5.5 -1.0 0.1 
 
 
5.4.6 Measurement Uncertainty Analysis 
The total measurement uncertainty has three sources, the 3D marker reconstruction 
uncertainty, the registration uncertainty, and the TPS marker identification uncertainty. 
The following sections describe each measurement uncertainty and how it contributes 
to the overall measurement uncertainty budget. 
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5.4.6.1 Reconstruction Uncertainty 
The 3D reconstruction uncertainty of the fiducial markers will influence the quality of 
registration between the planned and measurement space, and therefore will also 
influence the agreement between the measured and planned catheter paths. An analysis 
was performed to establish the 3D reconstruction uncertainty (Recon.3D) of a marker 
point (fiducial marker or catheter marker) determined from the two shift images. The 
reconstruction uncertainty was evaluated for marker points at 50, 100, 150, 200 and 250 
mm above the FPD imaging plane (hm), and for the imaging geometry defined in figure 
2 (d = 400 mm , FID = 1000 mm). Uncertainties of x-ray shift (Δd), marker 
identification (Δpixel), and x-ray source-to-imaging plane (ΔFID) of ±2.0 mm, ±0.8 
mm (1 pixel) and ±3.0 mm respectively was applied to calculate the total 3D 
reconstruction uncertainty. 
The parameters contributing to the total 3D reconstruction uncertainty, for the imaging 
geometry defined in figure 5.24 (d = 400 mm , FID = 1000 mm), is shown in figure 
5.32. The reconstruction uncertainty is the same for the x and y direction (figure 
5.32(a)) and is greater in the z direction (figure 5.32(b)). The contribution of each 
imaging parameter in the reconstruction process is shown. The x, y and z uncertainties 
are combined in quadrature to establish the total reconstruction uncertainty which is 
shown in figure 5.32(c). 
The imaging geometry parameters used to perform the reconstruction in this study (FID 
= 1000 mm, d = 400 mm) produce a reconstruction uncertainty for catheter marker 
points up to 150 mm from the imaging plane of approximately ±0.9 mm in the A-P 
direction (z axis) and ±0.4 mm in the S-I, L-R directions (x, y axis). Figure 5.32(a) 
shows that generally the process of assigning the coordinates of catheter marker points 
on each shift image contributes the greatest to the overall reconstruction uncertainty, 
except where catheters are furthest from the FPD whereupon the geometric uncertainty 
dominates. Reducing the detector pixel size will further improve the overall 
reconstruction uncertainty, although the current pixel resolution of 0.8 mm allows 
identification of clinically relevant catheter displacements. 
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Figure 5.32.  (a) The uncertainty of marker reconstruction in the x and y axes as a function of 
marker height hm from the detector plane, and (b) in the z axis (or distance from the detector 
plane). (c) The total combined 3-D reconstruction uncertainty. 
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5.4.6.2 Registration Uncertainty 
The registration uncertainty (Reg.3D) represents the uncertainty of the geometric 
transformation between the two spaces (TPS and measurement), and is derived from the 
reported registration residual as shown in equation 5.33: 
∆𝑅𝑒𝑔.3𝐷= √ 
𝑅
𝑛
  Eqn (5.33) 
 
where n is the number of fiducial marker pairs participating in the registration. Reg.3D 
may be interpreted as the square-weighted average residual error per marker, and is an 
indicator of the consequential error likely to be observed in other points under the same 
transformation. 
 
5.4.6.3 TPS Marker Identification Uncertainty 
Finally, the uncertainty of identifying catheters and fiducial markers in the TPS (TPS) 
was considered. In this study, CT imaging was performed on the phantom using 2.5 
mm contiguous slices. The uncertainty of identifying marker points in the axial plane of 
the images is related to the CT reconstruction pixel size, and the uncertainty in the 
couch long axis, which is typically half the CT slice thickness (±1.25mm) to account 
for possible partial volume effects. 
 
5.4.7 Measure of Catheter Agreement 
In a similar approach to that used in section 5.3.5, the agreement between planned and 
measured catheters positions was determined by evaluating the difference between each 
individual 10 mm spaced catheter marker points, in 3D. The quantified differences 
observed are reported in several ways: 
• The mean x, y and z (vector) difference for all catheter marker points calculated 
in the image.  
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• The mean absolute (scalar) difference for all catheter marker points calculated 
in the image.  
• The maximum mean absolute (scalar) catheter difference. This quantity is 
determined by calculating the mean absolute difference for each catheter. The 
maximum value across all calculated catheters is then reported. 
• The 3-D root mean square error (RMSE3-D). This quantity is the radius of the 
sphere centred at the true (planned) position, containing the reconstructed 
(measured) point with a probability of 68%. 
The mean x, y and z differences report the directional implant changes that have 
occurred between planning and treatment. The absolute differences reported represent 
the overall implant changes from the time of planning imaging (CT). The maximum 
absolute catheter difference reports the greatest absolute deviation by a single catheter 
in the implant. 
The reported catheter agreement quantities described are shown in table 5.10 for the 
measurements performed on the solid water phantom and the phantom rotation datasets. 
Using the coordinate system illustrated in figure 5.24, a positive marker point 
difference value represents a shift toward patient left, patient inferior and patient 
anterior. 
 
Table 5.10.  The mean vector difference between all planned and measured catheter marker 
points, the mean absolute difference for all points and the maximum mean catheter difference. 
The absolute difference for all catheters and the maximum individual catheter difference is also 
shown. The bracket values are 1 standard deviation. 
Dataset x (σx)  
mm 
y (σy)  
mm 
z (σz)  
mm 
Abs. (σabs)  
mm 
Max. Catheter  
mm 
RMSE3D 
mm 
Initial -0.1 (0.3) 0.0 (0.4) 0.1 (0.6) 0.7 (0.3) 1.0 0.8 
Repeat 1 -0.4 (0.3) -0.2 (0.5) 0.3 (0.6) 0.9 (0.4) 1.5 1.0 
Repeat 2 0.0 (0.3) -0.1 (0.5) 0.7 (0.7) 1.0 (0.5) 1.4 1.2 
1.9° rotation -0.1(0.4) -0.2(0.4) 1.0(0.8) 1.3(0.7) 1.7 1.4 
3.8° rotation 0.0(0.5) -0.1(0.5) 0.4(0.5) 0.9(0.3) 1.1 0.9 
5.7° rotation -0.3(0.4) 0.1(0.3) 0.7(0.9) 1.1(0.7) 1.8 1.3 
 
 
 Chapter 5: Pre-Treatment Verification Imaging 
153 
Figure 5.33 illustrates the individual catheter vector differences for the ‘Initial’ dataset 
acquired. All vector differences reported in figure 5.33 have no apparent systematic 
deviation. 
 
Figure 5.33.  The mean and maximum vector difference per catheter for the ‘Initial’ dataset, 
showing the Left-Right (x), Superior-Inferior (y) and Anterior-Posterior (z) orientations. 
Positive measured difference are Left, Inferior and Anterior. 
 
The common approach to measure catheter agreement in prostate brachytherapy is to 
evaluate the catheter tip position (only) relative to the fiducial markers[32-34, 37, 78], 
often using 2D planar imaging. Such an approach provides limited information and 
lacks detail of the catheter path agreement, especially through the prostate region, 
where geometric accuracy of the catheter positions is important. This measure of 
catheter agreement of reporting the directional differences provides an assessment of 
implant deviation in the S-I, A-P and L-R orientations throughout each catheter. This 
information is especially important for clinical staff who evaluate geometric deviations 
at the treatment delivery console immediately prior to treatment. A visual 
representation of deviations, as shown in figure 5.33, depicts the average vector 
difference per catheter, which can immediately inform the treatment staff of corrections 
that may need to be applied. 
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5.4.8 Catheter Displacement Detection 
The uncertainties described in the preceding uncertainty analysis sections were 
combined in quadrature to estimate a displacement detection threshold (Dt) for any 
point in a catheter. This was defined as the minimum magnitude of shift that can be 
detected with a confidence > 95% (i.e. 2σ) and is shown in equation 5.34:  
𝐷𝑡 = √∆𝑅𝑒𝑐𝑜𝑛.3𝐷
2 + ∆𝑅𝑒𝑔.3𝐷
2 + ∆𝑇𝑃𝑆
2
 Eqn (5.34) 
 
An assumption was made that the registration discrepancies were normally distributed 
with a standard deviation described by the registration uncertainty, Reg.3D (Equation 
5.33). The variances for geometric uncertainties and discretised image uncertainties 
(pixel dimensions) were calculated from triangular and rectangular probability 
distributions respectively. 
The geometric imaging uncertainty is a function of the height (hm) of the point above 
the imaging plane (see figure 5.23). The detection threshold was calculated for a broad 
range of hm expected to span the practical range (50-250 mm). To provide a clinical 
perspective, the CT data of 33 consecutive clinical HDR prostate cases were examined 
to measure the distance from the imaging plane to the most anterior catheter path (in 
each patient). This distance represents the range of hm likely to be observed at 
treatment, and allows the determination of the typical clinical detection threshold, Dt. 
The dependence of the detection threshold on the registration uncertainty – expected to 
be somewhat variable in the patient case – was also explored. 
The sensitivity to catheter displacement was investigated by simulating inferior catheter 
shifts by displacing all radio-opaque dwell position markers by 2, 3, 5 and 10 mm out 
of the catheters (toward the +y direction). Shift images were acquired for each 
displacement and the 3D catheter paths were reconstructed, registered with the TPS 
data for comparison, and displacements calculated. The registration results of the 
reconstructed fiducial points with the TPS fiducials for the displaced catheter datasets 
are shown in table 5.11, and are consistent with the values reported for the static case of 
table 5.7. 
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Table 5.11.  The reported residual, registration uncertainty and the reported rotation after 
registration between the TPS data and reconstructed fiducial markers for three datasets. 
Dataset Residual 
(mm) 
ΔReg.3D 
(mm) 
Tilt 
x-axis (ᵒ) 
Roll 
y-axis (ᵒ) 
Yaw 
z-axis (ᵒ) 
2 mm Shift 0.9 0.5 0.9 -0.7 0.3 
3 mm Shift 0.4 0.4 -0.7 -0.8 -0.6 
5 mm Shift 0.3 0.3 -0.6 -0.6 -0.3 
10 mm Shift 0.4 0.4 -0.7 -0.8 -0.6 
 
The differences between planned and measured catheter locations are summarised in 
table 5.12, for all applied catheter shifts. The measured shifts in the S-I direction, the 
direction of the applied shifts, are highlighted in bold. The measured displacement of 
each catheter is defined to be the mean across all markers in that catheter, and is given 
in each of the Cartesian directions. The absolute length of the net vector is given, along 
with the maximum individual catheter displacement. The latter is expected to be useful 
for identifying individual catheter bending or movement. 
 
Table 5.12. The mean vector difference between planned and measured catheter marker points 
for all catheters when a known catheter displacement is applied. (Applied shift uncertainty ±1.0 
mm). The absolute difference for all catheters and the maximum individual catheter difference 
is also shown. 
Dataset x (σx)  
mm 
y (σy)  
mm 
z (σz)  
mm 
Abs. (σabs)  
mm 
Max. Cath  
mm 
2mm Shift -0.1(0.5) 2.1(0.5) 0.3(0.9) 2.4(0.5) 3.1 
3mm Shift -0.2(0.5) 3.5(0.4) 0.9(0.8) 3.7(0.5) 4.4 
5mm Shift -0.1(0.4) 5.3(0.4) 0.8(0.7) 5.4(0.5) 5.9 
10mm Shift -0.2(0.5) 10.0(0.5) 0.7(0.9) 10.1(0.5) 10.9 
      
 
The displacement detection threshold, Dt, of any point in the catheter, was calculated 
from the reconstruction, registration and TPS localising uncertainties described in the 
preceding sections. As seen in Figure 5.32(c), the total reconstruction uncertainty has a 
geometric dependence on hm but in practice, this dependence becomes negligible over 
the clinically relevant range (from 50-150 mm above the imaging plane) when the 
uncertainties are combined as a quadrature sum, due to competing influences. The 
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registration quality achieved will also influence the threshold for detection of catheter 
movements. A total uncertainty budget for displacement detection Dt was calculated 
with a 95% confidence interval, using the reconstruction uncertainties shown in figure 
5.32 and the TPS imaging uncertainty as a function of the registration uncertainty and is 
shown in figure 5.34. 
 
Figure 5.34. The catheter displacement detection threshold (Dt) for a catheter marker point as a 
function of the registration uncertainty. The detection threshold is weakly dependent on marker 
height hm and more strongly dependent on registration uncertainty. 
 
It can be seen from figure 5.34 that the uncertainty, and hence Dt, is weakly dependent 
on hm, and is more strongly influenced by the registration uncertainty. Of the 33 sample 
clinical cases evaluated, the maximum measured height of the furthest catheter from the 
couch (hm) was 157.1 mm (mean 140.1 mm, s.d. 9.9 mm) and from figure 5.34, for a 
registration uncertainty of 0.4 mm, the displacement detection threshold, Dt, is 1.8 mm 
and would be detected with a confidence of 95%. 
The detection threshold for a S-I catheter shift is better than the uncertainty for an 
individual point due to the contribution of all markers in the catheter which will all 
move in approximately the same direction by the same amount. Thus the uncertainty is 
defined in equation 5.35 as 
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Δ𝑆−𝐼 =
𝑅𝑀𝑆𝐸3𝐷
√𝑚
≈
𝜎𝑦
√𝑚
 Eqn (5.35) 
 
where m=13 is the number of markers in the catheter. 
Adopting the RMSE3D of 1.1 mm observed experimentally over the 6 experiments 
(Table 5.10, n = 507) as our a priori pointwise uncertainty, the detection threshold for a 
S-I whole catheter displacement is given by  
𝐷𝑡,𝑆−𝐼 = 2 ×
𝑅𝑀𝑆𝐸3𝐷
√𝑚
=
2 × 1.1
√13
= 0.6 𝑚𝑚 Eqn (5.36) 
 
Figure 5.35 shows the measured mean inferior displacement of each catheter for the 
four datasets with applied catheter shifts. Each data point represents one catheter and 
the error bars denote one standard deviation of marker point differences in each 
catheter. The S-I catheter displacement detection threshold, Dt,S-I, is shown by the 
dashed line.  
 
Figure 5.35. The average inferior difference per catheter for the applied shifts of 2, 3, 5 and 10 
mm. The height above the imaging plane hm is 80 mm for catheters 1,3 and 5, 90 mm for 
catheter 6, 100 mm for catheters 11 and 13, and 110 mm for catheter 18 and is separated by the 
vertical lines in the figure. The Dt,S-I (0.6 mm) for these values is shown by the dashed line.  
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The catheter displacement detection threshold is determined from the measurement 
uncertainties, with the largest contribution being from the TPS imaging CT slice 
thickness. The identification of the catheter marker points and fiducial markers in the 
TPS has the greatest uncertainty in the S-I orientation. Reducing the CT slice thickness 
will reduce the catheter displacement detection threshold, and in this study, halving the 
CT slice thickness to 1.25 mm, would reduce Dt from 1.8 to 1.3 mm. The additional 
patient CT imaging dose and management of a larger image data set also needs to be 
considered. 
5.4.9 Optimising the Imaging Geometry 
An evaluation of the imaging geometry (d, FID, hm) was performed to determine an 
optimal geometry that produces a minimal marker point reconstruction uncertainty. The 
reconstruction uncertainty for a catheter marker point 150 mm above the imager was 
determined while varying the FID and the x-ray shift parameter d. 
The reconstruction uncertainty in the x, y and z directions was evaluated as a measure 
of changing imaging geometry used to perform the catheter reconstruction. The 
variation is shown in figure 5.36. Increasing the ceiling x-ray shift distance (d) reduced 
the z reconstruction uncertainty, without significant change to the x, y uncertainty. But 
for a reduced FID, the x, y uncertainty increases with increasing x-ray shift distance. 
Increasing the FID had only minor reduction on the x, y uncertainty. 
The data presented in figure 5.36 suggests an increased x-ray shift distance d, will 
result in a minimal marker point reconstruction uncertainty in the A-P direction (z axis), 
as this produces a greater apparent movement of the marker across each shift image. 
The x, y reconstruction uncertainty can be reduced for a large x-ray shift d, by 
increasing the FID. For a relatively poor imaging geometry setup with the FID= 500 
mm and a ceiling x-ray shift distance d= 500 mm, the reconstruction uncertainty in x,y 
and z is less than ±2.0 mm. 
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Figure 5.36. The reconstruction uncertainty of a marker at hm = 150 mm, as a function of x-ray 
shift distance d, for FID of 500, 1000 and 1500 mm, (a) in the x and y and (b) in the z direction. 
 
Other factors will also influence the imaging settings used, such as the brachytherapy 
treatment room size (limiting the x-ray shift d) and the physical dimensions of the FPD. 
For example, a small detector used with a large ceiling x-ray shift, may result in some 
of the catheter marker points (implant features) being projected beyond the imager and 
not captured in the shift image reconstruction process. This imaging geometry would 
restrict the capability to perform pre-treatment verification imaging. 
5.4.10 3D Pre-Treatment Imaging Conclusion 
The approach to perform shift image reconstruction of the catheter positions to enable 
3D comparison with the treatment plan enables a more comprehensive comparison 
verification of implant position. The demonstrated 3D catheter reconstruction, using a 
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shift image technique, was applied in the treatment bunker, to perform pre-treatment 
implant position verification. Although the shift image technique is not new, this is a 
novel application of the approach to provide valuable pre-treatment catheter 
verification information, desirable immediately before treatment.  
Assessment of catheter displacement can be performed throughout the implant volume, 
and not just at the catheter tip as typically performed with 2D verification approaches. 
Integration with a TPS would enable dosimetric evaluation relative to the current state 
of the implant geometry.  
At present all catheter marker points are considered with the same importance when 
reporting the catheter agreement values. But (for example) a discrepancy at the catheter 
tip, which is often beyond the prostate (or even in the bladder), will not impact the 
treatment delivered because it is not loaded with a source dwell, and could therefore be 
excluded from the agreement criteria. We foresee that a weighting factor could be 
applied to catheter marker positions within the prostate or some proximity to the 
defined organs at risk. 
The pre-treatment verification approach described in this work can be applied to CT (or 
MRI) based treatment planning, permitting a method to verify catheter positions in the 
treatment room. 
This approach could be applied to gynaecological brachytherapy, but would require 
fiducial markers implanted to establish a reference to the surrounding anatomy. Pre-
treatment imaging may also identify unwanted changes in the applicator configuration 
due to unlocked or loose applicator assembly mechanism.  
5.5 Conclusion 
Pre-Treatment verification imaging is an important process in the quality assurance 
process for treatment delivery and this chapter has described a 2D and 3D approach to 
achieve this in the treatment bunker. Both methods achieve registration with the TPS 
enabling direct comparison with the treatment plan in the same frame of reference. 
The 2D verification approach has the following advantages: 
• Simple hardware requirements (no ceiling suspended x-ray), only needs a 
mobile x-ray system 
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• Faster and simpler analysis and processing of the image 
• Clinical workflow benefits 
• Easy initial implementation to achieve verification 
• Sensitive to many errors 
The 3D verification approach requires additional hardware, but provides a more 
comprehensive reconstruction of the implanted catheters for comparison. 
This chapter has demonstrated the capacity to evaluate catheter positions from the 
catheter tip and along the catheter path. In a clinical case, this approach may overstate 
implant differences, as catheter differences outside the treatment region are not 
necessarily clinically relevant. For example, a prostate case where catheters are inserted 
into the bladder, evaluation of catheter agreement at the tip is less important than 
focussing attention on the treatment sub-region. To provide a more clinically relevant 
assessment of the implant agreement, the evaluations can also be performed for only 
catheter marker points that occur within the treatment region volume. 
Pre-treatment evaluation of the catheter positions is useful for evaluating the results of 
the source tracking process, especially for detecting treatment delivery errors. With the 
acquired knowledge of the actual catheter positions immediately before treatment, the 
source tracking method can compare measured dwell positions to the expected 
positions defined by the pre-treatment imaging, not just by the treatment plan. This pre-
treatment imaging agreement must be taken into account when setting tolerance limits 
for error detection during source tracking. 
In the following chapter, the combination of source tracking and pre-treatment imaging 
is shown to be extremely valuable for identifying a range of possible errors that can 
occur in treatment delivery. 
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Chapter 6 
Error Trapping 
 
6 Introduction  
The role of treatment verification is to ensure the treatment is delivered correctly to the 
patient, as intended by the treatment plan, and to identify errors if they occur. The use 
of a flat panel detector as a treatment delivery verification device provides a range 
information that can be interpreted in many ways to verify treatment delivery 
parameters.  
The source tracking and pre-treatment imaging capability of the FPD has been 
demonstrated in chapters 4 and 5 respectively. The aim of this chapter is to demonstrate 
the capability of this system to identify an error during the treatment delivery, typically 
difficult to detect with other approaches. This chapter investigates approaches to 
interpret the data provided by the combination of pre-treatment imaging with source 
tracking to establish metrics that can identify treatment errors. Erroneous treatment 
delivery to a solid water phantom for a variety of treatment errors was performed to 
evaluate the measurement metrics used to identify such errors.  
6.1 Treatment Delivery Errors 
Partly due to the high degree of manual involvement in the treatment process, HDR 
brachytherapy has a high relative risk of error, when compared to other radiotherapy 
treatment approaches. The causes of incorrect treatment delivery may include (i) human 
errors, (ii) unaccounted catheter (or applicator) displacement relative to the patient’s 
anatomy and (iii) afterloader malfunction.  
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Some of the more common human errors, which can occur during treatment planning, 
patient set up and during treatment delivery are listed below. 
• Incorrect patient plan selection at the treatment console 
o Selection of the wrong patient 
o Selection of the correct patient but incorrect treatment fraction 
• Incorrect channel (indexer) length selected for the applicator  
• Incorrect source step size 
• Incorrect connection of source transfer tubes from the afterloader to the patient 
The geometric changes of the implant that occur between imaging for treatment 
planning and the treatment delivery can impact the correct delivery of the plan. These 
errors are: 
• Movement of the catheters (applicator channels) relative to the surrounding 
anatomy 
• Movement of the catheters (applicator channels) relative to each other 
and these are due to: 
• Swelling of the surrounding tissue 
• Organ filling and/or displacements 
• External mechanical influence (e.g. pressure on the applicator/ bumping when 
transferring patient) 
Afterloader malfunction is an unlikely occurrence, and the resulting event may be 
unpredictable, but the result is likely to be a deviation from the intended treatment. 
The challenge of a comprehensive treatment verification system is to be capable of 
identifying all types of treatment delivery events. The FPD acquires data prior to and 
during treatment delivery, and this information can be evaluated to identify specific 
treatment errors described above. Certain combinations of errors flagged by each metric 
suggest the concept of ‘error signatures’ that are evident across multiple data analyses. 
The identification of an error signature may help guide the operator to the cause of the 
error and allow investigation and corrective action to be taken. 
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6.2 Error Detection Metrics – ‘Error Signatures’ 
The information acquired by the FPD can be analysed in various ways to confirm the 
treatment was delivered as expected or to identify a treatment error. The following 
sections provide a breakdown of the analysis performed on the data provided by the 
FPD in order to establish metrics that can be used to flag an error event. 
The FPD provides information on the current geometry of the implant obtained during 
pre-treatment imaging. Using the methods described in chapter 5, this treatment 
geometry can be directly related to the treatment plan, establishing a reference of where 
the planned source dwell positions are expected to occur (be delivered).  
As the treatment is delivered to the patient, and each source dwell position is measured 
in sequence by the FPD, analysis of the measured source dwell positions can occur in 
principle in real-time, immediately flagging an error. This real-time approach is not 
currently implemented in this analysis but is discussed in the future directions of this 
work. The approach taken here is to retrospectively analyse the measured source dwell 
positions post treatment and to report correct delivery or error events. 
The analysis performed compares the positions of the planned and measured source 
dwells in the plane of the FPD. The evaluation is currently a 2D approach as this is the 
intended initial clinical implementation of the system. Challenges associated with the 
3D application of this verification system are discussed in the conclusion of this thesis. 
The following sections describe the metrics reported and how they validate treatment 
delivery parameters. A single reported metric will not necessarily define which error 
event is occurring, but combinations of these metrics will narrow down the 
possibilities. 
6.2.1 Visual Comparison 
The measured dwell positions can be overlaid on the A-P image acquired during the 
pre-treatment imaging process. The TPS data is also registered with the FPD frame of 
reference and so the planned dwell positions can also be displayed on the A-P image. A 
visual representation of the agreement between planned and measured dwell positions 
provides a method to identify a treatment error. Visual inspection can be supplemented 
by several useful quantitative metrics. 
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6.2.2 Individual Dwell Position Difference 
The 2D difference vector is determined for each measured dwell position relative to its 
expected (or planned) position. The dwell position difference vector is defined in 
equation 6.1 as 
𝛿𝑖 = 𝑝𝑚𝑒𝑎𝑠,𝑖  − 𝑝𝑝𝑙𝑎𝑛,𝑖 Eqn. (6.1) 
where pmeas is the measured coordinate position of the source dwell and pplan is the 
expected (or planned) position of each source dwell i, in the FPD frame of reference. 
For each difference vector, the signed x and y components representing the L-R and S-I 
directional differences respectively, are extracted as defined in equation 6.2.  
𝛿 = 𝛿𝐿𝑅  + 𝛿𝑆𝐼 Eqn. (6.2) 
 
The L-R direction represents the x-axis of the FPD and the A-P is the y-axis, as defined 
by the coordinate system definition in figure 5.4. The length of the difference vector, 
the absolute individual dwell difference (δ) is also calculated.  
These individual dwell position difference metrics on their own may not identify an 
error, but can inform the operator of local dwell position deviations that have occurred 
post treatment planning. 
6.2.3 Mean Difference 
The mean (𝛿̅) and standard deviation (σ) are calculated across all dwell positions and 
represents the mean value of the absolute individual dwell difference (δ). This metric 
will be sensitive to errors affecting the whole implant or all dwells, e.g. whole implant 
displacements or indexer length error. For a multiple catheter (channel) treatment, 
where a single catheter exhibits a deviation, the magnitude of the deviation may be 
obscured by the averaging process performed. Another metric, maximum mean catheter 
difference, is presented below to catch these occurrences. 
6.2.4 Mean Directional Difference 
The mean (𝛿𝐿𝑅
̅̅ ̅̅ ) (𝛿𝑆𝐼
̅̅ ̅̅ ) and standard deviation (σLR) (σSI) directional differences for 
signed x and y components are calculated across all dwells delivered for the treatment. 
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These metrics can provide directional information about deviations and inform the user 
of any systematic displacement of dwell positions. For example, a small mean 
difference in the S-I direction and a large standard deviation suggests individual 
catheter displacement within the implant, such as catheter slip at the template.  
6.2.5 Absolute Mean Directional Difference  
The absolute mean directional difference (|𝛿|̅̅ ̅̅ ) is calculated for all dwell positions from 
the mean directional components (𝛿𝐿𝑅
̅̅ ̅̅ ) (𝛿𝑆𝐼
̅̅ ̅̅ ). This metric can be used to identify the 
systematic shift component of an implant. For example, a large absolute mean 
directional difference and a small standard deviation would suggest an entire implant 
displacement.  
6.2.6 Maximum Mean Catheter Difference 
The mean catheter difference (𝛿?̅?) can be calculated for each catheter, j. The maximum 
mean catheter difference (𝛿𝑚𝑎𝑥̅̅ ̅̅ ̅̅ ) across all catheters can be used to highlight individual 
catheter deviations. For example a large maximum mean catheter difference (𝛿𝑚𝑎𝑥̅̅ ̅̅ ̅̅ ) and 
a small mean difference (𝛿̅) would suggest a swapped channel connection error or an 
incorrectly defined channel (indexer) length for a single catheter in the implant. This 
metric will identify which catheter exhibits the observed error. 
6.2.7 Histogram of Absolute Individual Dwell Difference 
The distribution of differences reported by the absolute individual dwell difference (δ) 
can be represented as a histogram. This provides a representation of the spread of 
differences of all the dwell positions, and will also identify any outliers that may 
represent single dwell positions that have been incorrectly delivered. The histogram 
distribution may also be used to define an error action threshold, when a percentage of 
the total number of dwells deviate from their expected positions.  
6.2.8 Histogram of Individual Directional Difference 
These histograms illustrate the distributions reported by the signed components 
representing the L-R (𝛿𝐿𝑅) and S-I (𝛿𝑆𝐼) directional distributions. The distribution will 
show any systematic differences such as all dwells delivered inferior of their expected 
planned positions. These metrics could suggest an incorrect indexer length 
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(shorter/longer) or catheter displacements due to swelling or swapped channel 
connection error.  
6.2.9 Absolute Dwell Difference Profile 
The absolute individual dwell differences (δ) can be reported with a bar graph showing 
the absolute difference at each dwell position along the catheter path. This is reported 
for each catheter in the implant and allows interrogation of individual dwell differences 
and the position along the catheter they occur. The results may suggest differences due 
to geometric changes of the implant from anatomical displacements. 
6.2.10 Individual Dwell Time 
The individual dwell time can also be measured by the FPD by integrating the image 
time stamps for determined dwell positions that occur in the same location. The 
difference between the measured and planned dwell times can be evaluated and 
discrepancies can be highlighted at particular dwell positions along the catheter path. 
6.2.11 Catheter Treatment Time 
The per catheter treatment time can also be measured by integrating the FPD image 
time stamps as described above. A bar graph representing the catheter time profile for 
the whole treatment fraction can be created to verify the per catheter treatment times 
and identify individual catheter discrepancies. This metric can be useful in identifying 
incorrect treatment plan selection where the time profiles are different. It can also be 
used to identify swapped catheter errors, in the unlikely event where the catheter paths 
are overlaid on the 2D A-P image, and the dwell positions of each channel are identical.  
6.2.12 Overall Treatment Time 
The total treatment time can be measured by integrating the time stamps of the FPD 
images acquired that contain a brachytherapy source response. This is described in 
section 4.2.11, and has an uncertainty relative to the image acquisition frame rate. This 
value can be directly compared to the planned treatment time (corrected for current 
source AKR) and used as an additional metric for correct treatment delivery.  
The metrics defined in the previous sections are used within the following section to 
provide examples of how the FPD system can be used as an error trapping device. 
 
 Chapter 6: Error Trapping 
168 
6.3 Error Trapping Investigations 
The solid water phantom described in section 5.1 is used to perform a series of 
treatment delivery error events. The treatment is initially delivered correctly (without 
errors) to demonstrate a reference (or baseline) set of error trapping metrics. Treatment 
error events are then introduced and the acquired data evaluated to demonstrate error 
identification.  
6.3.1 Method 
The solid water phantom containing 18 plastic catheters and three fiducial markers was 
placed on the CT couch, radio-opaque CT markers were inserted, and a CT scan 
performed. The CT data was transferred to the Oncentra TPS and for demonstration 
purposes only a treatment plan was created using 6 of the 18 available catheters (as 
illustrated in figure 6.1). When the treatment plan was complete it was sent to the 
treatment console computer, where it was loaded ready for treatment delivery.  
The phantom was transferred to the HDR brachytherapy treatment bunker and placed 
on the treatment couch in preparation for treatment delivery. Radio-opaque x-ray dwell 
position marker wires were inserted into the 6 catheters used for treatment and a pre-
treatment A-P image was acquired using the imaging geometry previously defined in 
figure 5.2.  
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Figure 6.1.  The simple treatment plan created to demonstrate the error trapping capability of 
the FPD system. Six catheters were used and these were selected across three separate rows (A, 
B and C) providing a range of source to detector distances.  
 
The three fiducial markers were identified in the pre-treatment A-P image and a 2D 
rigid registration was performed as described in section 5.3.4. The paths of the planned 
catheters were transformed into the measurement frame of reference using the 
transformation established by the registration process. Analysis was performed to 
determine the agreement between the planned and measured catheter positions. The 
planned dwell positions were also transformed into the measurement space for 
comparison with the delivered dwell positions. 
3D View 
A 
B 
C 
Plane A 
1 3 5 11 13 18 
Plane B Plane C 
D1 
D6 
D5 
D4 
D3 
D2 
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The marker wires were removed from the catheters, the transfer tubes were connected 
between the catheters and the afterloader and the treatment started. During the 
treatment delivery, the FPD was operated in continuous capture mode acquiring images 
of the phantom exit radiation as the treatment was delivered to each catheter. 
The agreement between planned and measured source dwell positions was determined 
by evaluating the 2D difference, in the plane of the FPD, between each individual 
measured dwell position. The quantified differences observed are reported using the 
metrics defined in section 6.2: 
• Visual comparison 
• The mean difference for all dwell positions calculated, (𝛿̅) 
• The mean L-R and S-I differences for all dwell positions calculated, (𝛿𝐿𝑅
̅̅ ̅̅ ) (𝛿𝑆𝐼
̅̅ ̅̅ ) 
• The absolute mean directional difference for all dwell positions calculated, (|𝛿|̅̅ ̅̅ ) 
• The maximum mean catheter difference, (𝛿𝑚𝑎𝑥̅̅ ̅̅ ̅̅ ) 
• A graphical representation of the absolute differences of dwell positions per 
catheter. 
• Histograms of the distribution of absolute difference and directional differences 
for all dwell positions. 
• Total Treatment time, individual catheter times and individual dwell time 
profiles. 
The analysis of the measured dwell positions delivered by each of the treatment plans 
can be performed in two ways:  
(i) The entire set of measured dwell positions are compared to the planned set 
of dwell positions and the above measures of agreement are performed. This 
approach does not consider the sequence the dwells are delivered, and in 
some instances of errors (swapped channels, incorrect treatment plan), as 
will be illustrated later, the order the dwells are delivered are important for 
identifying an error. 
(ii) The error trapping analysis is performed with knowledge of the programmed 
sequence of catheter channels. For each planned catheter, the planned dwell 
positions for that catheter are used for comparison with each successive 
measured dwell. Each measured dwell is compared to a corresponding 
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planned dwell and this comparison is performed per catheter. The overall 
histogram distributions and the calculated mean and standard deviation 
values are then a summation of these results. This approach provides a dwell 
by dwell comparison and is more sensitive to identifying errors than 
comparing all delivered dwells with all planned dwells.  
The measured dwell positions delivered for each of the following plans were evaluated 
on a per catheter basis as described in (ii) above.  
 
6.3.1.1 Correct Delivery 
The plan was loaded on the treatment console without any modifications and the 
transfer tubes were connected to the phantom and independently confirmed to ensure 
no errors were introduced.  
6.3.1.2 Incorrect Plan Selection 
To produce an incorrectly loaded treatment plan error, an alternative treatment plan was 
created and sent to the treatment console. This ‘incorrect’ plan used the same treatment 
catheters but consisted of different dwell positions, was loaded and delivered to the 
phantom. 
6.3.1.3 Incorrect Channel Length 
The treatment plan was modified on the TPS by reducing the defined indexer length of 
each treatment channel by 5 mm. At the TPS (Oncentra BPS v4.3, Elekta), this error is 
difficult to identify as the isodose distributions relative to the patient’s anatomy remain 
unchanged, but the result at treatment is a systematic shift of the dose.  
6.3.1.4 Swapped Channel Connection 
The treatment plan was loaded on the treatment console without modification. The 
transfer tube channels 1 and 5 were swapped so that transfer tube 1 was connected to 
catheter 5 and vice versa for transfer tube 5.  
6.3.1.5 Incorrect Plan Dwell Times 
The treatment plan was modified with all dwell times increased to represent an 
incorrect calculation of dwell times at the treatment console, possibly due to a 
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systematic error of the afterloader system performing time calculations. This error 
represents a failure of the afterloader or possibly a discrepancy of source AKR 
specification between TPS and the afterloader. 
6.3.2 Results 
The data collected for the 5 treatment deliveries was processed and the metrics defined 
in section 6.2 were calculated. A summary of some of these values is given in table 6.1 
which shows the agreement between the planned and the delivered dwell positions for a 
correct delivery and each introduced error event. 
 
Table 6.1. The table shows the absolute mean difference, the mean directional differences, and 
the mean difference between planned and measured dwell positions for all dwells in the 
implant. The maximum mean catheter difference is also shown and the values in the brackets 
represent one standard deviation. 
Dataset |𝛿̅| 
mm 
𝛿𝐿𝑅
̅̅ ̅̅  
mm 
𝛿𝑆𝐼
̅̅ ̅̅  
mm 
𝛿̅ 
mm 
𝛿𝑚𝑎𝑥̅̅ ̅̅ ̅̅  
mm 
Correct Plan  0.2 -0.1 (0.4) -0.2 (0.4) 0.6 (0.2) 0.8 
Incorrect Plan Selection 12.2 -0.1 (0.4) 12.2 (9.6) 14.1 (6.5) 19.8 
Incorrect Channel Length 4.8 -0.2 (0.4) 4.8 (0.5) 4.8 (0.5) 5.3 
Swapped Channel Conn. 3.1 3.1 (48.8) -0.2 (0.5) 29.1 (38.8) 80.0 
Incorrect Dwell Times 0.3 -0.1 (0.4) -0.3 (0.5) 0.6 (0.3) 0.8 
 
 
A visual comparison of the measured and planned dwell positions is shown in figure 
6.2 where the red dots are the planned dwell positions and the blue circles are the 
measured dwell positions. 
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Figure 6.2.  (a) The pre-treatment AP images showing channel numbers, the planned inactive 
(green circles) and active (red dots) dwell positions mapped on to the pre-treatment image. (b) 
The correctly delivered plan showing the measured source dwell positions as blue circle-cross. 
(c) The incorrect plan delivered. (d) The incorrect indexer length plan delivered. (e) The 
swapped channel connections plan delivered and (f) the incorrect dwell times plan delivered. 
 
The following sections show the results for each delivered treatment plan, reporting the 
calculated error detection metrics described in section 6.2. 
(a) (b) 
(c) (d) 
(e) (f) 
Treatment Plan Correct Delivery 
Incorrect Indexer Length Incorrect Plan 
Swapped Channel Incorrect Dwell Times 
1 3 5 11 13 18 
 
 Chapter 6: Error Trapping 
174 
6.3.2.1 Correct Delivery 
The treatment was delivered correctly and the distribution of dwell position differences 
is shown in the histograms of figure 6.3, showing the absolute (a) and the directional 
dwell differences (b) and (c). The measured dwell positions agree to within 1.0 mm of 
the planned positions for all of the dwells. The visual comparison (d) of the measured 
dwell positions is also shown along with a summary of the calculated measures of 
agreement (e). The absolute individual dwell differences (δ) are illustrated with the bar 
graphs shown in figure 6.4, showing the dwell positions along the catheter path, that 
contained a programmed dwell stops. The circle-cross indicate a dwell position that did 
not have a programmed dwell position and therefore no comparison is performed at this 
position. 
The comparison of planned total catheter time with measured catheter time of each 
catheter is shown in figure 6.5, where the error bars are twice the sampling interval of 
the FPD. All measured catheters agree with the planned time within the measurement 
uncertainty. The total treatment time is compared with the measured treatment time, 
which is a summation of all measured catheter times. 
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Figure 6.3.  Histograms showing the distribution of dwell position differences for the correctly 
delivered treatment plan with (a) the absolute dwell difference (δ), (b) the S-I directional dwell 
difference (δSI), (c) the L-R directional dwell difference (δLR), (d) the visual comparison of 
dwell positions and (e) the summary of agreement metrics. 
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Figure 6.4.  The absolute difference (δ) of each dwell position for each catheter for the 
correctly delivered treatment plan. The circle-cross indicates that a source dwell was not 
programmed for that position (refer to treatment plan in figure 6.1). 
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Figure 6.5 The comparison of planned total catheter time with measured catheter time of each 
catheter for the correctly delivered treatment plan, where the error bars are twice the sampling 
interval of the FPD. The total treatment time is compared with the measured treatment time, 
which is a summation of all measured catheter times. 
 
6.3.2.2 Incorrect Plan Selection 
The incorrect plan was delivered as the treatment and the distribution of source dwell 
position differences is shown in the histograms of figure 6.6, showing the absolute 
dwell differences and the directional dwell differences. Large discrepancies are seen in 
the absolute difference histogram and the S-I directional histogram indicating 
incorrectly delivered dwell positions.  
The visual comparison (figure 6.6(d)) shows that all the catheters were used by this 
‘incorrect’ plan, but some catheters received incorrect number of dwells and/or 
incorrect spacing relative to the expected plan. A visual evaluation of the delivered 
dwells does not clearly expose the significance of this treatment error. The summary of 
metrics (figure 6.6(e)) highlights that almost all values indicate an error. In this case the 
L-R directional histogram shows good agreement with the expected plan, and this is 
due to the ‘incorrect’ plan using the same set of catheters. 
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Figure 6.6.  Histograms showing the distribution of dwell position differences for the incorrect 
plan selection delivered treatment plan with (a) the absolute dwell difference (δ), (b) the S-I 
directional dwell difference (δSI), (c) the L-R directional dwell difference (δLR), (d) the visual 
comparison of dwell positions and (e) the summary of agreement metrics, where red indicates 
disagreement. 
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illustrated by the bar graphs shown in figure 6.7, showing dwell positions along the 
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delivered additional dwells to some catheters (e.g. catheters 1, 3, 13 and 18) further 
complicating the process of error identification. 
 
 
Figure 6.7.  The absolute difference (δ) of each dwell position for each catheter for the 
incorrect plan selection delivered treatment plan. The circle-cross indicates that a source dwell 
was not programmed for that position (refer to treatment plan in figure 6.1). The triangles at 
dwell positons D3 and D4 of catheter 5 represent planned dwell positions that did not record a 
measurement, as this ‘incorrect’ plan only had 2 active dwell positions in catheter 5. A dwell 
position comparison at D3 and D4 was not performed. 
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The comparison of planned total catheter time with measured catheter time of each 
catheter is shown in figure 6.8, where the error bars are twice the sampling rate of the 
FPD. The green columns are measured catheters where the times agree with the 
planned time within the measurement uncertainty, red indicates disagreement. The total 
measured treatment time does not agree with the planned treatment time, as many of the 
individual catheters times are incorrect. 
 
Figure 6.8 The comparison of planned total catheter time with measured catheter time of each 
catheter for the incorrect delivered treatment plan, where the error bars are twice the sampling 
rate of the FPD. The green columns are measured catheters where the times agree with the 
planned time within the measurement uncertainty. The total treatment time is compared with 
the measured treatment time, which is a summation of each measured catheter time. 
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measures of agreements further highlight the systematic nature of this error showing an 
absolute and directional displacement (S-I direction) and both having small standard 
deviations indicating all dwells have been displaced by approximately the same 
magnitude.  
 
Figure 6.9.  Histograms showing the distribution of dwell position differences for the incorrect 
indexer length delivered treatment plan with (a) the absolute dwell difference (δ), (b) the S-I 
directional dwell difference (δSI), (c) the L-R directional dwell difference (δLR), (d) the visual 
comparison of dwell positions and (e) the summary of agreement metrics, where red indicates 
disagreement. 
 
The absolute individual dwell differences (δ) are illustrated with the bar graphs shown 
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programmed dwell stops. The circle-cross indicate a dwell position that did not have a 
programmed dwell position and therefore no comparison is performed at this position. 
The total catheter time histograms (not shown) do not feature any discrepancies, and 
appear as in figure 6.5 within the measurement uncertainty.  
 
Figure 6.10.  The absolute difference (δ) of each dwell position for each catheter for the 
incorrect indexer length delivered treatment plan. The circle-cross indicates that a source dwell 
was not programmed for that position (refer to treatment plan in figure 6.1). 
 
6.3.2.4 Swapped Channel Connection 
The treatment was delivered with the transfer tubes of channel 1 and 5 swapped. The 
distribution of source dwell position differences is shown in the histograms of figure 
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6.11, showing many of the absolute dwell differences are less than 1 mm, but with a 
group of dwells with an absolute error of approximately 80 mm. The directional dwell 
differences show a S-I distribution around zero, but the L-R distribution exhibits dwell 
differences of +80 mm and -80 mm. This ‘bimodal’ signature suggest two sequences of 
dwells that were delivered at opposite L-R positions in the implant, i.e. a catheter 
connection swap event. 
 
Figure 6.11.  Error metric reporting for swapped channel connection error (Details are as per 
figure 6.9) 
 
The visual comparison of the measured dwell positions is shown in figure 6.11(d), and 
due to the nature of this error, it is not easily visualised as dwells are delivered in 
corresponding swapped channels. But the summary of the calculated measures of 
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agreement highlight this error, where the mean difference and the standard deviation of 
the mean L-R directional difference clearly indicate a discrepancy.  
The absolute individual dwell differences (δ) are illustrated with the bar graphs shown 
in figure 6.12, showing the dwell positions along the catheter path, that contained 
programmed dwell positions.  
The total catheter time histograms (not shown) do not show any deviations from 
expectation, as in the case of incorrectly programmed channel length.  
 
Figure 6.12 The absolute difference (δ) of each dwell position for each catheter for the 
swapped channel connection delivered treatment plan. The circle-cross indicates that a source 
dwell was not programmed for that position (refer to treatment plan in figure 6.1). 
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6.3.2.5 Incorrect Plan Dwell Times 
The treatment plan was delivered with all dwell times increased by a factor of 2. The 
distribution of dwell position differences is shown in the histograms of figure 6.13, 
showing the absolute (a) and the directional dwell differences (b) and (c). The 
measured dwell positions agree to within 1.0 mm of the planned positions for 92% of 
the dwells. The visual comparison (d) of the measured dwell positions is also shown 
along with a summary of the calculated measures of agreement (e). The absolute 
individual dwell differences (δ) are illustrated with the bar graphs shown in figure 6.14, 
showing the dwell positions along the catheter path, that contained programmed dwell 
positions.  
 
Figure 6.13.  Histograms showing the distribution of dwell position differences for the 
incorrect dwell time treatment plan with (a) the absolute dwell difference (δ), (b) the S-I 
directional dwell difference (δSI), (c) the L-R directional dwell difference (δLR), (d) the visual 
comparison of dwell positions and (e) the summary of agreement metrics. 
0
1
2
3
4
5
-2.0 -1.8 -1.6 -1.4 -1.2 -1.0 -0.8 -0.6 -0.4 -0.2 0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0
F
re
q
u
e
n
c
y
L-R Difference (mm)
0
1
2
3
4
5
-2.0 -1.8 -1.6 -1.4 -1.2 -1.0 -0.8 -0.6 -0.4 -0.2 0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0
F
re
q
u
e
n
c
y
S-I Difference (mm)
0
1
2
3
4
5
6
7
0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2
F
re
q
u
e
n
c
y
Absolute Difference (mm)
(a) 
(b) 
(c) 
(d) 
(e) 
3 1 5 11 13 18 
𝛿̅ 0.6 (0.3) 
𝛿?̅?𝐼  -0.3 (0.5) 
𝛿?̅?𝑅 -0.1 (0.4) 
|𝛿̅| 0.3 
𝛿𝑚𝑎𝑥̅̅ ̅̅ ̅̅  0.8 
 
 
 Chapter 6: Error Trapping 
186 
 
Figure 6.14 The absolute difference (δ) of each dwell position for each catheter for the 
swapped channel connection delivered treatment plan. The circle-cross indicates that a source 
dwell was not programmed for that position (refer to treatment plan in figure 6.1). 
 
In this case figure 6.15 exhibits large catheter time errors and a large total treatment 
time error. To further illustrate these observed time differences, the per dwell time 
difference for each catheter is shown in figure 6.16, where all measured dwells are 
approximately twice as long as expected – in this case 5 seconds larger than the planned 
dwell time. 
 
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
D1 D2 D3 D4 D5 D6
D
if
fe
re
n
c
e
 (
m
m
)
Dwell Position
Catheter 18
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
D1 D2 D3 D4 D5 D6
D
if
fe
re
n
c
e
 (
m
m
)
Dwell Position
Catheter 13
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
D1 D2 D3 D4 D5 D6
D
if
fe
re
n
c
e
 (
m
m
)
Dwell Position
Catheter 5
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
D1 D2 D3 D4 D5 D6
D
if
fe
re
n
c
e
 (
m
m
)
Dwell Position
Catheter 3
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
D1 D2 D3 D4 D5 D6
D
if
fe
re
n
c
e
 (
m
m
)
Dwell Position
Catheter 1
  
    
    
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
D1 D2 D3 D4 D5 D6
D
if
fe
re
n
c
e
 (
m
m
)
Dwell Position
Catheter 11
 
 Chapter 6: Error Trapping 
187 
 
Figure 6.15 The comparison of planned total catheter time with measured catheter time of each 
catheter for the incorrect dwell times delivered treatment plan, where the error bars are twice 
the sampling interval of the FPD.  The total treatment time is compared with the measured 
treatment time, which is a summation of each measured catheter time. 
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Figure 6.16 The difference of dwell time for each programmed dwell position in each catheter. 
The error bars shown for each data point represent the sampling interval of the FPD (±1.8 
seconds). 
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6.3.3 Discussion 
The four errors introduced into the treatment plans are intended to illustrate error events 
that may occur and are difficult to identify with existing approaches. Error trapping is 
not performed blindly, and knowledge of the treatment delivery as it proceeds is 
available. In this work, the treatment order of the planned catheters is used to establish 
the sequence of planned dwell positions for comparison with each measured dwell 
position. The approach is important for generating per dwell metrics that can provide 
absolute and directional difference metrics. 
6.3.3.1 Correct Delivery 
The treatment plan was delivered with no introduced errors to illustrate the comparison 
metrics with deviation due only to measurement uncertainties. The mean absolute dwell 
position difference was 0.6 mm and a maximum mean catheter difference was 0.8 mm. 
The spread of the directional difference histogram comparisons were less than 1.0 mm 
suggesting all dwell positions were delivered as expected. 
6.3.3.2 Incorrect Plan Selection 
Treatment of a patient with an incorrect plan is an event that can have significant 
consequences. Depending on the magnitude of difference between the correct and 
incorrect plan the treatment error may be difficult to detect. For example, a multi-
fraction prostate treatment, where each treatment fraction is determined with a CT and 
optimised treatment plan, successive treatment fraction plans may be similar. The 
active catheter and the location of the dwell positions within each catheter may only be 
slightly different as the treatment plan optimisation deals with anatomical changes 
between fractions. Delivery of the incorrect treatment plan (fraction) may be difficult to 
identify and the target may be under-dosed and OARs over-dosed.  
Another challenge for an error trapping system is how to manage an incorrect plan 
delivery when the number of dwells in each catheter does not match the planned 
number of dwells. In this approach, the system is measuring dwells per catheter, and 
when the dwell count is incorrect an error will be indicated. Error trapping during 
treatment delivery would ideally flag this as a potential error by the end of the first 
catheter. Investigation would still be required to distinguish this error from the case of 
one or more dwells that were in fact delivered, but not captured for some reason such as 
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very short dwell times. In the example used, catheter 5 was delivered with only 2 
dwells out of an expected 4 dwells. The sequence of measured dwells, as shown in 
figure 6.7, confirmed the first delivered dwell (D6) was in the correct position, but the 
second measured dwell (D5) was incorrect by approximately 20 mm. The next two 
planned dwells, D4 and D3 were not measured as the ‘incorrect’ plan did not have any 
more programmed dwells in this catheter. In this case these dwells were flagged for no 
comparison as there was no corresponding measured dwell for comparison. The other 
catheters shown in figure 6.7 exhibit a 10 or 20 mm absolute difference for almost all 
dwell positions, confirming that the sequence the dwells were delivered is important in 
highlighting this type of error. In contrast, visual inspection of the dwell position 
agreement shown in figure 6.6(d) shows that many of the measured dwell positions 
appear to correspond with planned dwell positions. A broad comparison of all planned 
and measured points in this instance may down-grade the severity of the error 
suggesting only a few dwell positions were mis-aligned with the expected positions. 
Clearly the time profile information becomes an important component of the error 
signature in this case. 
6.3.3.3 Incorrect Channel Length 
The definition of channel length (or indexer length) is a parameter which has the 
potential to introduce an error if it is incorrectly specified. In at least one TPS it is 
possible for an operator to unwittingly accept a default channel length or enter an 
incorrect length for a given applicator type or channel. The error introduced to the 
treatment plan involved all channels exhibiting an incorrect channel length definition 5 
mm toward the inferior of the implant.  
The approach used here could clearly identify this systematic error due to the 
relationship established between the measurement frame of reference and the TPS. This 
enables absolute verification of measured dwell positions relative to the treatment plan 
and therefore the systematic offset in the treatment plan was identified. A relative 
verification of all dwell positions in this case would not identify this error type. 
The error ‘signature’ associated with this error type is unique, with the metrics 
exhibiting mean values of displacement (e.g. the absolute mean difference) with 
relatively small standard deviations, showing all dwells have been displaced by 
approximately the same amount. In addition, the maximum mean catheter displacement 
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is approximately equal to the reported absolute mean difference also showing that no 
single catheter has been displaced by significantly more than the others. 
6.3.3.4 Swapped Channel Connection 
One of the most likely, and difficult to detect, treatment delivery errors to occur in 
HDR prostate brachytherapy is swapped channel connection error due to the large 
number of catheters used and the manual process of connecting the transfer tubes. The 
identification of this error event can occur by interrogating the metrics provided in 
figure 6.11. The absolute difference histogram shows many of the dwell positions were 
delivered correctly with differences less than 1 mm. The distribution also shows 9 
dwells that were delivered to the incorrect position by approximately 80 mm. It is not 
immediately clear where this discrepancy is from as a visual comparison of the 
delivered dwells in figure 6.11(d) shows only 2 dwells delivered incorrectly. The L-R 
direction difference histogram (figure 6.11(c)) provides further detail, showing that 4 
dwells were delivered -80 mm from their planned position and 5 dwells were delivered 
approximately +80 mm from their planned position. The absolute difference per 
catheter dataset shown in figure 6.12 illustrates that catheter 1 and catheter 5 have had 
the correct number of dwells delivered, but the channels have been swapped. The 
distance between these two catheters is 80 mm, hence the reported discrepancies. 
This swapped catheter error event also has a specific signature that can identify what 
type of error has occurred. In this case, the histograms provide the indication that a 
swapped channel error has occurred. The two distinct clusters in the absolute 
histogram, one at zero and one at the magnitude of distance between the swapped 
channels. This similar distribution is observed in the L-R directional histogram. 
6.3.3.5 Incorrect Plan Dwell Times 
The treatment plan delivered with incorrect plan dwell times was included in this work 
to highlight the capability of this verification system to validate dwell time as well as 
dwell position. The time profile histograms form a useful component of the verification 
system by helping in two ways: to detect errors and also to identify the types/cause of 
errors when detected. The times for all dwells was increased by a factor of 2 to simulate 
a more likely error of time calculation that would impact all dwells rather than 
individual dwells.  
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The results obtained from the source tracking process show the treatment plan was 
delivered without any dwell position errors. The metrics shown in figures 6.13 and 6.14 
report position distributions similar to figures 6.2 and 6.3, for the correctly delivered 
treatment plan. The per catheter time comparison of figure 6.15 immediately shows a 
discrepancy from the planned catheter times and this is also reflected by the difference 
in total treatment time. The measurement system using the FPD to record dwell times 
provides an additional dimension to this error trapping system. The time difference 
comparison per dwell, as shown in figure 6.16, allows the individual dwells to be 
verified. The FPD frame rate is relatively slow, so dwell timing resolution is quite 
limited, however even this low resolution data is extremely valuable in diagnosing error 
types. 
6.3.4 Error Trapping Investigations Conclusion 
The metrics described in this section have been used successfully to identify all 
introduced treatment delivery errors. A notable advantage of this system is the 
capability to perform absolute dwell position verification and not just a relative 
verification measurement. This enables certain error types to be identified, that would 
otherwise go undetected.  
6.3.5 Comparison with other Error Trapping Systems 
There are several other treatment verification systems proposed in the literature, as 
described in chapter 2, but none has the capacity to comprehensively detect all of the 
known classes of error (table 6.2). The power of the present system is the combination 
of pre-treatment imaging and source tracking. This combination enables the system to 
perform both relative and absolute treatment verification allowing the system to 
monitor and account for geometric changes in the implant that will influence the level 
of treatment delivery agreement observed. Furthermore, this system is equally sensitive 
to any dwell position error, anywhere in the implant, independent of location relative to 
the detector. The limitations of these other verification systems hinder their ability to 
identify certain classes of treatment error and the detectable errors vary across these 
systems.  
The most directly comparable verification system is electromagnetic (EM) tracking, 
which performs mapping of the catheter paths immediately prior to treatment. The 
system described by Poulin et al [85] captures implanted catheter paths in a phantom, 
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where catheter trajectories are identified within a uncertainty of 0.7 mm, where each 
catheter reconstruction time is approximately 10 seconds. The reconstruction 
uncertainty for the 3D reconstruction approach described in this thesis is 1.0 mm (for a 
point 100 mm from the detector imaging plane) which is only slightly greater than the 
EM system, and is clinically equivalent. The obvious extension of EM tracking 
technology would be to integrate a sensor into the clinical source capsule to perform 
real time source tracking, but this is yet to be demonstrated. EM tracking in the clinical 
environment will require some calibration efforts to be included in the overall 
workflow. A proposed clinical workflow illustrated by Beaulieu et al [86], describes a 
calibration procedure to ensure all reference sensors are correctly calibrated and the 
imaging system is correctly registered with the EM tracking frame of reference. For the 
system described in this thesis, the registration of the imaging system to the tracking 
system occurs during the pre-treatment imaging step therefore no additional pre-
calibration steps are required. EM tracking has the potential to identify treatment errors 
such as catheter displacement due to implant geometry changes and incorrectly defined 
channel length, but would not identify a swapped channel connection error. 
While the present system actually tracks the source throughout the treatment delivery, 
others infer correct treatment delivery by comparison of a point dose with an 
expectation. The dose measurement uncertainty of many of these point dosimeters have 
been shown to be relatively small, but when used to perform in vivo measurements 
often large discrepancies relative to the expected value are reported. As discussed 
previously, these IVD approaches have limited value for treatment error detection due 
to a large proportion of the measurement uncertainty being due to the position 
uncertainty of the dosimeter. Mason et al [46] reported a position measurement 
uncertainty for a single MOSFET dosimeter of 4.1% (k=1) which results in a total plan 
measurement uncertainty of 12.3% (k=2). This value was used as the error detection 
threshold, but this is highly dependent on the location of the dosimeter and is 
insensitive to errors occurring far from the dosimeter position which contribute only a 
small percentage to the total measured dose. For 40 patients measured, only one patient 
measurement was identified above the error detection threshold and this was justified 
by likely needle reconstruction errors. Carrara et al [64] also quoted a large uncertainty 
due to detector position uncertainty (3.5%, k=1) which results in a total measurement 
uncertainty of 5.7% (k=1). If used as an error detection threshold, approximately 45% 
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of patients would have been flagged as having a treatment error. Only after re-imaging 
of the volume (post treatment) to verify the catheter (source) to detector distances, was 
the error detection rate reduced to approximately 18%. Both of these recent 
publications, where integrated measured dose is used as a surrogate to identify 
treatment delivery errors, are examples of how limited this approach is as a real time 
error detection mechanism. To overcome these limitations Johansen et al [115] describe 
a time resolved in vivo dosimetry system for performing source tracking during HDR 
prostate brachytherapy. A single radioluminescent crystal dosimeter was used inside a 
dedicated catheter, additional to the implanted clinical catheters, and acquired readings 
of dose rate every 50ms. The measured dose rate at each dwell position was then used 
to reconstruct the likely position of each dwell position relative to the dosimeter. This 
approach was then used to identify catheter displacements with an uncertainty of 
approximately 1mm. The approach also can catch some swapped catheter connection 
and incorrect indexer length treatment delivery errors. But currently these discrepancies 
are only relative to the dosimeter and not to the surrounding patient anatomy. The 
system described in this thesis combines imaging and source tracking, therefore 
discrepancies relative to the patient anatomy are possible. 
One key advantage of IVD over source tracking is to perform measurements that can be 
used to monitor organ at risk dose. The exact position of the dosimeter in this approach 
is not critical, as the dosimeter is likely to move with the organ as the patient geometry 
changes. But the resulting monitored dose value can be used as a safety system to 
monitor and limit organ total dose.  Improved detector design, incorporating fiducial 
markers in the detectors has produced improved confidence in localising detector 
position during pre-treatment imaging, as illustrated by the Urethral dose measurements 
performed by Suchowerska et al [50]. The addition of detector localisation improved 
the agreement of measured to predicted dose to be less than 10% for all patients.  
Small detector measurement volumes and angular and energy independence, such as 
the PSD [43], provide reduced uncertainty in dose measurements, but only sample the 
treatment volume at a single point. This approach limits the ability to identify treatment 
errors that have a spatial ‘signature’, (swapped catheter connection, incorrect channel 
length) as described in this chapter. IVD may flag a swapped catheter connection error, 
but would be incapable of identifying what type of error caused the IVD measurement 
discrepancy. Furthermore, in certain geometries where the incorrect source to detector 
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distance is similar to the correct source to detector distance (mirrored swapped catheter 
error), an error is unlikely to be identified. 
The concept of real time treatment verification using a C-arm operated in fluoroscopic 
mode was demonstrated by Nose et al [73]. Although this is real time, the approach is 
limited to only detecting gross errors, as there is no indication of where the expected 
dwell position is located relative to the observed patient anatomy. Without an absolute 
reference to the treatment plan, the identification of treatment errors is subjective by 
performing a visual comparison between the fluoroscopic screen and a plan printout, 
which limits the effectiveness of this approach. The system proposed in this thesis has 
the potential to identify errors in real time, establishes a direct reference between the 
treatment geometry and the treatment plan by performing pre-treatment imaging, and 
uses an algorithm to determine if an error has occurred. 
This verification system produces large amounts of data that can be interpreted to not 
only flag that an error has occurred, but also to suggest the potential source of the error. 
The identification of the error type occurs due to the signatures that different error types 
produce across the measured data. These error signatures are further explored in the 
next section where specific detection metrics are summarised for their sensitivity to 
particular error events. 
6.4 Summary of ‘Error Signatures’ 
This verification system produces large amounts of data that can be interpreted to not 
only flag that an error has occurred, but also to suggest the potential source of the error. 
The identification of the error type occurs due to the signatures that different error types 
produce across the measured data. These error signatures are further explored in the 
next section where specific detection metrics are summarised for their sensitivity to 
particular error events. 
The detection of a treatment error involves evaluation of many metrics in parallel that 
support an error event and can direct the operator to the likely cause of the error. Table 
6.2 summarises the error event and the likely detection by each defined metric. Mx 
represents that the error may be detected but is particular to the characteristics of the 
error and is further quantified in the text below the table. 
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Table 6.2. The summary of error events and detection metrics, showing the sensitivity of each 
metric to an error event. Y = sensitive, N = not sensitive and Mx = maybe -with a description of 
the signature below. 
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Incorrect Plan 
M1 Y Y M2 M3 Y Y Y Y Y M4 
Incorrect Channel 
Length 
Y M5 M6 M7 M8 Y Y Y Y Y N 
Swapped Channel 
Connection  
M9 Y Y N M10 N Y Y Y Y N 
Incorrect Dwell 
Times 
N N N N N N N N N N Y 
 
Incorrect Plan 
• M1 – The visual comparison of the dwells may not necessarily indicate a 
treatment error has occurred. If the incorrect treatment plan contains dwell 
positions that are very similar to the desired plan (possibly a successive 
fraction), then the overlay of dwell positions may not be significantly different. 
• M2 & M3 – The distribution of the measured dwells of the incorrect plan may 
not vary significantly from the correct plan. There is a possibility that the L-R 
direction distribution is similar to the original plan and so this metric on its own 
may not flag an error event. 
• M4 – It is not likely that the dwell time of the incorrect plan with be the same as 
the correct plan. There is a possibility that the total catheter times may resemble 
the planned times and so in this case these metrics on their own may not flag an 
error event. 
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Incorrect Channel Length 
• M5 – If all the catheter channels have been assigned an incorrect channel length, 
then the mean difference metric will be a strong indicator of an error and will 
resemble the incorrect offset applied to the channels. If only one or a few 
channels have been assigned incorrectly then this metric on its own may not 
necessarily flag an error event. 
• M6 – The standard deviation of the mean difference metric will flag an error in 
combination with the mean difference metric. A small value will suggest all 
channels have been assigned the incorrect channel length. 
• M7 – The mean directional difference metrics are likely to be valuable in the SI 
direction. If all the catheter channels have been assigned an incorrect channel 
length, then the metric will resemble the incorrect offset magnitude and 
direction, where a positive value represents an inferior offset. 
• M8 – The standard deviation of the mean directional difference metrics in 
combination with the mean directional difference will provide additional 
support of an error event in the case where all catheters have been assigned 
incorrectly. 
Swapped Channel Connection 
• M9 – The visual comparison of dwell positions may not clearly define a 
swapped channel connection event. The measured dwell positions will appear 
along the corresponding swapped catheter path and so may not be apparent to 
the operator. 
• M10 – The standard deviation of the mean directional difference metrics will 
identify an error in the LR direction. The magnitude of this reported value, in 
conjunction with a small value for the mean directional difference metric, will 
be a strong indicator of an error and represent approximately half the distance 
between the catheter paths of the swapped channels. 
6.5 Extension to Real-Time Error Detection 
The error detection investigated throughout this chapter has used a retrospective 
evaluation of the data. During this developmental phase, the system was used in a non-
interventional (retrospective) mode to improve the understanding of the system’s 
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capabilities, and to develop ways of presenting data to the operators/treating staff. All 
dwells were measured by the verification system and, after the treatment delivery, 
analysis was performed to verify correct delivery. As shown, this retrospective 
approach is comprehensive but it does not enable immediate action to be taken on an 
identified error to minimise the potential harm to a patient. 
The natural progression of a system is to perform the dwell position evaluation in real-
time, as the treatment is delivered, and using the range of error detection metrics 
available, establish if the treatment is proceeding according to the plan. The 5 treatment 
plans delivered to the phantom in section 6.2 were re-analysed in the dwell delivery 
order (to mimic real-time evaluation) and the sequential error detection metrics were 
calculated.  
The goal of error trapping clinical implementation is to continually monitor these 
metrics and when a metric reaches an investigation threshold, the operator could be 
notified of the discrepancy. If the metric reaches the action level threshold, the HDR 
brachytherapy afterloader could be triggered to halt treatment while the source of the 
identified error is determined. Some of the error trapping metrics described in section 
6.2 could be plotted in ‘real-time’ (dwell delivery sequence) as the treatment 
progresses. For example, the absolute individual dwell difference (δ) metric is shown in 
figure 6.17 for the correctly delivered plan and for each introduced error event. 
Potential investigation and action levels are also shown. 
In the case of swapped catheter channels, as illustrated in figure 6.17, the first delivered 
dwell position is incorrect by 80 mm, this metric would flag an error and halt treatment. 
The human error could be corrected, the plan my need to be modified to account for the 
incorrectly delivered dose, and the potential damage to the patient is minimised. The 
combination of other error metrics in real-time will allow identification of the potential 
error source, similar to the errors that are flagged in table 6.2. 
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Figure 6.17.  A concept for error metric presentation for real-time treatment verification. The 
absolute difference of each individual dwell is presented as each dwell is delivered in sequence. 
The correct plan and the 4 introduced error types are shown.  
 
6.6 Conclusion 
This chapter has illustrated the capability of this system as an error trapping device in 
HDR brachytherapy. A key advantage of this system is the rich source of data that can 
inform the treatment staff of treatment delivery status. The combination of information 
from data visualisation tools and metrics can aid in the identification and source of 
errors. The interpretation of the error ‘signatures’ are possibly amenable to automation, 
or at least algorithmic guidance. Expert interpretation is still recommended for 
evaluation of the information presented, for example the ‘incorrect plan’ demonstrates 
the complexity of interpretation. 
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The error trapping concepts explored in this chapter will apply even to other treatment 
verification systems, for example electromagnetic source tracking implementations. 
One of the greatest challenges will be to refine the techniques used to present the 
information to the operators in a meaningful, clear, efficient and unambiguous way. It 
is expected this will evolve with experience. Another significant factor in making such 
a system useful to clinical staff is a smooth integration into the treatment procedures. 
The integration into a clinical environment is explored in the next chapter. 
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Chapter 7 
Clinical Implementation 
 
7 Introduction 
The aim of the final part of this work was to transfer the methods and knowledge 
obtained in the previous chapters into the clinical environment where it will provide a 
direct benefit to patients. The translation of a phantom based study to the clinical 
environment can be a difficult process. Integration of new processes into an existing 
treatment workflow, without significantly adding to treatment procedure time is 
challenging. This chapter describes the steps taken to implement this treatment 
verification system in a HDR brachytherapy clinical environment. Modifications made 
to the treatment couch to accommodate the FPD and the x-ray equipment added to the 
treatment bunker to perform pre-treatment imaging is also covered. The clinical 
workflow was slightly modified, establishing a straight-forward approach, permitting 
verification to be performed routinely. Clinical results are presented for an example 
patient using the pre-treatment imaging and source tracking verification process.  
 
7.1 Introducing Treatment Verification to the Clinical Environment 
HDR prostate brachytherapy has been performed since 1998 at Alfred Health Radiation 
Oncology (AHRO), Alfred Health, Melbourne, Australia, as a boost to the EBRT 
schedule. CT data is used for treatment planning and the HDR brachytherapy 
prescription dose is delivered in two treatment fractions. The patient is transferred from 
the hospital ward bed onto the CT couch for treatment planning imaging using an air 
driven hover mattress. Moving the patient between the bed and the CT imaging couch 
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increases the risk of disturbing the brachytherapy implant geometry. To further reduce 
this risk at treatment, the patient remained on the hospital ward bed in the HDR 
brachytherapy bunker, as shown in figure 7.1. Only an external check of the catheters 
positions relative to the template was performed, no verification of the catheter 
positions using imaging was done.  
 
Figure 7.1.  The connection of afterloader transfer tubes in preparation for treatment delivery in 
the HDR brachytherapy bunker. The patient remains on the hospital ward bed for treatment. 
 
Establishing treatment verification in this clinical environment, which is similar to most 
CT based HDR brachytherapy clinics, was challenging as the treatment procedure does 
not easily lend itself to verification using the system described in this work. Although 
treating the patient on a hospital ward bed eliminated another movement that may 
potentially disturb the implant geometry, the uncertainty of the implant position due to 
the non-reproducible patient setup on a soft mattress was of greater concern. 
Furthermore, even if the FPD could be integrated into the ward bed patient setup, 
implant position verification imaging would be extremely difficult as the patient 
geometry does not reflect the reference geometry used for treatment planning.  
A change of clinical practice was introduced and the patient was transferred from the 
ward bed on to the brachytherapy treatment couch, containing the FPD, using a hover 
mattress. Any deviation of the implant geometry after the treatment planning CT (either 
due to swelling or patient movements) is identified and accounted for during image 
verification.  
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The following sections in this chapter describe the development of a treatment couch to 
contain the FPD, additional x-ray equipment installed in the bunker (to provide 3D 
implant position verification), patient setup, pre-treatment imaging and the source 
tracking procedure.  
7.1.1 Treatment Couch Design 
A treatment verification couch was designed which allowed integration of the FPD into 
the couch and permits the patient to be set up, in a position that closely matches that at 
treatment planning imaging (CT), in the HDR brachytherapy treatment bunker. An 
existing brachytherapy treatment couch, shown in figure 7.2, was previously used for 
treatment of other anatomical sites. This treatment couch (Betastar, Maquet Getinge 
Group, Sweden) is very typical of an operating theatre couch, has a modular design, 
allowing end sections to be removed if required.  
 
Figure 7.2.  The HDR brachytherapy couch at AHRO used for treatment of other anatomical 
sites. The couch can be tilted and couch ends can be removed for various setup requirements. 
 
A couch end attachment was designed that could host the FPD and support the pelvis of 
the patient above the detector imaging region and this design is shown in figure 7.3. 
The FPD was mounted below the patient allowing source tracking and pre-treatment 
imaging to occur. Positioning the FPD below the patient (rather than above the patient) 
produced the shortest brachytherapy source to detector distance for a prostate patient, 
and reduced possible air gaps limiting the influence of inhomogeneities during the 
source tracking process. The patient’s weight was also supported by a low density 
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carbon fibre couch top, protecting the sensitive region of the FPD, while not interfering 
with imaging.  
 
Figure 7.3.  The treatment verification couch design incorporating the FPD below the patient 
and a carbon fibre couch top to support the patient. The side rails allow attachment of leg 
support stirrups allowing the patient to be set up in a position that closely matches treatment 
planning imaging. 
 
Side rails were also added to the couch end attachment allowing patient leg support 
stirrups to be mounted. This provided a method to support and lower the patient legs to 
approximately horizontal, again to reproduce the CT imaging setup. 
7.1.2 Treatment Room Modifications 
HDR brachytherapy treatment bunkers are not typically designed with treatment 
verification in mind and therefore lack components that assist with the verification 
clinical workflow. 
Moving the patient on to the treatment couch is swift using the hover mattress system, 
but aligning the brachytherapy implant (pelvis) above the sensitive region of the FPD 
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can be challenging due to the hover mattress and other hospital bedding obscuring the 
imager localisation marks on the treatment couch. To overcome these potential 
problems, a laser system was installed in the HDR bunker, similar to a LINAC bunker 
laser system. Two lateral cross lasers and one sagittal laser was installed, so the couch 
could be aligned to the laser isocentre at the centre of the FPD imaging device (L-R & 
S-I). In addition to positioning the patient, the lateral cross lasers also enabled 
replication of the patient pelvic rotation at CT imaging using skin marks (See figures 
7.7 and 7.9(a)). 
To perform pre-treatment imaging, using the FPD as the image receptor, an in room x-
ray source was required. This was initially achieved by using a mobile x-ray system 
(AMX-4, GE Medical Systems, Milwaukee, Wisconsin, USA), on loan from the 
hospital Radiology department, and is shown in figure 7.4.  
This mobile x-ray system was used during our initial clinical work, but it became clear 
that positioning the x-ray source at a known distance (FID) was a challenge, as the 
system is not designed for such accurate positioning. The mobile device is quite bulky 
and in a relatively small brachytherapy bunker, the device was difficult manoeuvre and 
position. This type of system does not lend itself to perform shift imaging (as described 
in section 5.4.1), and so only 2D pre-treatment imaging was possible. 
 
Figure 7.4.  The mobile x-ray system GE AMX-4 model from Radiology department used 
initially for 2D pre-treatment image verification. 
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To overcome these limitations, AHRO installed a ceiling suspended x-ray system 
(QRad OTS x-ray suspension system, Carestream Health, Rochester, NY, USA) in the 
HDR brachytherapy bunker, as shown in figure 7.5(a). The ceiling suspended x-ray 
system moves in all directions by rolling along perpendicular rails suspended below the 
ceiling. The height of the x-ray head can be moved via a telescopic extension and the x-
ray head can also be rotated. Mechanical stops were added to the rails, relative to the 
central axis position of the FPD, to provide reference stop positions left and right 
(laterally) of the patient. These stop positions provide swift positioning movements 
during the pre-treatment imaging process, reducing the procedure time. When the 
system is not in use during a clinical case, it can be parked in the corner of the room, as 
shown in figure 7.5(b), providing access to move around the treatment room. 
 
Figure 7.5.  (a) The treatment room ceiling suspended x-ray system used for pre-treatment 
imaging and (b) the system parked out of the way during a clinical case. 
 
7.1.3 Clinical Workflow Changes 
The clinical workflow was modified to accommodate the addition of pre-treatment 
imaging and source tracking verification. The additions to the clinical workflow are 
shown in green, as illustrated in figure 7.6. The flowchart indicates the steps taken to 
implement treatment verification and the approximate time frame from patient arrival at 
the treatment bunker to the start of treatment delivery. 
(a) (b) 
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Figure 7.6.  The HDR prostate brachytherapy treatment verification workflow performed at 
AHRO. The green boxes represent additional steps included in the workflow to implement 
treatment verification. 
 
The only workflow change that occurs prior to the patient arriving at the treatment 
bunker (not described in figure 7.6) occurs at the CT imaging step. Skin marks are 
drawn on the patient’s pelvis, as shown in figure 7.7, using the CT lasers to capture the 
observed pelvic rotation. 
Patient arrives at bunker ready for treatment 
Transfer from bed to treatment couch 
Patient aligned above FPD imaging region 
Afterloader transfer tubes connected 
Markers inserted into subset of catheters 
Pre-Treatment x-ray images acquired (x3) 
Markers removed, final transfer tubes connected 
Treatment commenced 
Source tracking performed during delivery 
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Figure 7.7.  Skin marks drawn on the patient at CT imaging to capture the observed pelvic 
rotation. The skin marks are then used to align the patient at treatment using the treatment 
bunker lasers. 
 
At treatment, the patient is transferred to the treatment couch using the hover mattress. 
The patient legs are placed in the stirrups attached to the couch and lowered to a 
horizontal position. The skin marks on the pelvis are aligned with the treatment room 
lasers to centre the implant over the FPD and to replicate the set up seen at CT imaging. 
The afterloader transfer tubes are connected to the brachytherapy implant, except for 5 
catheter channels that have been designated to be used for imaging. Radio-opaque x-ray 
dwell position markers are inserted into these channels in preparation for imaging. An 
A-P image and two ‘shift’ (oblique) images are acquired using the process described in 
chapter 5 (and illustrated in figure 5.23). 
The A-P image is registered against the treatment plan (as described in section 5.3.4) 
and the planned catheter positions are directly compared with the measured catheter 
positions. A decision based on any measured catheter displacement is then made by the 
Radiation Oncologist and treatment proceeds if determined to be below some clinical 
threshold. The two captured ‘shift’ images are evaluated offline. The x-ray markers are 
removed, the final few transfer tubes are connected, and the treatment commences. 
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During treatment delivery source tracking is performed, with the FPD operated in 
‘continuous image acquisition’ mode, capturing images of the source radiation exiting 
the patient. The source tracking images are then processed and evaluated offline.  
Once treatment is completed, the patient is disconnected from the brachytherapy 
afterloader, and returned to the hospital ward bed using a hover mattress. 
7.2 Example Clinical Case 
This section describes in detail the end-to-end verification process performed for an 
example case and illustrates the analysis of the data obtained using the methods 
described in the previous chapters of this thesis.  
7.2.1 Method 
The initial implementation of this verification system in the clinical environment was 
performed as a passive study, and no intervention was performed, unless gross errors 
were observed. Visual comparison of the A-P image and plan was done online, but 
further analysis of the acquired verification data was performed post-treatment. 
7.2.1.1 Treatment Protocol 
The Alfred Health Radiation Oncology department currently performs HDR prostate 
brachytherapy boost along with an external beam component. Our technique is similar 
to that of many modern HDR prostate brachytherapy programmes, where up to 18 
plastic catheters (ProguideTM, Elekta AB, Stockholm, Sweden) are inserted into the 
prostate, and HDR brachytherapy treatment is delivered with a remote afterloader 
(microSelectronTM, Elekta AB, Stockholm, Sweden) in two fractions of 8.5 Gy. 
Treatment planning with the Oncentra TPS (Oncentra, v4.3, Elekta AB, Stockholm, 
Sweden) is based on CT imaging which is performed at each treatment fraction[116]. 
 
7.2.1.2 Treatment Procedure 
While the patient was anaesthetised in the operating theatre, the plastic catheters were 
inserted into the prostate and guided into position using trans-rectal ultrasound (TRUS) 
imaging. Three gold fiducial markers were implanted into the prostate and placed in the 
anterior, mid and base regions of the prostate. A CT scan was performed for treatment 
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planning purposes and skin marks were added for reproducible patient set up at 
treatment, as previously shown in figure 7.7. The treatment plan was created using the 
TPS following our departmental protocol. 
 
Figure 7.8.  The patient transfer process from the ward bed to the brachytherapy treatment 
verification couch performed with a hover mattress. The patient lies on a flat couch replicating 
the setup at treatment planning imaging (CT) and the legs are supported with stirrups. 
 
At the time of treatment, the patient was transferred on to the treatment couch 
containing the FPD as shown in figure 7.8. The patient was aligned such that the target 
(implant) region was centered over the sensitive imaging area of the FPD. The position 
of the patient on the treatment couch, specifically the hip rotation, was adjusted to 
replicate the supine position of the patient during the planning CT scan. This was 
achieved by aligning the patient skin marks to the in room lasers (figure 7.9(a)) and 
supporting the patient’s legs in stirrups (Yellow FinsTM, Allen Medical, Acton, MA, 
USA), attached to the treatment couch, as depicted in figure 7.9(b). 
 
 Chapter 7: Clinical Implementation 
211 
 
Figure 7.9.  (a) Alignment of the patient over the sensitive region of the FPD using the 
treatment room lasers and replicating the pelvic rotation with skin marks. (b) The patient in 
treatment position in preparation for pre-treatment imaging, replicating the legs down position 
at CT. 
 
A subset of the total number of implanted catheters (5 catheters) were designated to be 
used for pre-treatment imaging. A subset of catheters was used for pre-treatment 
imaging for three reasons: (i) to avoid excessive marker overlap in the pre-treatment 
images, (ii) to consider the workflow timeline and limit additional work and (iii) 
minimise the time between pre-treatment imaging and source tracking. These catheters 
are selected to represent the extent of the implant geometry, and so catheters are idealy 
selected from the posterior template row, left and right positions and the anterior 
template row. Using the information obtained from the CT data, an informed selection 
of these catheters was possible, minimising potential projection overlap on the A-P 
image. 
Radio-opaque x-ray dwell position markers were inserted into the selected catheters, as 
shown in figure 7.10(a). The ceiling suspended x-ray system was moved into position 
above the patient as shown in figure 7.10(b). A single A-P image was acquired using 
the FPD as the image capture device and the imaging geometry defined in figure 5.2. 
To correct for divergence in the image and to localise the x-ray source with the FPD, a 
BB array was included in the image capture (Section 5.3.2).  
(b) (a) 
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Figure 7.10.  (a) The x-ray markers being inserted into the selected subset of catheters in 
preparation for pre-treatment imaging. (b) The ceiling suspended x-ray system above the 
patient ready for imaging. The BB array is mounted below the x-ray collimator and is included 
in the A-P x-ray image. 
 
The BB array was removed and the shift imaging was performed according to the 
procedure previously described in section 5.4.1. The x-ray dwell position markers were 
removed from the catheters, and the few remaining transfer tubes were connected and 
the HDR brachytherapy treatment commenced. 
For source tracking during treatment delivery, the FPD was operated in ‘continuous 
acquisition’ mode as described in section 3.13. The capture process acquired a 
sequence of ‘images’ of patient exit radiation, as the source progressed through the 
programmed dwell positions, at a rate of 1 image every 1.8 seconds, where each image 
consists of 1 reset frame and 4 frame averages. The source tracking frame rate (0.625 
fps) limits the acquisition of very short programmed dwell positions. Planned source 
dwell positions with dwell times greater than 3.2 seconds (2× acquisition period) were 
captured with at least one image (at each dwell position) containing no artifact due to 
source motion.  
(a) (b) 
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Once treatment was completed, the sequence of images was processed to determine the 
source coordinate in the plane of the FPD. The measured dwell positions were then 
calculated from the sequence of source coordinates using the methods described in 
section 4.5, and these were then directly compared to the treatment plan for 
verification.  
The following sections describe the various comparisons of measured data with the 
treatment plan, each providing confirmation of aspects of treatment parameters, in order 
to achieve overall treatment delivery verification. 
7.2.1.3 2D Pre-Treatment Image Verification 
The A-P image acquired immediately before treatment was used to evaluate the current 
catheter positions immediately prior to treatment and identify any displacements. The 
image was processed using methods previously described in chapter 5. For clarity, the 
process is summarised by the following points: 
• Projected BB marker pairs were identified and are used to correct for image 
divergence 
• The fiducial markers visible in the image were identified and positions marked 
• The catheter paths observed in the image were identified and positions marked 
• Registration with the TPS was performed (described in section 5.3.4) 
• Planned catheter paths were projected onto the A-P image 
• Comparison of planned and measured catheter positions was performed using 
the methods established in section 5.3.2 
The 2D pre-treatment image processing described above was performed using in-house 
software enabling comparison of the catheter positions to be performed at the treatment 
console (Appendix C: Pre-Treatment Verification 2D). The projected BB pairs were 
manually selected by the user, and the centres of the BBs were calculated by 
performing a pixel threshold on a ROI surrounding each selected BB. A COM 
algorithm was then applied to determine the centre pixel position of each BB. The 
intersection point of the BB array was calculated using the method described in section 
5.3.3 to determine the x-ray CAX. The three fiducial markers were identified by the 
user selecting the centre of each marker visible on the A-P image. Each of the 5 
catheters were identified in the A-P by using the unique ‘dot-dash’ labelling of the 
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markers. The user then selected the centre of each catheter marker along its path to 
define the absolute position for comparison with the TPS. The treatment plan was 
exported from the TPS and imported into the in-house software, and a registration 
performed (section 5.3.4) using the 3 fiducial markers also specified in the treatment 
plan. The planned catheter paths imported from the treatment plan were then 
transformed into the measurement frame of reference using the transformation 
determined by the registration and these transformed planned catheter paths were 
overlaid on the A-P for direct comparison with the measured catheter paths. 
7.2.1.4 3D Catheter Reconstruction Image Verification 
The two ‘shift’ images acquired prior to treatment delivery were processed post 
treatment due to treatment time constraints. The images were used to establish a 3D 
representation of the catheter positions using the back projection reconstruction 
approach previously defined in section 5.4.2. A summary of this method is as follows: 
• The corresponding catheter marker points for each catheter are identified and 
marked in each image 
• The corresponding fiducial marker points in each image are identified and 
marked. 
• Using the known image acquisition geometry, the catheter points and the 
fiducial marker points are back projected to create a 3D representation of the 
implant geometry (see figure 5.2.4) 
• 3D registration of the reconstructed fiducial markers with the TPS is performed 
(see section 5.4.4) 
• Comparison of planned and measured catheter positions was performed using 
the methods established in section 5.4.7 
The shift images acquired during the pre-treatment imaging process were processed 
post-treatment using in-house software (Appendix C: Pre-Treatment Verification 3D). 
Each corresponding catheter is identified in each image using the ‘dot-dash’ marker 
labelling. The user manually selects corresponding marker points of each catheter until 
the path of each catheter is defined. The user also manually selects the corresponding 
fiducial markers in each image. The software performs the back projection of the 
catheters and fiducial markers as described in section 5.2.4 to calculate the 3D 
definition of the catheter paths and fiducial marker positions. The treatment plan is 
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imported and the software performs a 3D registration with the defined fiducial markers. 
The planned catheter paths are then transformed into the reconstructed implant 
(measurement) frame of reference and the catheter positions were then compared in 3D. 
7.2.1.5 Source Tracking 
The images acquired during source tracking were processed post-treatment to verify the 
positions of the source dwells. The sequence of images acquired for each catheter were 
processed using the COM approach defined in section 4.2.1.3 to calculate the 2D 
coordinate of the source in the plane of the FPD. The sequence of calculated source 
coordinates (one per image) for each catheter were further processed to establish the 
measured dwell position. Each measured dwell position is derived from a collection of 
calculated source coordinates, that are within a spatial threshold (as described in section 
4.5) where the dwell position co-ordinate is the mean of the source coordinates 
collection.  
The aim of this processing is to filter (a) measured dwell positions that are calculated 
from images that are a summation of multiple short dwells, and (b) calculated dwell 
positions that have almost identical coordinates, but differ due to measurement 
uncertainties. 
The measured dwell positions were then compared to the planned positions for each 
catheter using the software developed in-house (Appendix C - ‘Patient Analysis’).  
The measured positions were compared to the planned positions as defined by the TPS. 
Therefore, possible agreement achievable between measured and planned positions was 
limited by the implant changes observed at pre-treatment imaging. The error detection 
metrics used to describe the agreement are defined in section 6.2 
7.2.1.6 Individual Catheter Treatment Times 
During the source tracking process the verification system is continuously acquiring 
images. For each catheter, the acquisition starts before the source leaves the afterloader 
safe and continues until the source returns to the afterloader safe. The resulting set of 
images therefore contains a period of blank images at each end of the sequence. The 
total catheter treatment times were measured by using an algorithm to extract the 
timestamp from the start and end images containing a brachytherapy source response.  
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7.2.2 Results 
The following sections provide a detailed description of the results obtained for this 
example patient and the analysis performed. 
7.2.2.1 2D Pre-Treatment Image Verification 
The acquired A-P image, shown in figure 7.11, depicts the catheter positions derived 
from the radio-opaque x-ray dwell position markers, immediately prior to treatment, the 
three fiducial markers (black arrows) and the sets of BB projections (orange ellipses) 
from the BB array. The A-P image provides the geometric relationship between the 
implant, anatomy, x-ray source and the FPD required to perform quantitative pre-
treatment image verification. 
 
Figure 7.11.  Pre-treatment A-P image acquired with the x-ray dwell position markers inserted 
into the specified catheters and the 5 BB array pairs (orange ellipses) in the field. The three 
fiducial markers implanted into the prostate are also visible (black arrows). 
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The catheters selected for pre-treatment imaging (4, 5, 7, 16 and 17) identified in the A-
P image are shown in figure 7.12(a), where each catheter marker point defined by the 
user is shown as a red circle. The three fiducial markers were also identified in this 
image and are shown as green crosses (highlighted by black arrow). For comparison, 
figure 7.12(b) shows the TPS A-P view of the implant with the same 5 selected 
catheters and 3 fiducial marker positions. 
 
Figure 7.12.  (a) The measured catheter paths are identified in red along with the 3 fiducial 
markers (green crosses). (b) For comparison with the A-P image, the TPS A-P view of the 
implant showing the catheters used for pre-treatment imaging and the 3 fiducial markers 
identified in the CT data. 
 
The TPS catheter paths mapped to the FPD space are shown overlaid on the A-P image 
in figure 7.13(a). The agreement between the measured and planned catheters can be 
observed along the length of the catheter path. 
The difference in measured and planned catheter positions was calculated for all 
catheter marker points for 120 mm along the path of each catheter. For a more 
clinically relevant assessment of the differences in catheter marker points, the subset of 
points that exist within the treatment region was also evaluated. The treatment region 
was identified by using the active source dwell positions for each catheter shown as 
solid red dots in figure 7.13(b). As previously mentioned in chapter 5, this evaluation 
17 5 4 7 16 
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excludes points that exist in the bladder, that have the potential for large movements, 
but do not contain active source dwell positions. 
 
Figure 7.13.  (a) The pre-treatment image showing the measured catheter paths (red) with the 
TPS catheter paths (cyan) mapped on to the image, for direct comparison immediately prior to 
treatment delivery. (b) The addition of the active source dwell positions (solid red circles) 
showing the ‘treatment region’, defining the region where catheter agreement is critical because 
this is where the dose will be delivered to the patient. 
 
Histograms showing the distribution of absolute catheter differences for all catheter 
marker points and the directional catheter difference in the S-I direction are presented 
in figure 7.14. The 2D registration uncertainty and the resulting rotation is shown in 
column 2 and 3 of table 7.1. The absolute catheter marker differences, L-R and S-I 
difference for all points and the treatment region subset were calculated and the results 
are shown in column 4, 5 and 6 of table 7.1. The maximum mean catheter displacement 
is also reported. 
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Table 7.1. The reported registration uncertainty, ΔReg.2D, and rotation, θ, after the 2D 
registration. The mean directional difference between all planned and measured catheter marker 
points (L-R and S-I), the mean difference and the maximum mean catheter difference. The 
subset data for points only in the treatment region is also presented. The values in the brackets 
represent one standard deviation. 
Dataset ΔReg.2D 
(mm) 
Rotation θ L-R (σx)  
mm 
S-I (σy)  
mm 
Abs. (σabs) 
mm 
Max. Catheter 
mm 
       
Patient 1 0.6 1.2 0.4 (1.4) -0.3 (0.9) 1.3 (1.1) 2.9 
Subset    -0.1 (0.7) 0.0 (1.2) 1.1 (0.7) 2.1 
 
 
Figure 7.14.  The distribution of catheter marker point difference for all points (grey) and for 
the points in the treatment region (red) for (a) the histogram of absolute catheter marker 
differences (b) The histogram of superior-inferior (S-I) catheter marker difference and (c) the 
histogram of left-right (L-R) catheter marker difference. For (b) and (c) the positive axis 
represents a shift of the measured catheter markers to the patient inferior and the patient right 
direction relative to the planned position. 
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The absolute catheter marker difference profile for each of the 5 catheters used for pre-
treatment imaging is shown in figure 7.15. The absolute difference is presented for each 
catheter at each 10 mm spaced marker from the catheter tip to 120 mm along the 
catheter path. 
 
Figure 7.15.  Absolute catheter marker difference profiles showing the difference at each 10 
mm spaced catheter marker point for all 5 catheters inserted into the patient for pre-treatment 
imaging. The blue arrow provides orientation of the catheter tip and connector end. 
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7.2.2.2 Measurement Uncertainty 
The measurement uncertainty analysis for this patient, using the approach defined in 
section 5.3.6, results in the following total measurement uncertainty: 
• Reported registration uncertainty ( ΔReg.2D ) = 0.6 mm 
• Divergence correction uncertainty ( ΔDivCorr ) = 1.4 mm  (average hm = 150 mm) 
• Marker identification uncertainty ( ΔAPMarker ) = 0.784 mm (±1 pixel) 
• TPS marker identification uncertainty ( ΔTPS ) = 1.25 mm (½ CT slice thickness) 
The total calculated measurement uncertainty using equation 5.2 is 2.1 mm. This total 
uncertainty value can also be determined by using figure 5.22, with a registration 
uncertainty of 0.6 mm and an average marker height of 150 mm. The total 
measurement uncertainty value defines the 2D catheter displacement detection 
threshold and in this example patient case only one catheter (catheter 16) exhibits 
displacement that is identified above this threshold. 
7.2.2.3 3D Catheter Reconstruction Verification  
The acquired ‘shift’ images are shown in figure 7.16(a) depicting an observed shift 
relative to the FPD at each ‘LEFT’ and ‘RIGHT’ image acquisition position. The 
corresponding fiducial marker points and catheter marker points, that were identified by 
the user in each image, are shown in figure 7.16(b). To distinguish each catheter 
channel number, each corresponding catheter path is identified with a different colour. 
The corresponding fiducial markers are shown in figure 7.16(b) as red crosses.  
The 3D registration results between the reconstructed fiducial markers and the TPS 
fiducial marker is shown in table 7.2. The registration residual, registration uncertainty 
and the reported rotations (as described in section 5.4.4) are shown for this patient. 
Table 7.2.  The reported residual, registration uncertainty and the reported rotation after 
registration between the TPS data and reconstructed fiducial markers for the three datasets. 
Dataset Residual 
(mm) 
ΔReg.3D 
(mm) 
Tilt 
x-axis (ᵒ) 
Roll 
y-axis (ᵒ) 
Yaw 
z-axis (ᵒ) 
      
Patient 1 2.0 0.8 -2.3 6.8 3.8 
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Figure 7.16.  (a) The acquired ‘shift’ images of the patient prior to treatment captured with the 
x-ray source moved to the ‘LEFT’ and then ‘RIGHT’ of the patient. (b) The corresponding 
catheter marker points identified in each ‘shift’ image in preparation for 3D reconstruction. The 
fiducial marker points are also identified (large red crosses) in each image. 
 
The calculated difference between the 3D reconstructed catheter paths and the TPS 
catheter paths is summarised in Table 7.3. The distribution of absolute differences 
between the two datasets is represented as a histogram as shown in figure 7.17. The 3D 
directional difference is also provided in figure 7.18.  
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Table 7.3.  The mean vector difference between all planned and measured catheter marker 
points, the mean absolute difference for all points and the maximum mean catheter difference. 
The absolute difference for all catheters, the maximum individual catheter difference and the 
RMSE3D is also shown. The bracket values are 1 standard deviation. 
Dataset L-R (σx)  
mm 
S-I (σy)  
mm 
A-P (σz)  
mm 
Abs. (σabs)  
mm 
Max. Catheter  
mm 
RMSE3D 
mm 
       
Patient 1 0.9 (2.2) 1.6 (1.4) -1.4 (3.5) 4.3 (2.3) 7.2 4.9 
       
       
 
 
 
 
Figure 7.17.  The histogram of 3D absolute catheter marker difference for all 5 catheter marker 
wires inserted into the catheters for all catheter marker points (grey) and for the subset of points 
within the treatment region (red). 
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Figure 7.18.  For all 5 catheters used for pre-treatment imaging the distribution of differences 
is shown for all catheter marker points (grey) and for the points within the treatment volume 
(red) for: (a) the histogram of the right-left (R-L) catheter marker difference, (b) the histogram 
of superior-inferior (S-I) catheter marker difference and (c) the histogram of anterior-posterior 
(A-P) catheter marker difference. 
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Figure 7.19.  The mean and maximum vector difference per catheter, showing the Left-Right 
(x), Superior-Inferior (y) and Anterior-Posterior (z) orientations. Positive measured differences 
are Left, Inferior and Anterior. 
 
7.2.2.4 Source Tracking 
The source tracking data can also be presented overlaid on the A-P image by virtue of 
the combined imaging system using the same detector. Figure 7.20(a) shows the 
planned dwell positions (red circles) of the 5 catheters used for pre-treatment imaging 
and are compared with the measured source coordinates (blue circles-cross). The 
planned dwell positions do not incorporate any geometric implant changes that may 
have been identified since treatment planning imaging. Figure 7.20(b) shows modified 
planned dwell positions (orange circles) accounting for geometric changes determined 
during pre-treatment imaging.  
The measured source coordinates in figure 7.20(b) represent the calculated positions of 
the source (in 2D), for each image in the sequence acquired as the treatment was 
delivered to each catheter. These measured positions are not necessarily dwell 
positions, due to the image capture rate of the FPD, and so extraction of the dwell 
positions from the sequence of measured source coordinates was performed using the 
approach described in section 4.5. A subset of measured dwell positions for comparison 
with the treatment plan were then determined by initially combining source coordinate 
measured positions that were within 1 mm of each other. All positions that consisted of 
only one source coordinate were excluded. The resulting distribution of measured dwell 
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positions are shown in figure 7.21. The matching planned dwell positions are shown in 
figure 7.21 as magenta dots. 
 
Figure 7.20.  (a) The measured source co-ordinates shown as blue circles-cross and the planned 
dwell positions (solid red circles) from the treatment plan overlaid on the pre-treatment A-P 
image. (b) The planned dwell positions modified to account for the implant geometry changes 
(orange circles) determined during the pre-treatment imaging immediately prior to treatment. 
 
Figure 7.21.  The filtered dwell position distribution showing the planned dwell positions with 
dwell time of at least 3.2 seconds (Magenta dots). The measured dwell positions, for 
comparison with the planned dwells, are shown as blue circle-crosses and contain at least 2 
source coordinate measurements.  
(a) (b) 
10 mm 
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Figure 7.22.  Histograms showing the distribution of dwell position differences for the patient 
treatment plan with (a) the absolute dwell difference (δ), (b) the S-I directional dwell difference 
(δSI), (c) the L-R directional dwell difference (δLR), (d) the visual comparison of dwell 
positions and (e) the summary of agreement metrics. 
 
7.2.2.5 Individual Catheter Treatment Times 
The total treatment time was measured by using the time stamps for each FPD image 
containing the brachytherapy source. The comparison with the TPS data for each of the 
17 treatment catheters is shown in figure 7.23. 
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Figure 7.23.  The treatment time profile showing the measured total time for each catheter 
(grey) compared with the time derived from the TPS (black). 
 
7.2.3 Discussion 
The treatment verification process described here for this sample patient case illustrates 
the additional workflow changes that have been implemented within AHRO 
brachytherapy program. These workflow additions, shown in figure 7.6, are each only 
minor changes, but together they build a strong program of verification not possible 
with previous work practices. The additional overall time added to the process is 
minimal, typically less than 15 minutes, but this is easily justified by the benefits. These 
gains all relate directly to improving the quality of the treatment provided, decreasing 
the risk of error and adding to the patient safety net. 
7.2.3.1 2D Pre-Treatment Image Verification 
The 5 catheters used for pre-treatment imaging were selected to span the extent of the 
implant geometry (L-R and A-P) and so their projections on the A-P image would not 
overlap, as seen in figure 7.12(a). Catheter number 16 exhibits a left to right bend and 
shows slight overlap with catheter number 7 toward the superior end of the implant. 
The visual comparison of the implant immediately prior to treatment with the TPS 
(figure 7.12(b)) shows good agreement and possibly suggests that no significant 
movement has occurred post treatment planning. This visual evaluation can be 
misleading and only registration using the fiducial markers can provide the 
mathematical relationship between the TPS and measurement space, allowing 
quantitative evaluation of the implant position relative to the treatment plan. 
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In this patient example, a registration uncertainty of 0.6 mm is calculated which is on 
the order of magnitude observed with the phantom cases explored in chapter 5. This 
result suggests the relative position of each fiducial marker has not changed 
significantly since planning. This registration uncertainty is considered small and not 
likely to produce are large catheter displacement detection threshold (section 5.3.7). 
The TPS catheter paths are therefore mapped into the FPD space with greater 
confidence.  
The overlay of the TPS and measured catheter paths shown in figure 7.13 generally 
shows good agreement with the paths of the catheters agreeing well near the fiducial 
markers and agreeing less toward the tips of the catheters. The fiducial markers are a 
surrogate for the prostate and so agreement in this region of the image is desirable. 
Observed displacement toward the catheter tip has less clinical relevance as this is in 
the bladder and not likely to contain active source dwell positions. 
The average displacement of catheter points in the left-right and superior-inferior 
directions are 0.4 and -0.3 mm respectively, suggesting that for the 5 catheters 
measured the overall average displacement is not clinically significant. The maximum 
average absolute displacement is 2.9 mm and suggests that one catheter (catheter 16) 
has displacements that require further investigation. 
The histogram of absolute displacement for all catheter marker points (figure 7.14(a)) 
shows only a few outliers that have displacements greater than 2.9 mm. The actual 
locations of these larger displacements can be determined by investigating each 
individual catheter marker points displacement as provided by figure 7.15 and it is 
observed that catheter 16 has these larger displacements toward the catheter tip. This is 
also visible figure 7.13, showing the separation of the measured and TPS paths of 
catheter 16 in the bladder region of the implant.  
The capability of this approach to provide information on the magnitude, direction and 
location of displacements is a key advantage over catheter tip only based approaches 
that only provide a magnitude of displacement relative to some reference point and may 
over (or under) estimate the catheter displacement present.  
The 2D approach to pre-treatment verification of course has its limitations, but these 
can be justified to provide substantial verification information that can be practically 
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achieved in real time in a clinical scenario. The imaging of a subset of catheters is 
indeed a compromise as imaging all catheters (up to 18 for example) would be time 
consuming and the resulting A-P image would contain many overlapping catheter 
markers. A catheter not measured may move separately from the entire implant, but 
most likely only due to a mechanical slip of a catheter at the template. External visual 
inspection (or measurement) is likely to identify this event. The subset provides a 
sample of the implant, and with knowledge of the implant geometry from the CT data, 
strategic catheter selection occurs to minimise the possibility of overlap. The catheter 
displacements measured by the system are also only in the 2D plane, representing a L-R 
and S-I shift. The implant and anatomy is 3D and possible catheter displacements out of 
plane (in the A-P direction) are not be detected using this 2D approach. 
7.2.3.2 3D Catheter Reconstruction Verification  
Shift imaging is performed to achieve a 3D representation of the implant geometry in 
the treatment bunker immediately prior to treatment delivery. The two images captured 
by the FPD are shown in figure 7.16(a) where the relative shift of the catheter paths 
relative to the image can be seen. The catheter paths and fiducial markers in each image 
were identified and this process can be seen in figure 7.16(b). The reconstructed 3D 
geometry of the fiducial markers were registered with the TPS fiducial markers 
resulting in a 3D registration uncertainty of 0.8 mm. This value is on the order of the 
magnitude calculated with the 2D registration, further suggesting the stability of the 
relative positions of the fiducial markers. In this particular case, the calculated rotations 
resulting from the registration are relatively small. 
A summary of comparison of the planned and measured catheter paths are listed in 
table 7.3. The average L-R, S-I and A-P catheter marker point displacements are 
shown, with the average L-R and S-I displacements larger than reported by the 2D 
approach as the additional dimension (A-P axis) is now accounted for. (different 
transformation matrix). The average absolute catheter displacement of 4.3 mm and the 
maximum average catheter displacement are also larger than reported by the 2D 
approach.  
The histogram of absolute displacement shown in figure 7.17 also shows most points 
displaced by approximately 4 mm with a few outlier points 10 mm or greater. Figure 
7.18(c) shows that many of these outlier points are displaced in the A-P direction. The 
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magnitude of these displacements may only be clinically significant if the 
displacements have occurred in the target (prostate) region and not in the bladder. 
Similar to the 2D approach, a further breakdown of these catheter displacement per 
catheter shows that all of the calculated displacements occur toward the tip (in the 
bladder) and away from the treatment region of the implant. 
The 3D pre-treatment imaging approach provides many pieces of information that 
report on the agreement of the implant with the treatment plan. The challenge is to 
provide this information to the clinical staff in such a way to identify a problem if it 
occurs, highlight an item that may require additional investigation, or that the data sets 
agree. One useful approach is to show the agreement on a per catheter basis. Figure 
7.19 shows the average catheter marker points displacement in each L-R, S-I and A-P 
direction for each catheter. Also provided is the maximum marker points displacement 
in each direction per catheter flagging possible larger individual catheter displacements. 
7.2.3.3 Source Tracking  
The measurement of source dwell positions during treatment delivery allows for 
confirmation that the dose is being delivered to the correct location relative to the 
implanted fiducial markers, where these can be interpreted as a surrogate for patient 
anatomy. It also allows confirmation that the geometric arrangement of the set of dwell 
positions relative to each other is consistent with the plan. 
Figure 7.20(a) shows that the number of dwell positions determined by the source 
tracking system is less than the planned number. This is a direct result of the poor time 
resolution of the FPD. When operating in continuous acquisition mode, the FPD 
captures one image every 1.8 seconds and therefore limits its capability to uniquely 
capture source dwell positions with dwell times less than 1.8 s. The result may be (but 
not limited to) multiple dwell positions (with short dwell times) being captured in a 
single image or an image of a single dwell position containing source movement 
artefact as the source arrives and/or departs that dwell. 
Additionally, the challenge of assigning each measured dwell position with the 
corresponding planned dwell becomes more difficult if multiple dwell positions are 
blurred into a single captured image. This creates a challenge of registering each 
measured dwell to a corresponding planned point for a difference calculation, i.e. if the 
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number of dwells in the two lists differ, then it is not as simple as comparing each 
measured coordinate to the next on the list from the plan. Although not all measured 
dwells have corresponding planned dwells, the information is still extremely valuable, 
proving information about the source travel path during treatment.  
One approach to overcome the timing resolution limitation of the FPD is to utilise 
planned dwells that exhibit relatively large dwell times for comparison with measured 
dwells. The catheter dwell time profile is known from the treatment plan and therefore 
the measured dwells, corresponding to the large dwell times, can be identified by 
processing the sequence of calculated source position coordinates. For this patient 
example a planned dwell time threshold of 3.2 seconds (figure 7.21) produced the same 
number of measured dwell positions. 
The distribution of measured dwell positions, shown in figure 7.21, agree with the 
general shape of the planned dwell position distribution. The generated subset of dwell 
positions enabled a quantitative analysis to be performed to calculate the metrics of 
agreement, as described in section 6.2. The data for this patient is presented in the same 
format as illustrated by figure 6.3, to provide an overview of the source tracking results. 
For the 24 dwell positions analysed, the mean difference was 3.4 mm. The distribution 
of absolute and directional differences is shown in figure 7.22(a), (b) and (c) 
respectively. These histograms indicate a mean displacement of the measured dwell 
positions toward the superior of the patient and with an approximate even distribution 
of measured dwell differences to the patient left and right. These observed differences 
are likely to arise from combinations of (i) sub-degree rotations of the couch and FPD 
caused by patient weight induced couch sag and (ii) possible movement of the patient 
after pre-treatment imaging and (iii) the asymmetric scatter field caused by the finite 
geometry of the patient. The catheters that are at a greater distance from the FPD 
(catheters 16 and 17) exhibit a larger discrepancy due to the reduced detector signal, 
decreasing primary-scatter ratio, and greater geometric effect of any couch rotation. As 
the observable consequences are quite systematic, they are likely to be amenable to 
further improvement. Future versions of our system will incorporate more information 
on couch position, and asymmetric scatter compensation.  
There is considerable interest in interpreting the measurement uncertainty in terms of 
dosimetric uncertainty to answer the question: “What is the clinical significance?” It is 
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important to appreciate that this form of treatment verification addresses the source 
dwell position and time, rather than a direct dose measurement, and therefore the 
uncertainty will be specific to the patient plan, the patient geometry, each individual 
source dwell position and the location of the measured dwell position within the entire 
implant. The same is true of a dose measurement: the dose discrepancy at the detector 
is not necessarily representative of the clinically significance of dose discrepancies 
elsewhere in the patient or treatment volume. Ongoing work includes the development 
of a dose assessment tool to make this evaluation on a plan by plan basis. 
At present the data extracted from the system is used to watch for gross discrepancies 
or obvious errors. We anticipate adopting a 2σ or 3σ investigation level on source 
position deviations based on the 3-dimensional position uncertainty of that system. The 
source-tracking system is currently employed in a non-interventional or ‘record and 
verify’ capacity, so source tracking data is processed after completion of the treatment. 
When the full capability of the system is established, real-time analysis will facilitate 
interruption decisions in the event of a significant error being observed.  
7.2.3.4 Individual Catheter Treatment Times 
The measurement of total treatment time for each catheter provides a further 
verification that the treatment was delivered correctly. All total catheter times measured 
agree with the expected TPS times (figure 7.23), within measurement uncertainty due 
to the FPD timing limitation when operating in continuous acquisition mode. As 
described in section 6.4, certain delivery errors would be visible in this total catheter 
time profile data, such as interchanged transfer tubes and incorrect treatment plan (or 
fraction) selection by the operator. For instances where the treatment times are the same 
(or very similar) delivery errors will be flagged if source dwell positions do not agree. 
The FPD used in this work has a long acquisition time compared to some possible short 
dwell times delivered in a clinical treatment plan, making some individual dwell time 
verification difficult. One approach to overcome this is to limit the shortest dwell time 
allowed by the TPS, but this may restrict the optimisation algorithm achieving a 
clinically acceptable plan, especially so when the treatment source is ‘hot’. The other 
alternative is to overcome this technology limitation and purchase a new and faster FPD 
especially selected to meet the criteria of this verification purpose. This is the option 
presently being pursued in ongoing work. 
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These clinical workflow changes have established a routine treatment verification 
process, providing a quantitative method to perform pre-treatment imaging, allowing 
verification of catheter positions to be directly compared to the treatment plan. The 
novel approach of using the imaging FPD for source tracking allows verification of the 
delivered dwells to be compared to the plan and relative to the surrounding anatomy.  
 
7.3 Clinical Implementation Conclusion 
This chapter has described the steps taken to implement this treatment verification 
system in a HDR brachytherapy clinical environment. The addition of a couch mounted 
FPD, ceiling suspended x-ray system and in-room lasers established a platform to 
perform treatment verification routinely. The clinical workflow was modified to 
accommodate the introduction of treatment verification and only increased the overall 
treatment time by approximately 15 minutes. The example patient case presented 
showed that the verification procedure developed was practical and achievable in a 
clinical environment. 
This approach using in room imaging, with a well-defined geometry enables 
registration with the treatment plan and therefore verification of the catheter positions 
relative to the prostate against the treatment plan itself. For this patient case, the pre-
treatment imaging provided the clinical staff with information of how the catheters had 
deviated between treatment planning imaging and treatment delivery. It was determined 
from the AP image that the mean catheter displacement in the S-I direction was 0.4 mm 
INF, for the 5 catheters selected for imaging.  
The combination of pre-treatment imaging with source tracking enabled absolute 
verification of the delivered dwell positions against the treatment plan. In this patient 
case, the measured set of dwell positions differed from the planned positions by a mean 
of 3.4 mm. A systematic displacement of 2.5 mm to the patient superior direction of the 
implant was observed. The error detection metrics displayed in figure 7.22 provide a 
clear summary of the treatment delivery status. The visual representation of the dwells 
overlaid on the AP image in conjunction with the other error trapping metrics allows 
the system to identify possible errors introduced into the treatment process and provides 
the staff with an opportunity to evaluate and address an error where required. 
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Treatment verification in HDR prostate brachytherapy is challenging and potentially 
treatment errors occur without the treatment staff having any knowledge of the event. 
This approach of combining pre-treatment imaging and source tracking in a clinical 
environment is novel and provides information that is not easily achievable using other 
approaches. 
All verification comparisons were made directly against the treatment plan and not 
against the data on the treatment delivery console. This approach enables further 
treatment errors to be identified such as TPS to treatment console data transfer error, 
discrepancies of specified source activity between the TPS and treatment console, 
incorrect plan selection by the operator at the treatment console and incorrect manual 
changes to the plan made by the operator. 
This chapter illustrates the use of this system in a clinical environment. The relatively 
simple integration into the clinical workflow has enabled the process to become routine. 
It provides an increased level of safety for the patient and improves the quality of 
treatment delivered. 
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Chapter 8 
Conclusion and Recommendations 
8 Summary 
The aim of this thesis was to develop a treatment verification system for HDR 
brachytherapy that could be used to verify the planned treatment, detect a treatment 
delivery error and potentially improve patient safety. A novel approach was developed, 
using a FPD, to perform pre-treatment imaging immediately prior to treatment and 
implement source tracking during the treatment delivery.  
An available FPD was evaluated for its suitability for the proposed application, and 
characterised for its response to two radiation sources. The FPD responded to the 192Ir 
source, for a range of clinically relevant distances (20 to 200 mm) away from the FPD 
despite the low dose rates and the changing photon spectrum. The pixel resolution of 
the FPD (0.784 mm) and the detection region (300 x 400 mm) provided a suitable 
detector to perform pre-treatment imaging. The image acquisition time of the FPD 
when operating in continuous acquisition mode for source tracking was one image 
capture every 1.8 seconds. Although not designed for source tracking, the FPD was 
found to be adequate to perform this proof of principle work. 
Pre-treatment imaging, using the ceiling suspended x-ray system, allowed the position 
of the catheters to be verified relative to the treatment plan. The approach that was 
established enabled imaging to occur in the treatment bunker, immediately prior to 
treatment delivery, potentially detecting changes in the implant geometry that would 
otherwise go unnoticed and unaccounted for. A key benefit of this system is the 
relationship established between the FPD and the TPS. This allowed a direct 
quantitative comparison of the catheter positions with the treatment plan, permitting 
useful position verification metrics to be established. The system is capable of 
identifying catheter displacements (in 3D) of the order of 2.0 mm with a confidence of 
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95%. Pre-treatment imaging was able to detect changes in the implant prior to 
treatment, which are not necessarily errors, but when identified and accounted for 
improve the quality of the treatment delivered to the patient. 
Source tracking provided further challenges as the source is moving and stationary 
during the treatment delivery period. The source tracking acquisition was not 
synchronised with the afterloader source movements and so methods were developed to 
deal with moving and stationary source captures. The source coordinate could be 
determined to within 0.9 mm of the expected position in a phantom geometry, for 
distances of up to 200 mm away from the FPD. The differences between expected and 
measured source positions in a patient were larger due to the irregular patient geometry 
and other influences.  
The novel combination of pre-treatment imaging and source tracking allowed the 
development of error trapping regimes. A significant advantage of this system is the 
multitude of information it can provide about the treatment. The evaluation of these 
data streams from the system, enabled error signatures to be identified, and therefore 
flag an error when it occurred and predict the likely source of the error type. The error 
trapping capability was demonstrated and showed it could identify clinically relevant 
errors (incorrect plan selection, swapped channel connection, incorrect channel length, 
incorrect dwell times), as highlighted by the ICRP 97 report into prevention of HDR 
brachytherapy accidents[15], which are difficult to detect with other verification 
approaches. 
The integration into a clinical environment showed that the proposed verification 
approach could be applied in a typical clinical setting. Various modifications to 
workflow were required to accommodate treatment verification, but added only 
approximately 15 minutes to the overall treatment time. Some modifications were made 
to the treatment room to aid with patient set up, including a laser system for patient 
alignment. The clinical verification process was shown to be non-invasive, time 
economical and potentially sensitive to clinically relevant errors. In this instance, the 
system was used in a passive manor, with all data being evaluated retrospectively. 
While the system has already proved to provide valuable information, there are several 
limitations. The first is that of overlapping catheters in the pre-treatment projection 
images. This limits the number of catheters that can be verified, but still provides 
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extremely useful information about the stability of the implant. The source tracking 
functionality is inherently limited by the image capture rate, in its ability to capture 
very short dwells. This is readily addressed with improved hardware, and is discussed 
further below in ongoing work. Even while only able to reliably record the longer 
dwells, there is sufficient information to provide staff with greater confidence that 
certain errors have not occurred. In the clinical patient case, the source tracking suffers 
greater uncertainty than seen in the phantom measurements. The primary cause is likely 
due to the asymmetric and unpredictable scatter field resulting from the patient 
geometry. Lastly, the implementation requires considerable work by the attending 
physicist to perform the pre-treatment imaging and source tracking steps. Many of these 
tasks can be automated to streamline the process as also mentioned below in future 
directions. Even with these limitations, the system provides valuable information that 
has clinical significance, facilitating improvements in the quality of treatment 
delivered. 
8.1 Significance 
The verification system incorporating both pre-treatment imaging and source tracking 
is a novel approach of addressing many of the challenges in treatment verification 
highlighted by previous publications in this field. Pre-treatment verification has been 
performed previously, but rarely in the treatment bunker immediately before treatment 
and with limited quantitative comparison with the treatment plan. The ability to 
evaluate the geometry of the implant at the time of treatment in 2D and 3D has the 
potential to enable real time correction and optimisation algorithm to be developed.  
Source tracking has been pursued by other authors, but only for the purpose of system 
quality assurance. To date, to the author’s knowledge, no other publication has reported 
on HDR brachytherapy source tracking in a clinical environment. The challenges of 
including a treatment verification system into a clinical workflow have been addressed 
in this work, providing significant benefit to the treating staff, while enabling an 
approach that can be performed routinely. 
Many of the steps described in this thesis to capture and evaluate the data can be 
automated using intelligent image processing and visual representation of verification 
data. These automations will further streamline the clinical workflow, reinforcing the 
routine aspect of the procedure. This will potentially enable wide uptake of the 
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approach as the verification process can easily be performed by typical medical 
physicists and radiation therapy staff. 
Studies have suggested that dose escalation in HDR prostate brachytherapy will deliver 
a therapeutic gain while potentially maintaining acceptable rectal and urethral toxicities 
[117, 118]. Progression to large fractional or single fraction doses leaves no room for 
error, and so a verification system such as the one demonstrated here could ensure that 
the treatment is administered correctly, strictly to the plan, avoiding induced toxicities 
leading to poor patient quality of life or reduced tumour control.  
8.2 Ongoing Work and Future Directions 
The project has addressed many of the challenges in HDR brachytherapy treatment 
verification, but there are still aspects that need to be further developed and resolved. 
Our research group is actively involved in further development of this system. 
The pre-treatment imaging data shows the radio-opaque catheter markers inserted for 
verification against the treatment plan. Currently our research group is developing 
image processing algorithms to automatically identify and quantify these catheter 
markers. The auto-identification of each marker can be used to potentially automate the 
pre-treatment evaluation of catheter displacement. 
Major decisions are required when catheter displacement immediately prior to 
treatment delivery is identified. If the displacement is deemed clinically significant, a 
protocol of how to manage the discrepancies should be followed. Currently, for prostate 
HDR brachytherapy, a clinically relevant displacement threshold is yet to be agreed 
upon. Furthermore, the path to follow to address these displacements is also varied. The 
novel approach of this system establishes a relationship between the FPD and the TPS, 
therefore potentially allowing the dosimetric impact of the identified displacements to 
be immediately evaluated. Development of a new optimisation algorithm is needed to 
address these catheter displacements, with a focus on adaptive planning routines 
available at the treatment console. 
The limited image acquisition rate during source tracking has recently been addressed 
by trialling a new detector that is capable of capturing up to 30 frames per second. The 
improved imaging will enable short dwell times to be sampled correctly allowing 
verification of all dwell positions.  
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The new imaging device can be controlled via in-house software, therefore allowing 
routines to be included that can process the acquired images during treatment delivery. 
The system could then provide verification metrics to the user in real time potentially 
allowing treatment interruption to occur when deviations exceed some defined 
threshold. 
A significant advantage of this system over other approaches is the large range of data 
provided. One of the challenges is to present these data in a sensible, non-ambiguous 
and clear manor to the clinical staff at the treatment console. Further work is needed to 
investigate the data management and display to the user during pre-treatment imaging 
and treatment delivery (source tracking).  
The system captures the position of the source and the time it dwells at each position 
during the treatment delivery. At present these positions are compared to the expected 
positions for verification. The acquired information can be used to reconstruct the 3D 
dose distributions for direct comparison with the treatment plan. The delivered dose 
volume could be used to inform subsequent treatment planning events in order to 
account for possible underdosed or overdosed regions. The development of a dose 
reconstruction algorithm from measured dwell positions is the topic of a current project 
within our group. 
As briefly investigated in this thesis, the response of the FPD can be interpreted as dose 
and hence the treatment delivery can be verified by comparing predicted ‘dose 
response’ images with measured images. Further development of this approach is 
needed as it can provide complimentary information to the data already acquired. 
The focus of this work has been primarily for prostate brachytherapy as this is the 
dominant site treated at Alfred Health Radiation Oncology. Translation of these 
concepts to other anatomical sites treated with HDR brachytherapy should be readily 
achievable. Other pelvic treatments, such as cervical cancers, have similar 
characteristics as prostate treatments, albeit with different applicators, and are the most 
promising next step. 
Other sites, such as breast brachytherapy exhibit additional challenges, such as optimal 
detector positioning, non-uniform scatter fields and practical implementation that will 
require investment to resolve. 
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By developing a novel treatment verification system that is non-invasive, multi-
functional, and can be implemented with existing technology this work has the potential 
to meaningfully improve patient safety. 
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Clinical implementation of in vivo source position verification in high dose 
rate prostate brachytherapy 
Oral Presentation 
Ryan L Smith1,2, Annette Haworth2,3, Jeremy L Millar1,2, Bronwyn Matheson1, Ben Hindson1, 
Michael L Taylor2 and Rick D Franich1,2  
1 – William Buckland Radiotherapy Centre, The Alfred Hospital, Melbourne, Australia.  
2 – School of Applied Sciences, RMIT University, Melbourne, Australia.  
3 –Physical Sciences, Peter MacCallum Cancer Centre, East Melbourne, Australia. 
Aim.  
High dose rate (HDR) brachytherapy treatment is widely practiced but lacks independent 
routine treatment delivery verification to identify potential errors and ensure patient safety. We 
report our initial clinical experience with a novel, non-invasive, position-sensitive source-
tracking system based on a flat panel detector (FPD) for treatment verification in HDR prostate 
brachytherapy. 
Materials & Method.  
The FPD was mounted in a standard operating theatre couch (BetaStar, Marquet) under a 
customised carbon fibre couch top assembly. Four prostate patients (8 treatment fractions) were 
included in this initial study. At treatment each patient was aligned on the couch with the target 
region centred over the sensitive imaging area of the FPD. Prior to treatment, three x-ray dwell 
position markers were inserted into selected catheters and a radiograph captured with the FPD 
to localise the implant relative to the detector. As the HDR source treatment dwells were 
delivered, images were acquired with the FPD and post-processed to determine the position of 
the source inside the patient. The source positions determined by the tracking system were 
compared to the treatment plan to verify correct treatment delivery. 
Results. 
Measured source dwell positions confirmed correct transfer tube connection, source step size 
and patient/plan selection. The mean linear distance between measured and planned positions 
(example fraction shown in Figure 1) was 1.8mm (range 0.7 to 3.9mm) after rigid registration 
with the plan. The average measured dwell step size for all measured catheters was 2.5mm 
(range 1.9 to 3.1mm; s.d. 0.2mm). The absolute position of the measured source dwells was 
evaluated by comparing the measured dwell positions with x-ray dwell position markers from 
the pre-treatment radiograph (mean 3.9mm, range 0.8 to 9.9mm). This, together with the 
implanted gold fiducial markers, visible on the radiograph, provided verification of 
programmed treatment indexer length and therefore delivery to the correct anatomical location. 
The total impact on procedure time was less than 15 minutes. 
Conclusion.   
The novel, non-invasive HDR brachytherapy treatment verification system was implemented 
clinically, providing verification of many treatment parameters by tracking the position of the 
HDR source as treatment was delivered. The novel application of the FPD allows verification 
that treatment delivery was free of most potential human related errors identified in ICRP 97. 
This concept and system will meaningfully improve safety standards by allowing routine 
treatment verification in HDR brachytherapy across a range of clinical applications.  
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Appendix C 
Software 
This appendix contains a brief description and screen shot of the different software modules 
that were developed during this project to enable the application of many of the concepts 
described in this work.  
• BrachyLAB – A multi-purpose module that allows various source position calculation 
algorithms to be applied to FPD images, compared, and raw profile data exported.  
• Patient Analysis – A module that allows pre-treatment image analysis, identification 
of fiducial markers, identification of catheter marker points, importing of TPS catheter 
and dwell position data and 2D registration function for treatment verification. 
• Pre-Treatment Verification 2D – A module with a structured user-interface allowing 
clinical staff to import data from the TPS, import a pre-treatment A-P image and 
perform catheter displacement evaluation at the treatment console in real-time.  
• Pre-Treatment Verification 3D – A module that allows two oblique images to be 
loaded and corresponding features in each image to be identified for the purpose of 3D 
implant reconstruction. 
C.1 BrachyLAB 
The ‘BrachyLAB’ software was developed to allow various source position calculation 
algorithms to be applied to FPD images, compared, and raw profile data exported. 
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C.2 Patient Analysis 
The ‘Patient Analysis’ software was developed to perform post treatment processing of the A-P 
images acquired during pre-treatment imaging. The software functionality enabled the fiducial 
markers and catheter marker points in the image to be identified, importing of the TPS data for 
registration and comparison with the measured positions. The comparison data could be 
exported for further analysis.  
 
 
C.3 Pre-Treatment Verification 2D 
The ‘Pre-Treatment Verification 2D’ software was with a structured user-interface allowing 
clinical staff to import data from the TPS, import a pre-treatment A-P image and perform 
catheter displacement evaluation at the treatment console in real-time. 
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C.4 Pre-Treatment Verification 3D 
The ‘Pre-Treatment Verification 3D’ software was developed to allow two oblique images to 
be loaded and corresponding features in each image to be identified for the purpose of 3D 
implant reconstruction. 
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